This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Distlerath, L.M. and F.P. Guengerich (1987). Enzymology of human liver cytochromes P-450. In F.P. Guengerich (ed.) Mammalian Cytochromes P-450, Vol. 1. CRC Press, Boca Raton, FL, pp. 133–198.
Beaune, P., P. Dansette, J.P. Flinois, S. Columelli, D. Mansuy, and J.P. Leroux (1979). Partial purification of human liver cytochrome P-450. Biochem. Biophys. Res. Commun. 88, 826–832.
Wang, P., P.S. Mason, and F.P. Guengerich (1980). Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch. Biochem. Biophys. 199, 206–219.
Wang, P.P., P. Beaune, L.S. Kaminsky, G.A. Dannan, F.F. Kadlubar, D. Larrey et al. (1983). Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22, 5375–5383.
Mahgoub, A., J.R. Idle, L.G. Dring, R. Lancaster, and R.L. Smith (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet ii, 584–586.
Shimada, T., C.-H. Yun, H. Yamazaki, J.-C. Gautier, P.H. Beaune, and F.P. Guengerich (1992). Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol. Pharmacol. 41, 856–864.
Distlerath, L.M., P.E.B. Reilly, M.V. Martin, G.G. Davis, G.R. Wilkinson, and F.P. Guengerich (1985). Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057–9067.
Yun, C.-H., T. Shimada, and F.P. Guengerich (1991). Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40, 679–685.
Shimada, T., K.S. Misono, and F.P. Guengerich (1986). Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J. Biol. Chem. 261, 909–921.
Gut, J., T. Catin, P. Dayer, T. Kronbach, U. Zanger, and U.A. Meyer (1986). Debrisoquine/sparteinetype polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 261, 11734–11743.
Birgersson, C., E.T. Morgan, H. Jörnvall, and C. von Bahr (1986). Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver. Biochem. Pharmacol. 35, 3165–3166.
Guengerich, F.P., M.V. Martin, P.H. Beaune, P. Kremers, T. Wolff, and D.J. Waxman (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051–5060.
Watkins, P.B., S.A. Wrighton, P. Maurel, E.G. Schuetz, G. Mendez-Picon, G.A. Parker et al. (1985). Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82, 6310–6314.
Wrighton, S.A., C. Campanile, P.E. Thomas, S.L. Maines, P.B. Watkins, G. Parker et al. (1986). Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 29, 405–410.
Wrighton, S.A., P.E. Thomas, P. Willis, S.L. Maines, P.B. Watkins, W. Levin et al. (1987). Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J. Clin. Invest. 80, 1017–1022.
Gonzalez, F.J. (1989). The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243–288.
Larson, J.R., M.J. Coon, and T.D. Porter (1991). Alcohol-inducible cytochrome P-450IIE1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J. Biol. Chem. 266, 7321–7324.
Li, Y.C. and J.Y.L. Chiang (1991). The expression of a catalytically active cholesterol 7α-hydroxylase cytochrome P-450 in Escherichia coli. J. Biol. Chem. 266, 19186–19191.
Barnes, H.J., M.P. Arlotto, and M.R. Waterman (1991). Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. USA 88, 5597–5601.
Guengerich, F.P., E.M.J. Gillam, and T. Shimada (1996). New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26, 551–583.
Nebert, D.W., M. Adesnik, M.J. Coon, R.W. Estabrook, F.J. Gonzalez, F.P. Guengerich et al. (1987). The P450 gene superfamily: Recommended nomenclature. DNA 6, 1–11.
Nelson, D.R., T. Kamataki, D.J. Waxman, F.P. Guengerich, R.W. Estabrook, R. Feyereisen et al. (1993). The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12, 1–51.
Guengerich, F.P. (1995). Human cytochrome P450 enzymes. In P.R. Ortiz de Montellano (ed.), Cytochrome P450. Plenum Press, New York, pp. 473–535.
Niranjan, B.G., N.M. Wilson, C.R. Jefcoate, and N.G. Avadhani (1984). Hepatic mitochondrial cytochrome P-450 system: Distinctive features of cytochrome P-450 involved in the activation of aflatoxin B1 and benzo(a)pyrene. J. Biol. Chem. 259, 12495–12501.
Addya, S., H.K. Anandatheerthavarada, G. Biswas, S.V. Bhagwat, J. Mullick, and N.G. Avadhani (1997). Targeting of NH2-terminal-processed microsomal protein to mitochondria: A novel pathway for the biogensis of hepatic mitochondrial P450MT2. J. Cell Biol. 139, 589–599.
Robin, M.A., H.K. Anandatheerthavarada, G. Biswas, N.B. Sepuri, D.M. Gordon, D. Pain et al. (2002). Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J. Biol. Chem. 277, 40583–40593.
Tateishi, T., Y. Krivoruk, Y.-F. Ueng, A.J.J. Wood, F.P. Guengerich, and M. Wood (1996). Identification of human liver cytochrome P450 3A4 as the enzyme responsible for fentanyl and sulfentanyl N-dealkylation. Anesth. Analg. 82, 167–172.
Shimada, T., H. Yamazaki, 4. Mimura, Y. Inui, and F.P. Guengerich (1994). Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414–423.
Nebert, D.W. and D.W. Russell (2002). Clinical importance of the cytochromes P450. Lancet 360, 1155–1162.
Brodie, A.M.H. (1985). Aromatase inhibition and its pharmacologic implications. Biochem. Pharmacol. 34, 3213–3219.
Gonzalez, F.J. and S. Kimura (2003). Study of P450 function using gene knockout and transgenic mice. Arch. Biochem. Biophys. 409, 153–158.
Rendic, S. (2002). Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab. Rev. 34, 83–448.
Evans, W.E. and M.V. Relling (1999). Pharmacogenomics: Translating function genomics into rational therapeutics. Science 286, 487–491.
Guengerich, F.P. and T. Shimada (1991). Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391–407.
Breimer, D.D. and J.H. Schellens (1990). A “cocktail” strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol. Sci. 11, 223–225.
Breimer, D.D. (1994). Genetic polymorphisms in drug metabolism; clinical implications and consequences in ADME studies. In S. Walker, C. Lumley, and N. McAuslane (eds), The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Kluwer Academic Publishers, Dordrecht/Boston/London, pp. 13–26.
Guengerich, F.P. and D.C. Liebler (1985). Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. 14, 259–307.
Motulsky, A.G. (1957). Drug reactions, enzymes and biochemical genetics. J. Am. Med. Assoc. 165, 835–837.
Kalow, W. (1962). Pharmacogenetics. W.B. Saunders, Philadelphia, PA.
Remmer, H. (1957). The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Naunyn-Schmiedeberg’s Arch. Exp. Pathol. Pharmakol. 237, 296–307.
Keeney, D.S. and M.R. Waterman (1993). Regulation of steroid hydroxylase gene expression: Importance to physiology and disease. Pharmacol. Ther. 58, 301–317.
Conney, A.H., E.C. Miller, and J.A. Miller (1956). The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 16, 450–459.
Eichelbaum, M., N. Spannbrucker, B. Steincke, and H.J. Dengler (1979). Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183–187.
Woolhouse, N.M., B. Andoh, A. Mahgoub, T.P. Sloan, J.R. Idle, and R.L. Smith (1979). Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin. Pharmacol. Ther. 26, 584–591.
Johansson, I., E. Lundqvist, L. Bertilsson, M.L. Dahl, F. Sjoqvist, and M. Ingelman Sundberg (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90, 11825–11829.
Smith, R.L., J.R. Idle, A.A. Mahgoub, T.P. Sloan, and R. Lancaster (1978). Genetically determined defects of oxidation at carbon centres of drugs. Lancet i, 943–944.
Gonzalez, F.J., R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, D.W. Nebert et al. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442–446.
Nakamura, K., F. Goto, W.A. Ray, C.B. McAllister, E. Jacqz, G.R. Wilkinson et al. (1985). Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38, 402–408.
Daly, A.K. (2003). Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17, 27–41.
Nagata, K. and Y. Yamazoe (2002). Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metab. Pharmacokinet. 17, 167–189.
Daly, A.K., J. Brockmöller, F. Broly, M. Eichelbaum, W.E. Evans, F.J. Gonzalez et al. (1996). Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193–201.
Gaedigk, A., M. Blum, R. Gaedigk, M. Eichelbaum, and U.A. Meyer (1991). Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 48, 943–950.
Corchero, J., C.P. Granvil, T.E. Akiyama, G.P. Hayhurst, S. Pimprale, L. Feigenbaum et al. (2001). The CYP2D6 humanized mouse: Effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 60, 1260–1267.
Schuetz, E.G., D.R. Umbenhauer, K. Yasuda, C. Brimer, L. Nguyen, M.V. Relling et al. (2000). Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr 1 genes. Mol. Pharmacol. 57, 188–197.
Cummins, C.L., C.Y. Wu, and L.Z. Benet (2002). Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72, 474–489.
Renton, K.W. and L.C. Knickle (1990). Regulation of hepatic cytochrome P-450 during infectious disease. Can. J. Physiol. Pharmacol. 68, 777–781.
Kato, R. and Y. Yamazoe (1992). Sex-specific cytochrome P450 as a cause of sex-and species-related differences in drug toxicity. Toxicol. Lett. 64/65, 661–667.
Komori, M., K. Nishio, M. Kitada, K. Shiramatsu, K. Muroya, M. Soma et al. (1990). Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 29, 4430–4433.
Lacroix, D., M. Sonnier, A. Moncion, G. Cheron, and T. Cresteil (1997). Expression of CYP3A in the human liver: Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247, 625–634.
Loi, C.M. and R.E. Vestal (1988). Drug metabolism in the elderly. Pharmacol. Ther. 36, 131–149.
Durnas, C., C.M. Loi, and B.J. Cusack (1990). Hepatic drug metabolism and aging. Clin. Pharmacokinet. 19, 359–389.
George, J., K. Byth, and G.C. Farrell (1995). Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem. Pharmacol. 50, 727–730.
Lu, A.Y.H., R.W. Wang, and J.H. Lin (2003). Cytochrome P450 in vitro reaction phenotyping: A re-evaluation of approaches used for P450 isoform identification. Drug Metab. Dispos. 31, 345–350.
Correia, M.A. and P.R. Ortiz de Montellano (2004, in press). Inhibition and degradation of cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry. Plenum Press, New York (Chap. 7 of this monograph).
Correia, M.A. (2004, in press). Isoform functional markers, isoform substrate specificities, and fluorescent substrate assays. In P.R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry. Plenum Press, New York (Appendix of this monograph).
Harris, J.W., A. Rahman, B.-R. Kim, F.P. Guengerich, and J.M. Collins (1994). Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and of an unknown P450 enzyme. Cancer Res. 54, 4026–4035.
Tran, T.H., L.L. von Moltke, K. Venkatakrishnan, B.W. Granda, M.A. Gibbs, R.S. Obach et al. (2002). Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab. Dispos. 30, 1441–1445.
Austin, R.P., P. Barton, S.L. Cockroft, M.C. Wenlock, and R.J. Riley (2002). The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30, 1497–1503.
Yoo, J.S.H., R.J. Cheung, C.J. Patten, D. Wade, and C.S. Yang (1987). Nature of N-nitrosodimethylamine demethylase and its inhibitors. Cancer Res. 47, 3378–3383.
Chauret, N., A. Gauthier, and D.A. Nicoll-Griffith (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 26, 1–4.
Yuan, R., S. Madani, X.X. Wei, K. Reynolds, and S.M. Huang (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30, 1311–1319.
Guengerich, F.P. (1988). Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33, 500–508.
Butler, M.A., M. Iwasaki, F.P. Guengerich, and F.F. Kadlubar (1989). Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 86, 7696–7700.
Distlerath, L.M. and F.P. Guengerich (1984). Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs using antibodies raised to the analogous rat enzyme. Proc. Natl. Acad. Sci. USA 81, 7348–7352.
Soucek, P., M.V. Martin, Y.-F. Ueng, and F.P. Guengerich (1995). Identification of a common epitope near the conserved heme-binding region with polyclonal antibodies raised against cytochrome P450 family 2 proteins. Biochemistry 34, 16013–16021.
Thomas, P.E., D. Koreniowski, D. Ryan, and W. Levin (1979). Preparation of monospecific antibodies against two forms of rat liver cytochrome P-450 and quantitation of these antigens in microsomes. Arch. Biochem. Biophys. 192, 524–532.
Venkatakrishnan, K., L.L. von Moltke, M.H. Court, J.S. Harmatz, C.L. Crespi, and D.J. Greenblatt (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28, 1493–1504.
Venkatakrishnan, K., L.L. von Moltke, and D.J. Greenblatt (2001). Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 297, 326–337.
Venkatakrishnan, K., L.L. von Moltke, and D.J. Greenblatt (2001). Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J. Clin. Pharmacol. 41, 1149–1179.
Soars, M.G., H.V. Gelboin, K.W. Krausz, and R.J. Riley (2003). A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. Br. J. Clin. Pharmacol. 55, 175–181.
Schwab, M., M. Eichelbaum, and M.F. Fromm (2003). Genetic polymorphisms of the human mdr1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285–307.
Butler, M.A., N.P. Lang, J.F. Young, N.E. Caporaso, P. Vineis, R.B. Hayes et al. (1992). Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2, 116–127.
Ahsan, C.H., A.G. Renwick, B. Macklin, V.F. Challenor, D.G. Waller, and C.F. George (1991). Ethnic differences in the pharmacokinetics of oral nifedipine. Br. J. Clin. Pharmacol. 31, 399–403.
Kim, R.B., H. Yamazaki, M. Mimura, T. Shimada, F.P. Guengerich, K. Chiba et al. (1996). Chlorzoxazone 6-hydroxylation in Japanese and Caucasians. In vitro and in vivo differences. J. Pharmacol. Exp. Ther. 279, 4–11.
Conney, A.H. (1982). Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res. 42, 4875–4917.
Sutter, T.R., K. Guzman, K.M. Dold, and W.F. Greenlee (1991). Targets for dioxin: Genes for plasminogen activator inhibitor-2 and interleukin-1β. Science 254, 415–418.
Rivera, S.P., S.T. Saarikoski, and O. Hankinson (2002). Identification of a novel dioxin-inducible cytochrome P450. Mol. Pharmacol. 61, 255–259.
Shah, R.R., N.S. Oates, J.R. Idle, R.L. Smith, and J.D.F. Lockhart (1982). Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br. Med. J. 284, 295–299.
Steward, D.J., R.L. Haining, K.R. Henne, G. Davis, T.H. Rushmore, W.F. Trager et al. (1997). Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7, 361–367.
Aithal, G.P., C.P. Day, P.J. Kesteven, and A.K. Daly (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717–719.
Daly, A.K., C.P. Day, and G.P. Aithal (2002). CYP2C9 polymorphism and warfarin dose requirements. Brit. J. Clin. Pharmacol. 53, 408–409.
Chiba, K., K. Kobayashi, K. Manabe, M. Tani, T. Kamataki, and T. Ishizaki (1993). Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation J. Pharmacol. Exp. Ther. 266, 52–59.
Karam, W.G., J.A. Goldstein, J.M. Lasker, and B.I. Ghanayem (1996). Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 24, 1081–1087.
Bolt, H.M., M. Bolt, and H. Kappus (1977). Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol. 85, 189–197.
Schwarz, U.I., B. Buschel, and W. Kirch (2003). Unwanted pregnancy on self-medication with St. John’s wort despite hormonal contraception. Br. J. Clin. Pharmacol. 55, 112–113.
Guengerich, F.P. (1999). Inhibition of drug metabolizing enzymes: Molecular and biochemical aspects. In T. F. Woolf (ed.), Handbook of Drug Metabolism. Marcel Dekker, New York, pp. 203–227.
Bailey, D.G., J.D. Spence, B. Edgar, C.D. Bayliff, and J.M.O. Arnold (1990). Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12, 357–362.
Edgar, B., D.G. Bailey, R. Bergstrand, G. Johnsson, and L. Lurje (1990). Formulation dependent interaction between felodipine and grapefruit juice. Clin. Pharmacol. Ther. 47, 181.
He, K., R. Iyer, R.N. Hayes, M.W. Sinz, T.F. Woolf, and P.F. Hollenberg (1998). Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11, 252–259.
Schmiedlin-Ren, P., D.J. Edwards, M.E. Fitzsimmons, K. He, K.S. Lown, P.M. Woster et al. (1997). Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Drug Metab. Dispos. 25, 1228–1233.
Reimers, D. and A. Jezek (1971). Rifampicin und andere antituberkulotika bei gleichzeitiger oraler kontrzeption. Przx. Pneumolonology 25, 255–262.
Nocke-Finck, L. H. Brewer, and D. Reimers (1973). Wirkung van rifampicin auf den menstrationszylkus und die östrogenausscheidung bei einnahme oraler kontrazeptive. Deutsch. Med. Wochenschrifften 98, 1521–1523.
Kivistö, K.T., P.J. Neuvonen, and U. Klotz (1994). Inhibition of terfenadine metabolism: Pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokinet. 27, 1–5.
Thompson, D. and G. Oster (1996). Use of terfenadine and contraindicated drugs. J. Am. Med. Assoc. 275, 1339–1341.
Fischbach, T. and W. Lenk (1985). Additional routes in the metabolism of phenacetin. Xenobiotica 15, 149–164.
Guengerich, F.P., D. Müller-Enoch, and I.A. Blair (1986). Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287–295.
Halpert, J.R. and F.P. Guengerich (1997). Enzyme inhibition and stimulation. In F. P. Guengerich (ed.), Biotransformation, Vol. 3, Comprehensive Toxicology. Elsevier Science Ltd., Oxford, pp. 21–35.
Witherow, L.E. and J.B. Houston (1999). Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J. Pharmacol. Exp. Ther. 290, 58–65.
Lasker, J.M., M.-T. Huang, and A.H. Conney (1982). In vivo activation of zoxazolamine metabolism by flavone. Science 216, 1419–1421.
Lee, C.A., J.H. Lillibridge, S.D. Nelson, and J.T. Slattery (1996). Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. J. Pharmacol. Exp. Ther. 277, 287–291.
Ngui, J.S., W. Tang, R.A. Stearns, M.G. Shou, R.R. Miller, Y. Zhang et al. (2000). Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab. Dispos. 28, 1043–1050.
Shapiro, A.B., K. Fox, P. Lam, and V. Ling (1999). Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur. J. Biochem. 259, 841–850.
Mueller, G.C. and J.A. Miller (1948). The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J. Biol. Chem. 176, 535–544.
Jollow, D.J., J.R. Mitchell, W.Z. Potter, D.C. Davis, J.R. Gillette, and B.B. Brodie (1973). Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187, 195–202.
Neal, R.A. and J. Halpert (1982). Toxicology of thiono-sulfur compounds. Annu. Rev. Pharmacol. Toxicol. 22, 321–339.
Wing, K.D., A.H. Glickman, and J.E. Casida (1983). Oxidative bioactivation of S-alkyl phosphorothiolate pesticides: Stereospecificity of profenofos insecticide activation. Science 219, 63–65.
Nebert, D.W. (1989). The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects Crit. Rev. Toxicol. 20, 153–174.
Lee, S.S.T., J.T.M. Buters, T. Pineau, P. Fernandez-Salguero, and F.J. Gonzalez (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063–12067.
Buters, J.T.M., S. Sakai, T. Richter, T. Pineau, D.L. Alexander, Ü. Savas et al. (1999). Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. USA 96, 1977–1982.
Nebert, D.W. and H.V. Gelboin (1968). Substrate-inducible microsomal arylhydroxylase in mammalian cell culture: Assay and properties of induced enzyme. J. Biol. Chem. 243, 6242–6249.
Kellerman, G., M. Luyten-Kellerman, and C.R. Shaw (1973). Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 25, 327–331.
Kellerman, G., C.R. Shaw, and M. Luyten-Kellerman (1973). Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 298, 934–937.
Paigen, B., E. Ward, A. Reilly, L. Houten, H.L. Gurtoo, J. Minowada et al. (1981). Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes. Cancer Res. 41, 2757–2761.
Kouri, R.E., C.E. McKinney, D.J. Slomiany, D.R. Snodgrass, N.P. Wray, and T.L. McLemore (1982). Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 42, 5030–5037.
Chang, C., D.R. Smith, V.S. Prasad, C.L. Sidman, D.W. Nebert, and A. Puga (1993). Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics 3, 312–321.
Dolwick, K.M., J.V. Schmidt, L.A. Carver, H.I. Swanson, and C.A. Bradfield (1993). Cloning and expression of a human Ah receptor cDNA. Mol. Pharmacol. 44, 911–917.
Fujii-Kuriyama, Y., M. Ema, J. Mimura, N. Matsushita, and K. Sogawa (1995). Polymporphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics 5, S149–S153.
Kawajiri, K., J. Watanabe, H. Eguchi, K. Nakachi, C. Kiyohara, and S. Hayashi (1995). Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 5, 151–158.
Hayashi, S., J. Watanabe, K. Nakachi, and K. Kawajiri (1991). Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem. (Tokyo) 110, 407–411.
Tefre, T., D. Ryberg, A. Haugen, D.W. Nebert, V. Skaug, A. Brogger et al. (1991). Human CYP1A1 (cytochrome P1450) gene: Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1, 20–25.
Hirvonen, A., K. Husgafvel-Pursiainen, A. Karjalainen, S. Anttila, and H. Vainio (1992). Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomarkers Prev. 1, 485–489.
Wedlund, P.J., S. Kimura, F.J. Gonzalez, and D.W. Nebert (1994). I462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I 1.9kb (M2) allele or CYP1A1 inducibility in a three-generation family of East Mediterranean descent. Pharmacogenetics 4, 21–26.
Zhang, Z.-Y., M.J. Fasco, L. Huang, F.P. Guengerich, and L.S. Kaminsky (1996). Characterization of purified recombinant human CYP 1A1-Ile462 and Val462: Assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56, 3926–3933.
Persson, I., I. Johansson, and M. Ingelman-Sundberg (1997). In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun. 231, 227–230.
Toide, K., H. Yamazaki, R. Nagashima, K. Itoh, S. Iwano, Y. Takahashi et al. (2003). Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: Trimodal distribution of Japaneses population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiol. Biomarkers Prev. 12, 219–222.
Guengerich, F.P. (1998). The environmental genome project: Functional analysis of polymorphisms. Environ. Health Perspect. 106, 365–368.
Ayesh, R., J.R. Idle, J.C. Ritchie, M.J. Crothers, and M.R. Hetzel (1984). Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312, 169–170.
d’Errico, A., E. Taioli, X. Chen, and P. Vineis (1996). Genetic metabolic polymorphisms and the risk of cancer: A review of the literature. BioMarkers 1, 149–173.
Shimada, T. and F.P. Guengerich (1991). Activation of amino-α-carboline, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and a copper phthalo-cyanine cellulose extract of cigarette smoke condensate by cytochrome P-450 enzymes in rat and human liver microsomes. Cancer Res. 51, 5284–5291.
Vineis, P. (2002). The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 181, 457–462.
Stoilov, I., A.N. Akarsu, I. Alozie, A. Child, M. Barsoum-Homsy, M.E. Turacli et al. (1998). Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62, 573–584.
Shimada, T., J. Watanabe, F.P. Guengerich, K. Inoue, and E.M.J. Gillam (2001). Specificity of 17β-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P450 1B1 variants substituted at residues 48, 119, and 432. Xenobiotica 31, 163–176.
Watanabe, J., T. Shimada, E.M.J. Gillam, T. Ikuta, K. Suemasu, Y. Higashi et al. (2000). Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10, 25–33.
Zheng, W., DW. Xie, F. Jin, J.R. Cheng, Q. Dai, W.Q. Wen et al. (2000). Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 147–150.
Lang, N.P., M.A. Butler, J. Massengill, M. Lawson, R.C. Stotts, M. Maurer-Jensen et al. (1994). Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps Cancer Epidemiol. Biomarkers Prev. 3, 675–682.
Shimada, T., M. Iwasaki, M.V. Martin, and F.P. Guengerich (1989). Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Res. 49, 3218–3228.
Ariyoshi, N., M. Miyamoto, Y. Umetsu, H. Kunitoh, H. Dosaka-Akita, Y. Sawamura et al. (2002). Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. 11, 890–894.
Pianezza, M.L., E.M. Sellers, and R.F. Tyndale (1998). Nicotine metabolism defect reduces smoking. Nature 393, 750.
Kim, R.B., D. O’Shea, and G.R. Wilkinson (1994). Relationship in healthy subjects between CYP2E1 genetic polymorphism and the 6-hydroxylation of chlorozoxazone: A putative measure of CYP2E1 activity. Pharmacogenetics 4, 162–165.
Ioannides, C. and D.V. Parke (1993). Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab. Rev. 25, 485–501.
Rice, J.M., B.A. Diwan, J.M. Ward, R.W. Nims, and R.A. Lubet (1992). Phenobarbital and related compounds: Approaches to interspecies extrapolation. In Relevance of Animal Studies to the Evaluation of Human Cancer Risk. Wiley-Liss, Inc., pp. 231–249.
Olsen, J.H., J.D. Boice Jr., J.P.A. Jensen and J.F. Fraumeni Jr. (1989). Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 81, 803–808.
Kluwe, W.M. (1994). The relevance of hepatic peroxisome proliferation in rats to assessment of human carcinogenic risk for pharmaceuticals. Regul. Toxicol. Pharmacol. 20, 170–186.
Thomas, R.S., D.R. Rank, S.G. Penn, G.M. Zastrow, K.R. Hayes, K. Pande et al. (2001). Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 60, 1189–1194.
Omiecinski, C.J., C.A. Redlich, and P. Costa (1990). Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: Detection by the polymerase chain reaction. Cancer Res. 50, 4315–4321.
Kitada, M., M. Taneda, K. Itahashi, and T. Kamataki (1991). Four forms of cytochrome P-450 in human fetal liver: Purification and their capacity to activate promutagens. Jpn. J. Cancer Res. 82, 426–432.
Kitada, M. and T. Kamataki (1994). Cytochrome P450 in human fetal liver: Significance and fetal-specific expression. Drug Metab. Rev. 26, 305–323.
Liu, N., Q.Y. Zhang, D. Vakharia, D. Dunbar, and L.S. Kaminsky (2001). Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 or CYP1A2?. Arch. Biochem. Biophys. 389, 130–134.
Fagan, J.B., J.V. Pastewka, S.R. Chalberg, E. Gozukara, F.P. Guengerich, and H.V. Gelboin (1986). Noncoordinate regulation of the mRNAs encoding cytochromes P-450BNF/MC-B and p-450ISF/BNF-G. Arch. Biochem. Biophys. 244, 261–272.
Kim, J.H., M.E. Sherman, F.C. Curreiro, F.P. Guengerich, P.T. Strickland, and T.R. Sutter (2004, in press). Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol. Appl. Pharmacol.
Prough, R.A., Z. Sipal, and S.W. Jakobsson (1977). Metabolism of benzo(a)pyrene by human lung microsomal fractions. Life Sci. 21, 1629–1636.
Fujino, T., K. Gottlieb, D.K. Manchester, S.S. Park, D. West, H.L. Gurtoo et al. (1984). Monoclonal antibody phenotyping of interindividual differences in cytochrome P-450-dependent reactions of single and twin human placenta. Cancer Res. 44, 3916–3923.
Robie-Suh, K., R. Robinson, H.V. Gelboin, and F.P. Guengerich (1980). Aryl hydrocarbon hydroxylase is inhibited by antibody to rat liver cytochrome P-450. Science 208, 1031–1033.
Shimada, T., H. Yamazaki, M. Mimura, N. Wakamiya, F.P. Guengerich, and Y. Inui (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab. Dispos. 24, 515–522.
McLemore, T.L., S. Adelberg, M.C. Liu, N.A. McMahon, S.J. Yu, W.C. Hubbard et al. (1990). Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst. 82, 1333–1339.
Anttila, S., X.D. Lei, E. Elovaara, A. Karjalainen, W.M. Sun, H. Vainio et al. (2000). An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 10, 741–751.
Anttila, S., P. Tuominen, A. Hirvonen, M. Nurminen, A. Karjalainen, O. Hankinson et al. (2001). CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor. Pharmacogenetics 11, 501–509.
Bradfield, C.A. (2004, in press). Induction of P450 enzymes: Receptors. In P.R. Ortiz De Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, Plenum, New York (Chap. 8 of this monograph).
Lucier, G.W., K.G. Nelson, R.B. Everson, T.K. Wong, R.M. Philpot, T. Tiernan et al. (1987). Placental markers of human exposure to polycholrinated biphenyls and polychlorinated dibenzofurans. Environ. Health Perspect. 76, 79–87.
Diaz, D., I. Fabre, M. Daujat, B. Saintaubert, P. Bories, H. Michel et al. (1990). Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome-P450. Gastroenterology 99, 737–747.
Yun, C.-H., T. Shimada, and F.P. Guengerich (1992). Roles of human liver cytochrome P-4502C and 3A enzymes in the 3-hydroxylation of benzo[a]pyrene. Cancer Res. 52, 1868–1874.
Prough, R.A., M.D. Burke, and R.T. Mayer (1978). Direct fluorometric methods for measuring mixed-function oxidase activity. Meth. Enzymol. 52, 372–377.
Guo, Z., E.M.J. Gillam, S. Ohmori, R.H. Tukey, and F.P. Guengerich (1994). Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties. Arch. Biochem. Biophys. 312, 436–446.
Shou, M., K.R. Korzekwa, C.L. Crespi, F.J. Gonzalez, and H.V. Gelboin (1994). The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene rans-7,8-dihydrodiol. Mol. Carcinogen. 10, 159–168.
Bauer, E., Z. Guo, Y.-F. Ueng, L.C. Bell, and F.P. Guengerich (1995). Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 136–142.
Shou, M., K.W. Krausz, F.J. Gonzalez, and H.V. Gelboin (1996). Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450. Arch. Biochem. Biophys. 328, 201–207.
Shou, M., K.W. Krausz, F.J. Gonzalez, and H.V. Gelboin (1996). Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes. Carcinogenesis 17, 2429–2433.
Shimada, T., C.L. Hayes, H. Yamazaki, S. Amin, S.S. Hecht, F.P. Guengerich et al. (1996). Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. 56, 2979–2984.
Balani, S.K., H.J.C. Yeh, D.E. Ryan, P.E. Thomas, W. Levin, and D.M. Jerina (1985). Absolute configuration of the 5,6-oxide formed from 7,12-dimethylbenz[a]anthracene by cytochrome P450c. Biochem. Biophys. Res. Commun. 130, 610–616.
Lewis, D.F.V., B.G. Lake, S.G. George, M. Dickins, P.J. Eddershaw, M.H. Tarbit et al. (1999). Molecular modeling of CYP family enzymes CYP1A1, CYP1A2, CYP1A6, and CYP1B1 based on sequence homology with CYP102. Toxicology 139, 53–79.
Shimada, T., H. Yamazaki, M. Foroozesch, N.E. Hopkins, W.L. Alworth, and F.P. Guengerich (1998). Selectivity of polycyclic inhibitors for human cytochromes P450 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 11, 1048–1056.
McManus, M.E., W.M. Burgess, M.E. Veronese, A. Huggett, L.C. Quattrochi, and R.H. Tukey (1990). Metabolism of 2-acetylaminofluorene and benzo[a]pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450. Cancer Res. 50, 3367–3376.
Mercurio, M.G., S.J. Shiff, R.A. Galbraith, and S. Sassa (1995). Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem. Biophys. Res. Commun. 210, 350–355.
Pantuck, E.J., K.-C. Hsiao, A. Maggio, K. Nakamura, R. Kuntzman, and A.H. Conney (1974). Effect of cigarette smoking on phenacetin metabolism. Clin. Pharmacol. Ther. 15, 9–17.
Vesell, E.S. and J.G. Page (1968). Genetic control of drug levels in man: Antipyrine. Science 161, 72–73.
Rasmussen, B.B., T.H. Brix, K.O. Kyvik, and K. Brøsen (2002). The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12, 473–478.
Zhou, H., P.D. Josephy, D. Kim, and F.P. Guengerich (2004). Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Bioch. Biophys. 422, 23–30.
Kalow, W. and B.K. Tang (1993). The use of caffeine for enzyme assays: A critical appraisal. Clin. Pharmacol. Ther. 53, 503–514.
Quattrochi, L.C., T. Vu, and R.H. Tukey (1994). The human CYP1A2 gene and induction by 3-methylcholanthrene: A region of DNA that supports Ah-receptor binding and promoter-specific induction. J. Biol. Chem. 269, 6949–6954.
Kondraganti, S.R., W.W. Jiang, and B. Moorthy (2002). Differential regulation of expression of hepatic and pulmonary cytochrome P4501A enzymes by 3-methylcholanthrene in mice lacking the CYP1A2 gene. J. Pharmacol. Exp. Ther. 303, 945–951.
Fisher, G.J., H. Fukushima, and J.L. Gaylor (1981). Isolation, purification, and properties of a unique form of cytochrome P-450 in microsomes of isosafrole-treated rats. J. Biol. Chem. 256, 4388–4394.
Vistisen, K., H.E. Poulsen, and S. Loft (1992). Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 13, 1561–1568.
Rost, K.L., H. Brösicke, J. Brockmöller, M. Scheffler, H. Helg, and I. Roots (1992). Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 52, 170–180.
Fisher, C.W., D.L. Caudle, C. Martin-Wixtrom, L.C. Quattrochi, R.H. Tukey, M.R. Waterman et al. (1992). High-level expression of functional cytochrome P450 1A2 in Escherichia coli, FASEB J. 6, 759–764.
Sandhu, P., Z. Guo, T. Baba, M.V. Martin, R.H. Tukey, and F.P. Guengerich (1994). Expression of modified human cytochrome P450 1A2 in Escherichia coli: Stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch. Biochem. Biophys. 309, 168–177.
Patten, C.J., P.E. Thomas, R.L. Guy, M. Lee, F.J. Gonzalez, F.P. Guengerich et al. (1993). Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 6, 511–518.
Engel, G., U. Hofmann, H. Heidemann, J. Cosme, and M. Eichelbaum (1996). Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59, 613–623.
Yamazaki, H., Z. Guo, M. Persmark, M. Mimura, F.J. Gonzalez, C. Sugahara et al. (1994). Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol. Pharmacol. 46, 568–577.
Berthou, F., V. Carriere, D. Ratanasavanh, T. Goasduff, F. Morel, J.C. Gautier et al. (1993). On the specificity of chlorozoxazone as drug probe of cytochrome P4502E1. In Abstracts, 5th European ISSX Meeting, Vol. 3. p. 116, 26–29 September, Tours, France.
Woolf, T.F., W.F. Pool, M. Kukan, S. Bezek, K. Kunze, and W.F. Trager (1993). Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: Evidence for CYP1A2 involvement. In Abstracts, 5th North American ISSX Meeting, Vol. 4, p. 139, 17–21 October, Tucson, AZ.
Benoit, G.G., C.F. Naud, M.A. Simard, and A.L. Astier (1997). Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. Biochem. Pharmacol. 53, 423–427.
Zhang, Z.Y. and L.S. Kaminsky (1995). Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50, 205–211.
Yamazaki, H., Y. Oda, Y. Funae, S. Imaoka, Y. Inui, F.P. Guengerich et al. (1992). Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-diethylnitrosamine to products genotoxic in Salmonella typhimurium NM2009. Carcinogenesis 13, 979–985.
Yamazaki, H., P.M. Shaw, F.P. Guengerich, and T. Shimada (1998). Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem. Res. Toxicol. 11, 659–665.
Michnovicz, J.J., R.J. Hershcopr, H. Naganuma, H.L. Bradlow, and J. Fishman (1986). Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New Engl. J. Med. 315, 1305–1309.
Bradlow, H.L., R.J. Hershcopf, C.P. Martucci, and J. Fishman (1985). Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: A possible model for the hormonal etiology of breast cancer in humans. Proc. Natl. Acad. Sci. USA 82, 6295–6299.
Hiroya, K., M. Ishigooka, T. Shimizu, and M. Hatano (1992). Role of Glu318 and Thr319 in the catalytic function of cytochrome P450d (P4501A2): Effects of mutations on the methanol hydroxylation. FASEB J. 6, 749–751.
Ishigooka, M., T. Shimizu, K. Hiroya, and M. Hatano (1992). Role of Glu318 at the putative distal site in the catalytic function of cytochrome P450d. Biochemistry 31, 1528–1531.
Shimizu, T., A.J.M. Sadeque, G.N. Sadeque, M. Hatano, and Y. Fujii-Kuriyama (1991). Ligand binding studies of engineered cytochrome P-450d wild type, peroximal mutants, and distal mutants. Biochemistry 30, 1490–1496.
Fuhr, U., G. Strobl, F. Manaut, E.M. Anders, F. Sörgel, E. Lopez-de-Brinas et al. (1993). Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. 43, 191–199.
Lozano, J.J., E. López-de-Briñas, N.B. Centeno, F. Sanz, and R. Guigo (1997). Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ. J. Comput. Aided Mol. Des. 11, 395–408.
Parikh, A., P.D. Josephy, and F.P. Guengerich (1999). Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 38, 5283–5289.
Yun, C.-H., G.P. Miller, and F.P. Guengerich (2000). Rate-determining steps in phenacetin oxidation by human cytochrome P450 1A2 and selected mutants. Biochemistry 39, 11319–11329.
Yun, C.-H., G.P. Miller, and F.P. Guengerich (2001). Oxidations of p-alkoxyacylanilides by human cytochrome P450 1A2: Structure-activity relationships and simulation of rate constants of individual steps in catalysis. Biochemistry 40, 4521–4530.
Miller, G.P. and F.P. Guengerich (2001). Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: Evidence for two binding sites. Biochemistry 40, 7262–7272.
Racha, J.K., A.E. Rettie, and K.L. Kunze (1998). Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: Detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37, 7407–7419.
Voorman, R. and S.D. Aust (1987). Specific binding of polyhalogenated aromatic hydrocarbon inducers of cytochrome P-450d to the cytochrome and inhibition of its estradiol 2-hydroxylase activity. Toxicol. Appl. Pharmacol. 90, 69–78.
Sesardic, D., A. Boobis, B. Murray, S. Murray, J. Segura, R. De La Torre et al. (1990). Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br. J. Clin. Pharmacol. 29, 651–663.
Kappas, A., A.P. Alvares, K.E. Anderson, E.J. Pantuck, C.B. Pantuck, R. Chang et al. (1978). Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin. Pharmacol. Ther. 23, 445–450.
Feldman, C.H., V.E. Hutchinson, C.E. Pippenger, T.A. Blemenfeld, B.R. Feldman, and W.J. Davis (1980). Effect of dietary protein and carbohydrate on theophylline metabolism in children. Pediatrics 66, 956–962.
Otto, S., C. Marcus, C. Pidgeon, and C. Jefcoate (1991). A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism. Endocrinology 129, 970–982.
Murray, B.P. and M.A. Correia (2001). Ubiquitin-dependent 26S proteasomal pathway: A role in the degradation of native human liver CYP3A4 expressed in Saccharomyces cerevisiae? Arch. Biochem. Biophys. 393, 106–116.
Murray, G.I., M.C. Taylor, M.C. McFadyen, J.A. McKay, W.F. Greenlee, M.D. Burke et al. (1997). Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026–3031.
Chang, T.K.H., J. Chen, V. Pillay, J.-Y. Ho, and S.M. Bandiera (2003). Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol. Sci. 71, 11–19.
Stoilov, I., A.N. Akarsu, and M. Sarfarazi (1997). Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6, 641–647.
Shimada, T., E.M.J. Gillam, T.R. Sutter, P.T. Strickland, F.P. Guengerich, and H. Yamazaki (1997). Roles of recombinant human cytochrome P450 1B1 in the oxidation of xenobiotic chemicals. Drug Metab. Dispos. 25, 617–622.
Shimada, T., Y. Oda, E.M.J. Gillam, F.P. Guengerich, and K. Inoue (2001). Metabolic activation of polycyclic aromatic hydrocarbons and their dihydrodiol derivatives and other procarcinogens by cytochrome P450 1A1 and 1B1 allelic variants and other human cytochrome P450 enzymes in Salmonella typhimurium NM2009. Drug Metab. Dispos. 29, 1176–1182.
Yamazaki, H., N. Hatanaka, R. Kizu, K. Hayakawa, N. Shimada, F.P. Guengerich et al. (2000). Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 472, 129–138.
Hayes, C.L., D.C. Spink, B.C. Spink, J.Q. Cao, N.J. Walker, and T.R. Sutter (1996). 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA 93, 9776–9781.
Shimada, T., J. Watanabe, K. Kawajiri, T.R. Sutter, F.P. Guengerich, E.M.J. Gillam et al. (1999). Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607–1614.
Shimada, T., E.M.J. Gillam, Y. Oda, F. Tsumura, T.R. Sutter, F.P. Guengerich et al. (1999). Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem. Res. Toxicol. 12, 623–629.
Savas, Ü., C.P. Carstens, and C.R. Jefcoate (1997). Recombinant mouse CYP1B1 expressed in Escherichia coli exhibits selective binding by polycyclic hydrocarbons and metabolism which parallels C3H10T1/2 cell microsomes, but differs from human recombinant CYP1B1. Arch. Biochem. Biophys. 347, 181–192.
Hanna, I.H., S. Dawling, N. Roodi, F.P. Guengerich, and F. Parl (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60, 3440–3444.
Shou, M., K.R. Korzekwa, E.N. Brooks, K.W. Krausz, F.J. Gonzalez, and H.V. Gelboin (1997). Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18, 207–214.
Bolton, J.L., E. Pisha, F. Zhang, and S. Qiu (1998). Role of quinoids in estrogen carcinogenesis. Chem. Res. Toxicol. 11, 1113–1127.
Liehr, J.G., M.J. Ricci, C.R. Jefcoate, E.V. Hannigan, J.A. Hokanson, and B.T. Zhu (1995). 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. USA 92, 9220–9224.
Lewis, D.F.V., M. Dickins, P.J. Eddershaw, M.H. Tarbit, and P.S. Goldfarb (1999). Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries. Drug Metabol. Drug Interact. 15, 1–49.
Jang, M., L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W.W. Beecher et al. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218–220.
Chun, Y.-J., M.-F. Kim, and F.P. Guengerich (1999). Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun. 262, 20–24.
Potter, G.A., L.H. Patterson, E. Wanogho, P.J. Perry, P.C. Butler, T. Ijaz et al. (2002). The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer 86, 774–778.
Chun, Y.-J., S. Kim, D. Kim, S.-K. Lee, and F.P. Guengerich (2001). A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 61, 8164–8170.
Shen, L., S. Qiu, R.B. van Breemen, F. Zhang, Y. Chen, and J.L. Bolton (1997). Reaction of the premarin metabolite 4-hydroxyequilenin semiquinone radical with 2′-deoxyguanosine: Formation of unusual cyclic adducts. J. Am. Chem. Soc. 119, 11126–11127.
Yamano, S., J. Tatsuno, and F.J. Gonzalez (1990). The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322–1329.
Hakkola, J., M. Pasanen, J. Hukkanen, O. Pelkonen, J. Mäenpää, R.J. Edwards et al. (1996). Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 51, 403–411.
Ding, X. and L.S. Kaminsky (2003). Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43, 149–173.
Godoy, W., R.M. Albano, E.G. Moraes, P.R. Pinho, R.A. Nunes, E.H. Saito et al. (2002). CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: Regional and inter-individual variation in expression and relevance to nitrosamine metabolism. Carcinogenesis 23, 611–616.
Raunio, H., R. Juvonen, M. Pasanen, O. Pelkonen, P. Paakko, and Y. Soini (1998). Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 27, 427–432.
Rae, J.M., M.D. Johnson, M.E. Lippman, and D.A. Flockhart (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299, 849–857.
Donato, M.T., P. Viitala, C. Rodriguez-Antona, A. Lindfors, J.V. Castell, H. Raunio et al. (2000). CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos. 28, 1321–1326.
Jover, R., R. Bort, M.J. Gomez-Lechon, and J.V. Castell (2001). Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus-mediated antisense targeting. Hepatology 33, 668–675.
Ding, S., B.G. Lake, T. Friedberg, and C.R. Wolf (1995). Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem. J. 306, 161–166.
Oscarson, M., R.A. McLellan, V. Asp, M. Ledesma, M.L. Ruiz, B. Sinues et al. (2002). Characterization of a novel CYP2A7/CYP2A6 hybrid allel (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat. 20, 275–283.
Hadidi, H., K. Zahlsen, J.R. Idle, and S. Cholerton (1997). A single amino acid substitution (Leu60His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol. 35, 903–907.
Nakajima, M., J.-T. Kwon, N. Tanaka, T. Zenta, Y. Yamamoto, H. Yamamoto et al. (2001). Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther. 69, 72–78.
Tyndale, R.F. and E.M. Sellers (2001). Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Dispos. 29, 548–552.
Yoshida, R., M. Nakajima, Y. Watanabe, J.T. Kwon, and T. Yokoi (2002). Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. 54, 511–517.
Gu, D.F., L.J. Hinks, N.E. Morton, and I.N. Day (2000). The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64, 383–390.
Rao, Y., E. Hoffmann, M. Zia, L. Bodin, M. Zeman, E.M. Sellers et al. (2000). Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58, 747–755.
Xu, C., S. Goodz, E.M. Sellers, and R.F. Tyndale (2002). CYP2A6 genetic variation and potential consequences. Adv. Drug Deliv. Rev. 54, 1245–1256.
Tyndale, R.F. and E.M. Sellers (2002). Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther. Drug Monit. 24, 163–171.
Kamataki, T., K. Nunoya, Y. Sakai, H. Kushida, and K. Fujita (1999). Genetic polymorphism of CYP2A6 in relation to cancer. Mutat. Res. 428, 125–130.
Miyamoto, M., Y. Umetsu, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh et al. (1999). CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 261, 658–660.
London, S.J., J.R. Idle, A.K. Daly, and G.A. Coetzee (1999). Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 353, 898–899.
Schulz, T.G., P. Ruhnau, and E. Hallier (2001). Lack of correlation between CYP2A6 genotype and smoking habits. Adv. Exp. Med. Biol. 500, 213–215.
Raunio, H., A. Rautio, H. Gullsten, and O. Pelkonen (2001). Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52, 357–363.
Tricker, A.R. (2003). Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 183, 151–173.
Loriot, M.A., S. Rebuissou, M. Oscarson, S. Cenee, M. Miyamoto, N. Ariyoshi et al. (2001). Genetic polymorphisms of cytochrome P450 2A6 in a casecontrol study on lung cancer in a French population. Pharmacogenetics 11, 39–44.
Zhang, X., K. Amemo, S. Ameno, K. Iwahashi, H. Kinoshita, T. Kubota et al. (2001). Lack of association between smoking and CYP2A6 gene polymorphisms in a Japanese population. Nihon Arukoru Yakubutsu Igakkai Zasshi 36, 486–490.
Oscarson, M. (2001). Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos. 29, 91–95.
Nakajima, M., Y. Kuroiwa, and T. Yokoi (2002). Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Drug Metab. Rev. 34, 865–877.
Daly, A.K., S. Cholerton, W. Gregory, and J.R. Idle (1993). Metabolic polymorphisms. Pharmacol. Ther. 57, 129–160.
Cholerton, S., M.E. Idle, A. Vas, F.J. Gonzalez, and J.R. Idle (1992). Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J. Chromatogr. 575, 325–330.
Rautio, A., H. Kraul, A. Kojo, E. Salmela, and O. Pelkonen (1992). Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2, 227–233.
Soucek, P. (1999). Expression of cytochrome P450 2A6 in Escherichia coli: Purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch. Biochem. Biophys. 370, 190–200.
Nowell, S., C. Sweeney, G. Hammons, F.F. Kadlubar, and N.P. Lang (2002). CYP2A6 activity determined by caffeine phenotyping: Association with colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 377–383.
Le Gal, A., Y. Dreano, P.G. Gervasi, and F. Berthou (2001). Human cytochrome P450 2A6 is the major enzyme involved in the metabolism of three alkoxyethers used as oxyfuels. Toxicol. Lett. 124, 47–58.
Duescher, R.J. and A.A. Elfarra (1994). Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: Evidence for major roles by cytochrome P450 2A6 and 2E1. Arch. Biochem. Biophys. 311, 342–349.
Nunoya, K., T. Yokoi, K. Kimura, K. Inoue, T. Kodama, M. Funayama et al. (1998). A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8, 239–249.
Nunoya, K., T. Yokoi, K. Kimura, T. Kainuma, K. Satoh, M. Kinoshita et al. (1999). A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther. 289, 437–442.
Komatsu, T., H. Yamazaki, N. Shimada, M. Nakajima, and T. Yokoi (2000). Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos. 28, 1457–1463.
Ikeda, K., K. Yoshisue, E. Matsushima, S. Nagayama, K. Kobayashi, C.A. Tyson et al. (2000). Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro, Clin. Cancer Res. 6, 4409–4415.
Minoda, Y. and E.D. Kharasch (2001). Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology 95, 509–514.
Crespi, C.L., B.W. Penman, J.A. Leakey, M.P. Arlotto, A. Stark, A. Parkinson et al. (1990). Human cytochrome P450IIA3:cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11, 1293–1300.
Yamazaki, H., Y. Inui, C.-H. Yun, M. Mimura, F.P. Guengerich, and T. Shimada (1992). Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13, 1789–1794.
Smith, T.J., Z. Guo, F.J. Gonzalez, F.P. Guengerich, G.D. Stoner, and C.S. Yang (1992). Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res. 52, 1757–1763.
Crespi, C.L., B.W. Penman, H.V. Gelboin, and F.J. Gonzalez (1991). A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12, 1197–1201.
Tiano, H.F., R.L. Wang, M. Hosokawa, C. Crespi, K.R. Tindall, and R. Langenbach (1994). Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 15, 2859–2866.
von Weymarn, L.B., N.D. Felicia, X. Ding, and S.E. Murphy (1999). N-Nitrosobenzylmethylamine hydroxylation and coumarin 7-hydroxylation: Catalysis by rat esophageal microsomes and cytochrome P450 2A3 and 2A6 enzymes. Chem. Res. Toxicol. 12, 1254–1261.
Kushida, H., K. Fujita, A. Suzuki, M. Yamada, T. Endo, T. Nohmi et al. (2000). Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 21, 1227–1232.
Fujita, K. and T. Kamataki (2001). Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen. 38, 339–346.
Nakajima, M., T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue et al. (1996). Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24, 1212–1217.
Messina, E.S., R.F. Tyndale, and E.M. Sellers (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282, 1608–1614.
Yamazaki, H., K. Inoue, M. Hashimoto, and T. Shimada (1999). Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol. 73, 65–70.
Nakajima, M., T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue et al. (1996). Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 1010–1015.
Hecht, S.S., J.B. Hochalter, P.W. Villata, and S.E. Murphy (2000). 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: Formation of a lung carcinogen precursor. Proc. Natl. Acad. Sci. USA 97, 12493–12497.
Su, T., Z.P. Bao, Q.Y. Zhang, T.J. Smith, J.Y. Hong, and X.X. Ding (2000). Human cytochrome P450 CYP2A13: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 60, 5074–5079.
Gillam, E.M.J., L.M. Notley, H. Cai, J.J. DeVoss, and F.P. Guengerich (2000). Oxidation of indole by cytochrome P450 enzymes. Biochemistry 39, 13817–13824.
Nakamura, K., I.H. Hanna, H. Cai, Y. Nishimura, K.M. Williams, and F.P. Guengerich (2001). Coumarin substrates for cytochrome P450 2D6 fluorescence assays. Anal. Biochem. 292, 280–286.
Lindberg, R.L.P. and M. Negishi (1989). Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature 339, 632–634.
Kitagawa, K., N. Kunugita, M. Kitagawa, and T. Kawamoto (2001). CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem. 276, 17830–17835.
Lewis, D.F.V., M. Dickins, B.G. Lake, P.J. Eddershaw, M.H. Tarbit, and P.S. Goldfarb (1999). Molecular modeling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 133, 1–33.
Lewis, D.F. (2002). Molecular modeling of human cytochrome P450-substrate interactions. Drug Metab. Rev. 34, 55–67.
Lewis, D.F. (2002). Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 32, 305–323.
Lewis, D.F. and J.W. Gorrod (2002). Molecular orbital calculations and nicotine metabolism: A rationale for experimentally observed metabolite ratios. Drug Metabol. Drug Interact. 19, 29–39.
Guengerich, F.P., D.-H. Kim, and M. Iwasaki (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168–179.
Kharasch, E.D., D.C. Hankins, P.J. Baxter, and K.E. Thummel (1998). Single-dose disulfiram does not inhibit CYP2A6 activity. Clin. Pharmacol. Ther. 64, 39–45.
Murphy, S.E., L.M. Johnson, L.M. Losey, S.G. Carmella, and S.S. Hecht (2001). Consumption of watercress fails to alter coumarin metabolism in humans. Drug Metab. Dispos. 29, 786–788.
Draper, A.J., A. Madan, and A. Parkinson (1997). Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys. 341, 47–61.
Zhang, W.J., T. Kilicarslan, R.F. Tyndale, and E.M. Sellers (2001). Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 26, 897–902.
Taavitsainen, P., R. Juvonen, and O. Pelkonen (2001). In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor. trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos. 29, 217–222.
Koenigs, L.L., R.M. Peter, S.J. Thompson, A.E. Rettie, and W.F. Trager (1997). Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos. 25, 1407–1415.
Sellers, E.M., H.L. Kaplan, and R.F. Tyndale (2000). Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68, 35–43.
Koenigs, L.L. and W.F. Trager (1998). Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37, 10047–10061.
Khojasteh-Bakht, S.C., L.L. Koenigs, R.M. Peter, W.F. Trager, and S.D. Nelson (1998). (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26, 701–704.
Wen, X., J.S. Wang, P.J. Neuvonen, and J.T. Backman (2002). Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57, 799–804.
Howard, L.A., E.M. Sellers, and R.F. Tyndale (2002). The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 3, 185–199.
Tan, W., G.F. Chen, D.Y. Xing, C.Y. Song, F.F. Kadlubar, and D.X. Lin (2001). Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer 95, 96–101.
Satarug, S., M.A. Lang, P. Yongvanit, P. Sithithaworn, E. Mairiang, P. Mairiang et al. (1996). Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. Cancer Epidemiol. Biomarkers Prev. 5, 795–800.
Pasanen, M., Z. Rannala, A. Tooming, E.A. Sotaniemi, O. Pelkonen, and A. Rautio (1997). Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 123, 177–184.
Koskela, S., J. Hakkola, J. Hukkanen, O. Pelkonen, M. Sorri, A. Saranen et al. (1999). Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57, 1407–1413.
Oscarson, M., R.A. McLellan, H. Gullsten, J.A.G. Agundez, J. Benitez, A. Rautio et al. (1999). Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett. 460, 321–327.
Fernandez-Salguero, P., S.M.G. Hoffman, S. Cholerton, H. Mohrenweiser, H. Raunio, A. Rautio et al. (1995). A genetic polymorphism in coumarin 7-hydroxylation. Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57, 651–660.
Koskela, S., J. Hakkola, J. Hukkanen, O. Pelkonen, M. Sorri, A. Saranen et al. (1999). Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem. Pharmacol. 57, 1407–1413.
Zhang, X., T. Su, Q.Y. Zhang, J. Gu, M. Caggana, H. Li et al. (2002). Genetic polymorphisms of the human CYP2A13 gene: Identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J. Pharmacol. Exp. Ther. 302, 416–423.
Von Weymarn, L.B. and S.E. Murphy (2003). CYP2A13-catalysed coumarin metabolism: Comparison with CYP2A5 and CYP2A6. Xenobiotica 33, 73–81.
Mimura, M., T. Baba, Y. Yamazaki, S. Ohmori, Y. Inui, F.J. Gonzalez et al. (1993). Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048–1056.
Hukkanen, J., A. Pelkonen, J. Hakkola, and H. Raunio (2002). Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32, 391–411.
van der Hoeven, T.A., D.A. Haugen, and M.J. Coon (1974). Cytochrome P-450 purified to apparent homogeneity from phenobarbital-induced rabbit liver microsomes: Catalytic activity and other properties. Biochem. Biophys. Res. Commun. 60, 569–575.
Imai, Y. and R. Sato (1974). A gel-electrophoretically homogeneous preparation of cytochrome P-450 from liver microsomes of phenobarbital-pretreated rabbits. Biochem. Biophys. Res. Commun. 60, 8–14.
Phillips, I.R., E.A. Shephard, A. Ashworth, and B.R. Rabin (1985). Isolation and sequence of a human cytochrome P-450 cDNA clone. Proc. Natl. Acad. Sci. USA 82, 983–987.
Stresser, D.M. and D. Kupfer (1999). Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab. Dispos. 27, 517–525.
Code, E.L., C.L. Crespi, B.W. Penman, F.J. Gonzalez, T.K.H. Chang, and D.J. Waxman (1997). Human cytochrome P4502B6. Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25, 985–993.
Ekins, S., M. VandenBranden, B.J. Ring, J.S. Gillespie, T.J. Yang, H.V. Gelboin et al. (1998). Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286, 1253–1259.
Imaoka, S., T. Yamada, T. Hiroi, K. Hayashi, T. Sakaki, Y. Yabusaki et al. (1996). Multiple forms of human P450 expressed in Saccharomyces cerevisiae: Systematic characterization and comparison with those of the rat. Biochem. Pharmacol. 51, 1041–1050.
Roy, P., L.J. Yu, C.L. Crespi, and D.J. Waxman (1999). Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos. 27, 655–666.
Gervot, L., B. Rochat, J.C. Gautier, F. Bohnenstengel, H. Kroemer, V. de Berardinis et al. (1999). Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9, 295–306.
Hanna, I.H., J.R. Reed, F.P. Guengerich, and P.F. Hollenberg (2000). Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver. Arch. Biochem. Biophys. 376, 206–216.
Sueyoshi, T., T. Kawamoto, I. Zelko, P. Honkakoski, and M. Neigishi (1999). The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274, 6043–6046.
Jover, R., R. Bort, M.J. Gomezlechon, and J.V. Castell (1998). Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett. 431, 227–230.
Goodwin, B., L.B. Moore, C.M. Stoltz, D.D. McKee, and S.A. Kliewer (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 60, 427–431.
Willson, T.M. and S.A. Kliewer (2002). PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1, 259–266.
Makinen, J., C. Frank, J. Jyrkkarinne, J. Gynther, C. Carlberg, and P. Honkakoski (2002). Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol. Pharmacol. 62, 366–378.
Drocourt, L., J.C. Ourlin, J.M. Pascussi, P. Maurel, and M.J. Vilarem (2002). Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 277, 25125–25132.
Chang, T.K., S.M. Bandiera, and J. Chen (2003). Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab. Dispos. 31, 7–10.
Maglich, J.M., D.J. Parks, L.B. Moore, J.L. Collins, B. Goodwin, A.N. Billin et al. (2003). Identification of a novel human CAR agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278, 17277–17283.
Wang, H., S. Faucette, T. Sueyoshi, R. Moore, S. Ferguson, M. Negishi et al. (2003). A novel distal enhancer module regulated by PXR/CAR is essential for the maximal induction of CYP2B6 gene expression. J. Biol. Chem. 278, 14146–14152.
Miles, J.S., A.W. McLaren, F.J. Gonzalez, and C.R. Wolf (1990). Alternative splicing in the human cytochrome P450IIB6 gene: Use of a cryptic exon within intron 3 and splice acceptor site within exon 4. Nucleic Acids Res. 18, 189.
Zanger, U.M., J. Fischer, K. Klein, and T. Lang (2002). Detection of single nucleotide polymorphisms in CYP2B6 gene. Meth. Enzymol. 357, 45–53.
Lang, T., K. Klein, J. Fischer, A.K. Nussler, P. Neuhaus, U. Hofmann et al. (2001). Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399–415.
Ariyoshi, N., M. Miyazaki, K. Toide, Y. Sawamura, and T. Kamataki (2001). A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281, 1256–1260.
Haugen, D.A. and M.J. Coon (1976). Properties of electrophoretically homogenous phenobarbitalinducible and β-naphthoflavone-inducible forms of liver microsomal cytochrome P-450. J. Biol. Chem. 251, 7929–7939.
Coon, M.J. (1981). The 1980 Bernard B. Brodie Award lecture. Drug metabolism by cytochrome P-450: Progress and perspectives. Drug Metab. Dispos. 9, 1–4.
Guengerich, F.P. (1977). Separation and purification of multiple forms of microsomal cytochrome P-450. Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J. Biol. Chem. 252, 3970–3979.
Lu, A.Y.H. and S.B. West (1978). Reconstituted mammalian mixed-function oxidases: Requirements, specificities and other properties. Pharmacol. Ther. 2, 337–338.
Ekins, S. and S.A. Wrighton (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31, 719–754.
Chang, T.K.H., G.F. Weber, C.L. Crespi, and D.J. Waxman (1993). Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629–5637.
Xie, H.J., U. Yasar, S. Lundgren, L. Griskevicius, Y. Terelius, M. Hassan et al. (2003). Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3, 53–61.
Yanagihara, Y., S. Kariya, M. Ohtani, K. Uchino, T. Aoyama, Y. Yamamura et al. (2001). Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 29, 887–890.
Court, M.H., S.X. Duan, L.M. Hesse, K. Venkatakrishnan, and D.J. Greenblatt (2001). Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94, 110–119.
Heyn, H., R.B. White, and J.C. Stevens (1996). Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab. Dispos. 24, 948–954.
Ko, J.W., Z. Desta, and D.A. Flockhart (1998). Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab. Dispos. 26, 775–778.
Ekins, S., M. VandenBranden, B.J. Ring, and S.A. Wrighton (1997). Examination of purported probes of human CYP2B6. Pharmacogenetics 7, 165–179.
Ariyoshi, N., K. Oguri, N. Koga, H. Yoshimura, and Y. Funae (1995). Metabolism of highly persistent PCB congener, 2, 4,5, 2′,4′,5′-hexachlorobiphenyl, by human CYP2B6. Biochem. Biophys. Res. Commun. 212, 455–460.
Lewis, D.F.V., B.G. Lake, M. Dickins, P.J. Eddershaw, M.H. Tarbit, and P.S. Goldfarb (1999). Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: Evaluation of CYP2B6 substrate characteristics, the cytochrome b 5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 29, 361–393.
Lewis, D.F., S. Modi, and M. Dickins (2001). Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metabol. Drug Interact. 18, 221–242.
Bathelt, C., R.D. Schmid, and J. Pleiss (2002). Regioselectivity of CYP2B6: Homology modeling, molecular dynamics simulation, docking. J. Mol. Model. (Online) 8, 327–335.
Domanski, T.L., K.M. Schultz, F. Roussel, J.C. Stevens, and J.R. Halpert (1999). Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. J. Pharmacol. Exp. Ther. 290, 1141–1147.
Scott, E.E., Y.A. He, M.A. Wester, C.C. Clin, J.R. Halpert, E.F. Johnson, and C.D. Stout (2003). An open conformation of mammalian cytochrome P450 2B4 at 1.6-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 100, 13121–13122.
Guo, Z., S. Raeissi, R.B. White, and J.C. Stevens (1997). Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab. Dispos. 25, 390–393.
Stiborova, M., L. Borek-Dohalska, P. Hodek, J. Mraz, and E. Frei (2002). New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. 403, 41–49.
Rae, J.M., N.V. Soukhova, D.A. Flockhart, and Z. Desta (2002). Triethylenethiophosphoramide is a specific inhibitor of cytochrome P4502B6: Implications for cyclophosphamide metabolism. Drug Metab. Dispos. 30, 525–530.
Kent, U.M., D.E. Mills, R.V. Rajnarayanan, W.L. Alworth, and P.F. Hollenberg (2002). Effect of 17α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: Characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300, 549–558.
Küpfer, A. and R. Preisig (1984). Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26, 753–759.
Wedlund, P.J., W.S. Aslanian, C.B. McAllister, G.R. Wilkinson, and R.A. Branch (1984). Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36, 773–780.
Knodell, R.G., S.D. Hall, G.R. Wilkinson, and F.P. Guengerich (1987). Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241, 1112–1119.
Brian, W.R., P.K. Srivastava, D.R. Umbenhauer, R.S. Lloyd, and F.P. Guengerich (1989). Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993–4999.
Ged, C., D.R. Umbenhauer, T.M. Bellew, R.W. Bork, P.K. Srivastava, N. Shinriki et al. (1988). Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylase. Biochemistry 27, 6929–6940.
Romkes, M., M.B. Faletto, J.A. Blaisdell, J.L. Raucy, and J.A. Goldstein (1991). Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30, 3247–3255.
Wrighton, S.A., J.C. Stevens, G.W. Becker, and M. VandenBranden (1993). Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240–245.
Goldstein, J.A., M.B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J.L. Raucy et al. (1994). Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743–1752.
Nelson, D.R., L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman et al. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6, 1–42.
Dai, D., D.C. Zeldin, J.A. Blaisdell, B. Chanas, S.J. Coulter, B.I. Ghanayem et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597–607.
Klose, T.S., J.A. Blaisdell, and J.A. Goldstein (1999). Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. 13, 289–295.
Bahadur, N., J.B. Leathart, E. Mutch, D. Steimel-Crespi, S.A. Dunn, R. Gilissen et al. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64, 1579–1589.
Gerbal-Chaloin, S., J.M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, J.M. Fabre et al. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29, 242–251.
Soyama, A., Y. Saito, N. Hanioka, N. Murayama, O. Nakajima, N. Katori et al. (2001). Nonsynonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24, 1427–1430.
Rahman, A., K.R. Korzekwa, J. Grogan, F.J. Gonzalez, and J.W. Harris (1994). Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543–5546.
Leo, M.A., J.M. Lasker, J.L. Raucy, C.I. Kim, M. Black, and C.S. Lieber (1989). Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 269, 305–312.
Yamazaki, H., A. Shibata, M. Suzuki, M. Nakajima, N. Shimada, F.P. Guengerich et al. (1999). Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and 3A4 in human liver microsomes. Drug Metab. Dispos. 27, 1260–1266.
Marques-Soares, C., S. Dijols, A.-C. Macherey, M.R. Wester, E.F. Johnson, P.M. Dansette et al. (2003). Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochrome P450 2Cs: Identification of a new high affinity substrate common to those CYP 2C enzymes. Biochemistry 42, 6363–6369.
Wester, M.R., E.F. Johnson, C. Marques-Soares, P. Dansette, D. Mansuy, and C.D. Stout (2003). The structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: Evidence for multiple substrate binding modes. Biochemistry 42, 9335–9345.
Schoch, G.A., J.K. Yano, M.R. Wester, K.J. Griffin, C.D. Stout, and E.F. Johnson (2004). Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem. 279, 9497–9503.
Ha-Duong, N.T., S. Dijols, C. Marques-Soares, C. Minoletti, P.M. Dansette, and D. Mansuy (2001). Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily. J. Med. Chem. 44, 3622–3631.
Ha-Duong, N.T., C. Marques-Soares, S. Dijols, M.A. Sari, P.M. Dansette, and D. Mansuy (2001). Interaction of new sulfaphenazole derivatives with human liver cytochrome P4502Cs: Structural determinants required for selective recognition by CYP2C9 and for inhibition of human CYP2Cs. Arch. Biochem. Biophys. 394, 189–200.
Zilly, W., D.D. Breimer, and E. Richter (1975). Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 9, 219–227.
Umbenhauer, D.R., M.V. Martin, R.S. Lloyd, and F.P. Guengerich (1987). Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 26, 1094–1099.
Knodell, R.G., R.K. Dubey, G.R. Wilkinson, and F.P. Guengerich (1988). Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation. J. Pharmacol. Exp. Ther. 245, 845–849.
Yasumori, T., N. Murayama, Y. Yamazoe, A. Abe, Y. Nogi, T. Fukasawa et al. (1989). Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol. Pharmacol. 35, 443–449.
Srivastava, P.K., C.-H. Yun, P.H. Beaune, C. Ged, and F.P. Guengerich (1991). Separation of human liver tolbutamine hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69–79.
Treluyer, J.M., G. Gueret, G. Cheron, M. Sonnier, and T. Cresteil (1997). Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 7, 441–452.
Brenner, S.S., C. Herrlinger, K. Dilger, T.E. Murdter, U. Hofmann, C. Marx et al. (2003). Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet. 42, 283–292.
Obach, R.S., Q.Y. Zhang, D. Dunbar, and L.S. Kaminsky (2001). Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab. Dispos. 29, 347–352.
Morel, F., P.H. Beaune, D. Ratanasavanh, J.-P. Flinois, C.-S. Yang, F.P. Guengerich et al. (1990). Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur. J. Biochem. 191, 437–444.
Raucy, J.L., L. Mueller, K. Duan, S.W. Allen, S. Strom, and J.M. Lasker (2002). Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther. 302, 475–482.
Gerbal-Chaloin, S., M. Daujat, J.M. Pascussi, L. Pichard-Garcia, M.J. Vilarem, and P. Maurel (2002). Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. 277, 209–217.
Ferguson, S.S., E.L. LeCluyse, M. Negishi, and J.A. Goldstein (2002). Regulation of human CYP2C9 by the constitutive androstane receptor: Discovery of a new distal binding site. Mol. Pharmacol. 62, 737–746.
Pascussi, J.M., S. Gerbal-Chaloin, L. Drocourt, P. Maurel, and M.J. Vilarem (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta 1619, 243–253.
Ibeanu, G.C. and J.A. Goldstein (1995). Transcriptional regulation of human CYP2C genes: Functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 34, 8028–8036.
Scott, J. and P.L. Poffenbarger (1978). Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28, 41–51.
Ohgiya, S., M. Komori, H. Ohi, K. Shiramatsu, N. Shinriki, and T. Kamataki (1992). Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity. Biochem. Int. 27, 1073–1081.
Goldstein, J.A. and S.M.F. Demorais (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4, 285–299.
Inoue, K., H. Yamazaki, K. Imiya, S. Akasaka, F.P. Guengerich, and T. Shimada (1997). Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation in livers of Japanese and Caucasian populations. Pharmacogenetics 7, 103–113.
Lee, C.R., J.A. Goldstein, and J.A. Pieper (2002). Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251–263.
Xie, H.G., H.C. Prasad, R.B. Kim, and C.M. Stein (2002). CYP2C9 allelic variants: Ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257–1270.
Dickmann, L.J., A.E. Rettie, M.B. Kneller, R.B. Kim, A.J. Wood, C.M. Stein et al. (2001). Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60, 382–387.
Shintani, M., I. Ieiri, K. Inoue, K. Mamiya, H. Ninomiya, N. Tashiro et al. (2001). Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin. Pharmacol. Ther. 70, 175–182.
Warner, S.C., C. Finta, and P.G. Zaphiropoulos (2001). Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol. Biol. Evol. 18, 1841–1848.
Yasar, U., S. Lundgren, E. Eliasson, A. Bennet, B. Wiman, U. de Faire et al. (2002). Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun. 299, 25–28.
Miners, J.O. and D.J. Birkett (1998). Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525–538.
Giancarlo, G.M., K. Venkatakrishnan, B.W. Granda, L.L. von Moltke, and D.J. Greenblatt (2001). Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol. 57, 31–36.
Draper, A.J. and B.D. Hammock (2000). Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase. Arch. Biochem. Biophys. 376, 199–205.
McSorley, L.C. and A.K. Daly (2000). Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem. Pharmacol. 60, 517–526.
Lee, C.R., J.A. Pieper, R.F. Frye, A.L. Hinderliter, J.A. Blaisdell, and J.A. Goldstein (2003). Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J. Clin. Pharmacol. 43, 84–91.
Sandberg, M., U. Yasar, P. Stromberg, J.O. Hoog, and E. Eliasson (2002). Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br. J. Clin. Pharmacol. 54, 423–429.
Tang, C., M. Shou, T.H. Rushmore, Q. Mei, P. Sandhu, E.J. Woolf et al. (2001). In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 11, 223–235.
Tang, C.Y., M.G. Shou, and A.D. Rodrigues (2000). Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P4502C9 (CYP2C9) activity. Drug Metab. Dispos. 28, 567–572.
Yamazaki, H., E.M.J. Gillam, M.-S. Dong, W.W. Johnson, F.P. Guengerich, and T. Shimada (1997). Reconstitution of recombinant human cytochrome P450 2C9 and comparison with cytochrome P450 and other forms: Effects of cytochrome P450:P450 and cytochrome P450:b 5 interactions. Arch. Biochem. Biophys. 342, 329–337.
Yamazaki, H., T. Komatsu, K. Ohyama, M. Nakamura, S. Asahi, N. Shimada et al. (2002). Roles of NADPH-P450 reductase and apo-and holo-cytochrome b 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr. Purif. 24, 329–337.
Backes, W.L., C.J. Batie, and G.F. Cawley (1998). Interactions among P450 enzymes when combined in reconstituted systems: Formation of a 2B4-1A2 complex with a high affinity for NADPH cytochrome P450 reductase. Biochemistry 37, 12852–12859.
Hutzler, J.M., D. Kolwankar, M.A. Hummel, and T.S. Tracy (2002). Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: Kinetics and structural requirements. Drug Metab. Dispos. 30, 1194–1200.
Hutzler, J.M., L.C. Wienkers, J.L. Wahlstrom, T.J. Carlson, and T.S. Tracy (2003). Activation of cytochrome P450 2C9-mediated metabolism: Mechanistic evidence in support of kinetic observations. Arch. Biochem. Biophys. 410, 16–24.
Ueng, Y.-F., T. Kuwabara, Y.-J. Chun, and F.P. Guengerich (1997). Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370–381.
Takanashi, K., H. Tainaka, K. Kobayashi, T. Yasumori, M. Hosakawa, and K. Chiba (2000). CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics 10, 95–104.
Yasar, U., E. Eliasson, C. Forslund-Bergengren, G. Tybring, M. Gadd, F. Sjoqvist et al. (2001). The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. 57, 729–735.
Ridderstrom, M., C. Masimirembwa, S. Trump-Kallmeyer, M. Ahlefelt, C. Otter, and T.B. Andersson (2000). Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem. Biophys. Res. Commun. 270, 983–987.
Flanagan, J.U., L.A. McLaughlin, M.J. Paine, M.J. Sutcliffe, G.C. Roberts, and C.R. Wolf (2003). Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Biochem. J. 370, 921–926.
He, M., K.R. Korzekwa, J.P. Jones, A.E. Rettie, and W.F. Trager (1999). Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch. Biochem. Biophys. 372, 16–28.
Mancy, A., S. Dijols, S. Poli, F.P. Guengerich, and D. Mansuy (1997). Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the sub-strate binding topology. Biochemistry 35, 16205–16212.
Mancy, A., P. Broto, S. Dijols, P.M. Dansette, and D. Mansuy (1995). The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34, 10365–10375.
Tsao, C.C., M.R. Wester, B. Ghanayem, S.J. Coulter, B. Chanas, E.F. Johnson et al. (2001). Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 40, 1937–1944.
Jung, F., K.J. Griffin, T.H. Richardson, M. Yang, and E.F. Johnson (1998). Identification of amino acid substitutions that confer a high affinity for sulphaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37, 16270–16279.
Niwa, T., A. Kageyama, K. Kishimoto, Y. Yabusaki, F. Ishibashi, and M. Katagiri (2002). Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19. Drug Metab. Dispos. 30, 931–936.
Melet, A., N. Assrir, P. Jean, M. Pilar Lopez-Garcia, C. Marques-Soares, M. Jaouen et al. (2003). Substrate selectivity of human cytochrome P450 2C9: Importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys. 409, 80–91.
Guengerich, F.P., I.H. Hanna, M.V. Martin, and E.M.J. Gillam (2003). Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry 42, 1245–1253.
Lewis, D.F.V., M. Dickins, R.J. Weaver, P.J. Eddershaw, P.S. Goldfarb, and M.H. Tarbit (1998). Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and site-directed mutagensis experiments in the CYP2C subfamily. Xenobiotica 28, 235–268.
Afzelius, L., I. Zamora, M. Ridderstrom, T.B. Andersson, A. Karlen, and C.M. Masimirembwa (2001). Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol. Pharmacol. 59, 909–919.
Ridderström, M., I. Zamora, O. Fjellström, and T.B. Andersson (2001). Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 44, 4072–4081.
de Groot, M.J., A.A. Alex, and B.C. Jones (2002). Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem. 45, 1983–1993.
Williams, P.A., J. Cosme, A. Ward, H.C. Angove, D. Matak Vinkovic, and H. Jhoti (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464–468.
Wester, M.R., C.D. Stout, G. Schoch, J.K. Yano, and E.F. Johnson (2003). Crystallization of human P450 2C9. FASEB J. 17, A609.
Veronese, M.E., J.O. Miners, D. Randles, D. Gregov, and D.J. Birkett (1990). Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin. Pharmacol. Ther. 47, 403–411.
Wen, X., J.S. Wang, J.T. Backman, J. Laitila, and P.J. Neuvonen (2002). Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. 30, 631–635.
Wen, X., J.S. Wang, K.T. Kivisto, P.J. Neuvonen, and J.T. Backman (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br. J. Clin. Pharmacol. 52, 547–553.
Zhang, Z.Y., J. Kerr, R.S. Wexler, H.Y. Li, A.J. Robinson, P.P. Harlow et al. (1997). Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. Thromb. Res. 88, 389–398.
Beaune, P., P.M. Dansette, D. Mansuy, L. Kiffel, M. Finck, C. Amar et al. (1987). Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. USA 84, 551–555.
Dansette, P.M., D.C. Thang, H. El Amri, and D. Mansuy (1992). Evidence for thiophene-S-oxide as a primary reactive metabolite of thiophene in vivo: Formation of a dihydrothiophene sulfoxide mercapturic acid. Biochem. Biophys. Res. Commun. 186, 1624–1630.
Beaune, P., D. Pessayre, P. Dansette, D. Mansuy, and M. Manns (1994). Autoantibodies against cytochromes P450: Role in human diseases. Adv. Pharmacol. 30, 199–245.
Carlile, D.J., N. Hakooz, M.K. Bayliss, and J.B. Houston (1999). Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol. 47, 625–635.
Goldstein, J.A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349–355.
Kaminsky, L.S. and Z.Y. Zhang (1997). Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67–74.
Yamazaki, H. and T. Shimada (1997). Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem. Pharmacol. 54, 1195–1203.
Kunze, K.L., A.C. Eddy, M. Gibaldi, and W.F. Trager (1991). Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3, 24–29.
Rettie, A.E., K.R. Korzekwa, K.L. Kunze, R.F. Lawrence, A.C. Eddy, T. Aoyama et al. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54–59.
Rettie, A.E., L.C. Wienkers, F.J. Gonzalez, W.F. Trager, and K.R. Korzekwa (1994). Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39–42.
Yamazaki, H., K. Inoue, and T. Shimada (1998). Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28, 103–115.
Scordo, M.G., V. Pengo, E. Spina, M.L. Dahl, M. Gusella, and R. Padrini (2002). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702–710.
Higashi, M.K., D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinouanprachanh, F.M. Farin et al. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J. Am. Med. Assoc. 287, 1690–1698.
Tassies, D., C. Freire, J. Pijoan, S. Maragall, J. Monteagudo, A. Ordinas et al. (2002). Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 87, 1185–1191.
Gentry, P.R., C.E. Hack, L. Haber, A. Maier, and H.J. Clewell, III (2002). An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Toxicol. Sci. 70, 120–139.
Lee, C.R., J.A. Pieper, A.L. Hinderliter, J.A. Blaisdell, and J.A. Goldstein (2002). Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin. Pharmacol. Ther. 72, 562–571.
Shon, J.H., Y.R. Yoon, K.A. Kim, Y.C. Lim, K.J. Lee, J.Y. Park et al. (2002). Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12, 111–119.
Miners, J. (2002). CYP2C9 polymorphism: Impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 12, 91–92.
Hallberg, P., J. Karlsson, L. Kurland, L. Lind, T. Kahan, K. Malmqvist et al. (2002). The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J. Hypertens. 20, 2089–2093.
Yun, C.-H., H.S. Lee, H. Lee, J.K. Rho, H.G. Jeong, and F.P. Guengerich (1995). Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: Role of cytochrome P450 3A(4) in formation of the active metabolite EXP 3174. Drug Metab. Dispos. 23, 285–289.
Stearns, R.A., P.K. Chakravarty, R. Chen, and S.H.L. Chiu (1995). Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207–215.
Aithal, G.P., C.P. Day, J.B. Leathart, and A.K. Daly (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10, 511–518.
Martinez, C., E. Garcia-Martin, J.M. Ladero, J. Sastre, F. Garcia-Gamito, M. Diaz-Rubio et al. (2001). Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22, 1323–1326.
Yasar, U., E. Eliasson, and M.L. Dahl (2002). Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 23, 665; author reply 667–668.
Garcia-Martin, E., C. Martinez, J.M. Ladero, F.J. Gamito, A. Rodriguez-Lescure, and J.A. Agundez (2002). Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett. 180, 41–46.
Minoletti, C., S. Dijols, P.M. Dansette, and D. Mansuy (1999). Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: Application to the design of a specific substrate of CYP 2C18. Biochemistry 38, 7828–7836.
Richardson, T.H., K.J. Griffin, F. Jung, J.L. Raucy, and E.F. Johnson (1997). Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C5. Arch. Biochem. Biophys. 338, 157–164.
Zaphiropoulos, P.G. (1999). RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Nucleic Acids Res. 27, 2585–2590.
Mace, K., E.D. Bowman, P. Vautravers, P.G. Shields, C.C. Harris, and A.M. Pfeifer (1998). Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur. J. Cancer 34, 914–920.
Mizugaki, M., M. Hiratsuka, Y. Agatsuma, Y. Matsubara, K. Fujii, S. Kure et al. (2000). Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase chain reaction. J. Pharm. Pharmacol. 52, 199–205.
Zhu-Ge, J., Y.N. Yu, Y.L. Qian, and X. Li (2002). Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing. World J. Gastroenterol. 8, 888–892.
Payne, V.A., Y.T. Chang, and G.H. Loew (1999). Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes. Proteins 37, 204–217.
Meier, U.T. and U.A. Meyer (1987). Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry 26, 8466–8474.
Wilkinson, G.R., F.P. Guengerich, and R.A. Branch (1989). Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53–76.
Yasumori, T., N. Murayama, Y. Yamazoe, and R. Kato (1990). Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin. Pharmacol. Ther. 47, 313–322.
Kim, M.J., J.S. Bertino, Jr., A. Gaedigk, Y. Zhang, E.M. Sellers, and A.N. Nafziger (2002). Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin. Pharmacol. Ther. 72, 192–199.
Zhou, H.H., L.B. Anthony, A.J. Wood, and G.R. Wilkinson (1990). Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br. J. Clin. Pharmacol. 30, 471–475.
Blaisdell, J., H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter, B. Chanas et al. (2002). Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703–711.
Desta, Z., X. Zhao, J.G. Shin, and D.A. Flockhart (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913–958.
de Morais, S.M.F., G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, and J.A. Goldstein (1994). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419–15422.
Ferguson, R.J., S.M. De Morais, S. Benhamou, C. Bouchardy, J. Blaisdell, G. Ibeanu et al. (1998). A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356–361.
Wester, M.R., J.M. Lasker, E.F. Johnson, and J.L. Raucy (2000). CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab. Dispos. 28, 354–359.
Kaminsky, L.S., D.A. Dunbar, P.P. Wang, P. Beaune, D. Larrey, F.P. Guengerich et al. (1984). Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. Drug Metab. Dispos. 12, 470–477.
Wienkers, L.C., C.J. Wurden, E. Storch, K.L. Kunze, A.E. Rettie, and W.F. Trager (1996). Formation of (R)-8-hydroxywarfarin in human liver microsomes: A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24, 610–614.
Zhang, W., Y. Ramamoorthy, R.F. Tyndale, S.D. Glick, I.M. Maisonneuve, M.E. Kuehne et al. (2002). Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metab. Dispos. 30, 663–669.
Ando, Y., E. Fuse, and W.D. Figg (2002). Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 8, 1964–1973.
Yamazaki, H. and T. Shimada (1997). Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 346, 161–169.
Kappers, W.A., R.J. Edwards, S. Murray, and A.R. Boobis (2001). Diazinon is activated by CYP2C19 in human liver. Toxicol. Appl. Pharmacol. 177, 68–76.
Ibeanu, G.C., B.I. Ghanayem, P. Linko, L. Li, L.G. Pedersen, and J.A. Goldstein (1996). Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J. Biol. Chem. 271, 12496–12501.
Furuta, T., N. Shirai, M. Takashima, F. Xiao, H. Hanai, K. Nakagawa et al. (2001). Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11, 341–348.
Furuta, T., N. Shirai, F. Watanabe, S. Honda, K. Takeuchi, T. Iida et al. (2002). Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 72, 453–460.
Kita, T., T. Sakaeda, N. Aoyama, T. Sakai, Y. Kawahara, M. Kasuga et al. (2002). Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: Pharmacokinetic considerations. Biol. Pharm. Bull. 25, 923–927.
Kita, T., T. Sakaeda, T. Baba, N. Aoyama, M. Kakumoto, Y. Kurimoto et al. (2003). Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol. Pharm. Bull. 26, 386–390.
Chau, T.K., S. Marakami, B. Kawai, K. Nasu, T. Kubota, and A. Ohnishi (2000). Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci. 67, 1719–1724.
Roddam, P.L., S. Rollinson, E. Kane, E. Roman, A. Moorman, R. Cartwright et al. (2000). Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10, 605–615.
Treluyer, J.M., E. Jacqz-Aigrain, F. Alvarez, and T. Cresteil (1991). Expression of CYP2D6 in developing human liver. Eur. J. Biochem. 202, 583–588.
Lo Guidice, J.M., D. Marez, N. Sabbagh, M. LegrandAndreoletti, C. Spire, E. Alcaïde et al. (1997). Evidence for CYP2D6 expression in human lung. Biochem. Biophys. Res. Commun. 241, 79–85.
Siegle, I., P. Fritz, K. Eckhardt, U.M. Zanger, and M. Eichelbaum (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11, 237–245.
Miksys, S., Y. Rao, E. Hoffmann, D.C. Mash, and R.F. Tyndale (2002). Regional and cellular expression of CYP2D6 in human brain: Higher levels in alcoholics. J. Neurochem. 82, 1376–1387.
Idle, J.R., A. Mahgoub, R. Lancaster, and R.L. Smith (1978). Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci. 22, 979–984.
Alvan, G., C. von Bahr, P. Seideman, and F. Sjoqvist (1982). High plasma concentrations of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet i, 333.
Evans, D.A.P., D. Harmer, D.Y. Downham, E.J. Whibley, J.R. Idle, J. Ritchie et al. (1983). The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J. Med. Genet. 20, 321–329.
Skoda, R.C., F.J. Gonzalez, A. Demierre, and U.A. Meyer (1988). Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA 85, 5240–5243.
Gaedigk, A., R.R. Gotschall, N.S. Forbes, S.D. Simon, G.L. Kearns, and J.S. Leeder (1999). Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669–682.
Raimundo, S., J. Fischer, M. Eichelbaum, E.U. Griese, M. Schwab, and U.M. Zanger (2000). Elucidation of the genetic basis of the common ‘intermediate metabolizer’ phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10, 577–581.
Zanger, U.M., J. Fischer, S. Raimundo, T. Stuven, B.O. Evert, M. Schwab et al. (2001). Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573–585.
Tyndale, R., T. Aoyama, F. Broly, T. Matsunaga, T. Inaba, W. Kalow et al. (1991). Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype. Pharmacogenetics 1, 26–32.
Yu, A., B.M. Kneller, A.E. Rettie, and R.L. Haining (2002). Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 303, 1291–1300.
Fletcher, B., D.B. Goldstein, A.L. Bradman, M.E. Weale, N. Bradman, and M.G. Thomas (2003). High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics 81, 166–174.
Dahl, M.L., I. Johansson, L. Bertilsson, M. Ingelman-Sundberg, and F. Sjoqvist (1995). Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516–520.
Lundqvist, E., I. Johansson, and M. Ingelman-Sundberg (1999). Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226, 327–338.
Lovlie, R., A.K. Daly, A. Molven, J.R. Idle, and V.M. Steen (1996). Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392, 30–34.
Köhnke, M.D., E.U. Griese, D. Stosser, I. Gaertner, and G. Barth (2002). Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35, 116–118.
Guengerich, F.P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611–650.
Wolff, T., L.M. Distlerath, M.T. Worthington, J.D. Groopman, G.J. Hammons, F.F. Kadlubar et al. (1985). Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 45, 2116–2122.
Islam, S.A., C.R. Wolf, M.S. Lennard, and M.J.E. Sternberg (1991). A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12, 2211–2219.
Strobl, G.R., S. von Kruedener, J. Stöckigt, F.P. Guengerich, and T. Wolff (1993). Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies. J. Med. Chem. 36, 1136–1145.
Koymans, L., N.P.E. Vermeulen, S.A.B.E. van Acker, J.M. te Koppele, J.J.P. Heykants, K. Lavrijsen et al. (1992). A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5, 211–219.
de Groot, M.J., G.J. Bijloo, B.J. Martens, F.A.A. van Acker, and N.P.E. Vermeulen (1997). A refined substrate model for human cytochrome P450 2D6. Chem. Res. Toxicol. 10, 41–48.
Upthagrove, A.L. and W.L. Nelson (2001). Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol derivatives. Preparation, identification of metabolite regioisomers, and metabolism by CYP2D6. Drug Metab. Dispos. 29, 1377–1388.
Miller, G.P., I.H. Hanna, Y. Nishimura, and F.P. Guengerich (2001). Oxidation of phenylethylamine derivatives by cytochrome P450 2D6: The issue of substrate protonation in binding and catalysis. Biochemistry 40, 14215–14223.
Grace, J.M., M.T. Kinter, and T.L. Macdonald (1994). Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7, 286–290.
Niwa, T., Y. Yabusaki, K. Honma, N. Matsuo, K. Tatsuta, F. Ishibashi et al. (1998). Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 28, 539–547.
Hiroi, T., T. Chow, S. Imaoka, and Y. Funae (2000). Catalytic specificity of each CYP2D isoform in rat and human. Abstracts, 13th Int. Sympos. Microsomes and Drug Oxidations, 10–14 July, Stresa: p. 113.
Guengerich, F.P., G.P. Miller, I.H. Hanna, M.V. Martin, S. Léger, C. Black et al. (2002). Diversity in the oxidation of substrates by cytochrome P450 2D6. Lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41, 11025–11034.
Martinez, C., J.A. Agundez, G. Gervasini, R. Martin, and J. Benitez (1997). Tryptamine: A possible endogenous substrate for CYP2D6. Pharmacogenetics 7, 85–93.
Yu, A.M., J.R. Idle, T. Herraiz, A. Küpfer, and F.J. Gonzalez (2003). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13, 307–319.
Yu, A.M., J.R. Idle, L.G. Byrd, K.W. Krausz, A. Kupfer, and F.J. Gonzalez (2003). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13, 173–181.
Koymans, L., N.P.E. Vermeulen, A. Baarslag, and G. Donne-Op den Kelder (1993). A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J. Comput. Aided Mol. Des. 7, 281–289.
de Groot, M.J., N.P.E. Vermeulen, J.D. Kramer, F.A.A. van Acker, and G.M. Donné-Op den Kelder (1996). A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structure of P450 101, P450 102, and P450 108. Chem. Res. Toxicol. 9, 1079–1091.
Lewis, D.F.V., P.J. Eddershaw, P.S. Goldfarb, and M.H. Tarbit (1997). Molecular modeling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27, 319–340.
Modi, S., M.J. Paine, M.J. Sutcliffe, L.Y. Lian, W.U. Primrose, C.R. Wolf et al. Roberts (1996). A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35, 4540–4550.
de Groot, M.J., M.J. Ackland, V.A. Horne, A.A. Alex, and B.C. Jones (1999). A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42, 4062–4070.
Kirton, S.B., C.A. Kemp, N.P. Tomkinson, S. St.-Gallay, and M.J. Sutcliffe (2002). Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 49, 216–231.
Venhorst, J., A.M. ter Laak, J.N. Commandeur, Y. Funae, T. Hiroi, and N.P. Vermeulen (2003). Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J. Med. Chem. 46, 74–86.
Crespi, C.L., D.T. Steimel, B.W. Penman, K.R. Korzekwa, P. Fernandez-Salguero, J.T.M. Buters et al. (1995). Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics 5, 234–243.
Ellis, S.W., K. Rowland, M.J. Ackland, E. Rekka, A.P. Simula, M.S. Lennard et al. (1996). Influence of amino acid residue 374 of cytochrome P-450 2D6(CYP2D6) on the regio-and enantio-selective metabolism of metoprolol. Biochem. J. 316, 647–654.
Ellis, S.W., G.P. Hayhurst, G. Smith, T. Lightfoot, M.M.S. Wong, A.P. Simula et al. (1995). Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 270, 29055–29058.
Hanna, I.H., M.-S. Kim, and F.P. Guengerich (2001). Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation. The role of aspartate 301 in structural integrity. Arch. Biochem. Biophys. 393, 255–261.
Paine, M.J., L.A. McLaughlin, J.U. Flanagan, C.A. Kemp, M.J. Sutcliffe, G.C. Roberts et al. (2003). Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J. Biol. Chem. 278, 4021–4027.
Smith, G., S. Modi, I. Pillai, L.-Y. Lian, M.J. Sutcliffe, M.P. Pritchard et al. (1998). Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: Design and construction of a mutant with testosterone hydroxylase activity. Biochem. J. 331, 783–792.
Wiseman, H. and D.F. Lewis (1996). The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: Potential importance to its proposed anti-carcinogenic/carcinogenic actions. Carcinogenesis 17, 1357–1360.
Lightfoot, T., S.W. Ellis, J. Mahling, M.J. Ackland, F.E. Blaney, G.J. Bijloo et al. (2000). Regioselectivity hydroxylation of debrisoquine by cytochrome P4502D6: Implications for active site modelling. Xenobiotica 30, 219–233.
Ellis, S.W., G.P. Hayhurst, T. Lightfoot, G. Smith, J. Harlow, K. Rowland-Yeo et al. (2000). Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6. Biochem. J. 345, 565–571.
Hayhurst, G.P., J. Harlow, J. Chowdry, E. Gross, E. Hilton, M.S. Lennard et al. (2001). Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. Biochem. J. 355, 373–379.
Ramamoorthy, Y., R.F. Tyndale, and E.M. Sellers (2001). Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11, 477–487.
Modi, S., D.E. Gilham, M.J. Sutcliffe, L.-Y. Lian, W.U. Primrose, C.R. Wolf et al. (1997). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: Allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36, 4461–4470.
Hanna, I.H., J.A. Krauser, H. Cai, M.-S. Kim, and F.P. Guengerich (2001). Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. J. Biol. Chem. 276, 39553–39561.
Guengerich, F.P., G.P. Miller, I.H. Hanna, H. Sato, and M.V. Martin (2002). Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. J. Biol. Chem. 277, 33711–33719.
Fukuda, T., Y. Nishida, S. Imaoka, T. Hiroi, M. Naohara, Y. Funae et al. (2000). The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380, 303–308.
Otton, S.V., T. Inaba, and W. Kalow (1984). Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 34, 73–80.
Palamanda, J.R., C.N. Casciano, L.A. Norton, R.P. Clement, L.V. Favreau, C.C. Lin et al. (2001). Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine. Drug Metab. Dispos. 29, 863–867.
Oates, N.S., R.R. Shah, J.R. Idle, and R.L. Smith (1983). Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin. Pharmacol. Ther. 34, 827–834.
Oates, N.S., R.R. Shah, P.L. Drury, J.R. Idle, and R.L. Smith (1982). Captopril-induced agranulocytosis associated with an impairment of debrisoquine hydroxylation. Br. J. Pharmacol. 14, 601P.
Rau, T., R. Heide, K. Bergmann, H. Wuttke, U. Werner, N. Feifel, and T. Eschenhagen (2002). Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12, 465–472.
Dorne, J.L., K. Walton, W. Slob, and A.G. Renwick (2002). Human variability in polymorphic CYP2D6 metabolism: Is the kinetic default uncertainty factor adequate? Food Chem. Toxicol. 40, 1633–1656.
Chou, W.H., F.X. Yan, J. de Leon, J. Barnhill, T. Rogers, M. Cronin et al. (2000). Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 20, 246–251.
Dahl, M.L. (2002). Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing?. Clin. Pharmacokinet. 41, 453–470.
Scolnick, E.M. (2002). Discovery and development of antidepressants: A perspective from a pharmaceutical discovery company. Biol. Psychiatry 52, 154–156.
Caporaso, N., R.B. Hayes, M. Dosemeci, R. Hoover, R. Ayesh, M. Hetzel et al. (1989). Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 49, 3675–3679.
Bouchardy, C., S. Benhamou, and P. Dayer (1996). The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 56, 251–253.
Shaw, G.L., R.T. Falk, J.N. Frame, B. Weiffenbach, J.V. Nesbitt, H.I. Pass et al. (1998). Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 7, 215–219.
Rostami-Hodjegan, A., M.S. Lennard, H.F. Woods, and G.T. Tucker (1998). Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s desease. Pharmacogenetics 8, 227–238.
Legrand-Andreoletti, M., I. Stucker, D. Marez, P. Galais, J. Cosme, N. Sabbagh et al. (1998). Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 8, 7–14.
Christensen, P.M., P.C. Gøtzsche, and K. Brøsen (1997). The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis. Eur. J. Clin. Pharmacol. 51, 389–393.
Fleming, C.M., A. Kaisary, G.R. Wilkinson, P. Smith, and R.A. Branch (1992). The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 2, 128–134.
Worrall, S.F., M. Corrigan, A. High, D. Starr, C. Matthias, C.R. Wolf et al. (1998). Susceptibility and outcome in oral cancer: Preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 8, 433–439.
Barbeau, A., M. Roy, S. Paris, T. Cloutier, L. Plasse, and J. Poirier (1985). Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet ii, 1213–1215.
Armstrong, M., A.K. Daly, S. Cholerton, D.N. Bateman, and J.R. Idle (1992). Mutant debrisoquine hydroxylation genes in Parkinson’s disease. Lancet 339, 1017–1018.
Harhangi, B.S., B.A. Oostra, P. Heutink, C.M. van Duijn, A. Hofman, and M.M. Breteler (2001). CYP2D6 polymorphism in Parkinson’s disease: The Rotterdam Study. Mov. Disord. 16, 290–293.
Allam, M.F., A. Serrano del Castillo, and R. Fernandez-Crehuet Navajas (2002). Smoking and Parkinson’s disease: Explanatory hypothesis. Int. J. Neurosci. 112, 851–854.
Zanger, U.M., H.P. Hauri, J. Loeper, J.C. Homberg, and U.A. Meyer (1988). Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type II. Proc. Natl. Acad. Sci. USA 85, 8256–2860.
Manns, M.P. (1991). Cytochrome P450 enzymes as human autoantigens. Immunol. Res. 10, 503–507.
Manns, M.P., K.J. Griffin, K.F. Sullivan, and E.F. Johnson (1991). LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J. Clin. Invest. 88, 1370–1378.
Loeper, J., V. Descatoire, M. Maurice, P. Beaune, J. Belghiti, D. Houssin et al. (1993). Cytochromes P-450 in human hepatocyte plasma membrane: Recognition by several autoantibodies. Gastroenterology 104, 203–216.
Vergani, D. (2000). LKM antibody: Getting in some target practice. Gut 46, 449–450.
Vitozzi, S., P. Lapierre, I. Djilali-Saiah, and F. Alvarez (2002). Autoantibody detection in type 2 autoimmune hepatitis using a chimera recombinant protein. J. Immunol. Meth. 262, 103–110.
Nolte, W., F. Polzien, B. Sattler, G. Ramadori, and H. Hartmann (1995). Recurrent episodes of acute hepatitis associated with LKM-1 (cytochrome P450 2D6) antibodies in identical twin brothers. J. Hepatol. 23, 734–739.
Orme-Johnson, W.H. and D.M. Ziegler (1965). Alcohol mixed function oxidase activity of mammalian liver micoromes. Biochem. Biophys. Res. Commun. 21, 78–82.
Lieber, C.S. and L.M. DeCarli (1970). Hepatic microsomal ethanol oxidizing system: In vitro chracteristics and adaptive properties in vivo. J. Biol. Chem. 245, 2505–2512.
Teschke, R., Y. Hasumura, and C.S. Lieber (1974). Hepatic microsomal ethanol-oxidizing system: Solubilization, isolation and characterization. Arch. Biochem. Biophys. 163, 404–415.
Ryan, D.E., L. Ramanathan, S. Iida, P.E. Thomas, M. Haniu, J.E. Shively et al. (1985). Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J. Biol. Chem. 260, 6385–6393.
Wrighton, S.A., P.E. Thomas, D.E. Ryan, and W. Levin (1987). Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch. Biochem. Biophys. 258, 292–297.
Umeno, M., O.W. McBride, C.-S. Yang, H.V. Gelboin, and F.J. Gonzalez (1988). Human ethanol-inducible P450IIE1: Complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27, 9006–9013.
Guengerich, F.P. and C.G. Turvy (1991). Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256, 1189–1194.
Vieira, I., M. Sonnier, and T. Cresteil (1996). Developmental expression of CYP2E1 in the human liver: Hypermethylation control of gene expression during the neonatal period. Eur. J. Biochem. 238, 476–483.
Ding, X. and L.S. Kaminsky (2003). Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43, 149–173.
Warner, M. and J.A. Gustafsson (1994). Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. USA 91, 1019–1023.
Upadhya, S.C., P.S. Tirumalai, M.R. Boyd, T. Mori, and V. Ravindranath (2000). Cytochrome P4502E (CYP2E) in brain: Constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch. Biochem. Biophys. 373, 23–34.
Kazakoff, K., P. Iversen, T. Lawson, J. Baron, F.P. Guengerich, and P. Pour (1994). Involvement of cytochrome P450 2E1-like isoform in the activation of N-nitrosobis(2-oxopropyl)amine in the rat nasal mucosa. Eur. J. Cancer 30B, 179–185.
Norton, I.D., M.V. Apte, P.S. Haber, G.W. McCaughan, R.C. Pirola, and J.S. Wilson (1998). Cytochrome P4502E1 is present in rat pancreas and is induced by chronic ethanol administration. Gut 42, 426–430.
Larson, J.R., M.J. Coon, and T.D. Porter (1991). Purification and properties of a shortened form of cytochrome P-450 2E1: Deletion of the NH2-terminal membrane-insertion signal peptide does not alter the catalytic activities. Proc. Natl. Acad. Sci. USA 88, 9141–9145.
Gillam, E.M.J., Z. Guo, and F.P. Guengerich (1994). Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch. Biochem. Biophys. 312, 59–66.
Neve, E.P.A. and M. Ingelman-Sundberg (1999). A soluble NH2-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria. FEBS Lett. 460, 309–314.
Robin, M.A., H.K. Anandatheerthavarada, J.K. Fang, M. Cudic, L. Otvos, and N.G. Avadhani (2001). Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N-terminus and requires mitochondrial specific electron transfer proteins for activity. J. Biol. Chem. 276, 24680–24689.
Neve, E.P. and M. Ingelman-Sundberg (2000). Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. J. Biol. Chem. 275, 17130–17135.
Thomas, P.E., S. Bandiera, S.L. Maines, D.E. Ryan, and W. Levin (1987). Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes. Biochemistry 26, 2280–2289.
Koop, D.R. and D.J. Tierney (1990). Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. BioEssays 12, 429–435.
Ueno, T. and F.J. Gonzalez (1990). Transcriptional control of the rat hepatic CYP2E1 gene. Mol. Cell Biol. 10, 4495–4505.
Woodcroft, K.J. and R.F. Novak (1999). The role of phosphatidylinositol 3-kinase, Src kinase, and protein kinase A signaling pathways in insulin and glucagon regulation of CYP2E1 expression. Biochem. Biophys. Res. Commun. 266, 304–307.
Siewert, E., R. Bort, R. Kluge, P.C. Heinrich, J. Castell, and R. Jover (2000). Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32, 49–55.
Lagadic-Gossmann, D., C. Lerche, M. Rissel, F. Joannard, M. Galisteo, A. Guillouzo et al. (2000). The induction of the human hepatic CYP2E1 gene by interleukin 4 is transcriptional and regulated by protein kinase C. Cell Biol. Toxicol. 16, 221–233.
Hakkola, J., Y. Hu, and M. Ingelman-Sundberg (2003). Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J. Pharmacol. Exp. Ther. 304, 1048–1054.
Kim, S.G. and R.F. Novak (1990). Induction of rat hepatic P450IIE1 (CYP 2E1) by pyridine: Evidence for a role of protein synthesis in the absence of transcriptional activation. Biochem. Biophys. Res. Commun. 166, 1072–1079.
Kocarek, T.A., R.C. Zangar, and R.F. Novak (2000). Post-transcriptional regulation of rat CYP2E1 expression: Role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Arch. Biochem. Biophys. 376, 180–190.
Roberts, B.J., B.J. Song, Y. Soh, S.S. Park, and S.E. Shoaf (1995). Ethanol induces CYP2E1 by protein stabilization: Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J. Biol. Chem. 270, 29632–29635.
Yang, M.X. and A.I. Cederbaum (1997). Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. Arch. Biochem. Biophys. 341, 25–33.
Emery, M.g., C. Jubert, K.E. Thummel, and E.D. Kharasch (1999). Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J. Pharmacol. Exp. Ther. 291, 213–219.
Chien, J.Y., K.E. Thummel, and J.T. Slattery (1997). Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175.
Watanabe, J., S. Hayashi, and K. Kawajiri (1994). Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem. (Tokyo) 116, 321–326.
Fairbrother, K.S., J. Grove, I. de Waziers, D.T. Steimel, C.P. Day, C.L. Crespi et al. (1998). Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 8, 543–552.
Fritsche, E., G.S. Pittman, and D.A. Bell (2000). Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mutat. Res. 432, 1–5.
Powell, H., N.R. Kitteringham, M. Pirmohamed, D.A. Smith, and B.K. Park (1998). Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. Pharmacogenetics 8, 411–421.
Inoue, K., H. Yamazaki, and T. Shimada (2000). Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. Arch. Toxicol. 74, 372–378.
O’Shea, D., S.N. Davis, R.B. Kim, and G.R. Wilkinson (1994). Effect of fasting and obesity in humans on the 6-hydroxylation of chloroxazone: A putative probe of CYP2E1 activity. Clin. Pharmacol. Ther. 56, 359–367.
Koop, D.R. and J.P. Casazza (1985). Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J. Biol. Chem. 260, 13607–13612.
Bondoc, F.Y., Z. Bao, W.Y. Hu, F.J. Gonzalez, Y. Wang, C.S. Yang et al. (1999). Acetone catabolism by cytochrome P450 2E1: Studies with CYP2E1-null mice. Biochem. Pharmacol. 105, 83–88.
Kashiwagi, T., S. Ji, J.J. Lemasters, and R.G. Thurman (1982). Rates of alcohol dehydrogenase-dependent ethanol metabolism in periportal and pericentral regions of the perfused rat liver. Mol. Pharmacol. 21, 438–443.
Kono, H., B.U. Bradford, M. Yin, K.K. Sulik, D.R. Koop, J.M. Peters et al. (1999). CYP2E1 is not involved in early alcohol-induced liver injury. Am. J. Physiol. 277, G1259–G1267.
Terelius, Y., C. Norsten-Höög, T. Cronholm, and M. Ingelman-Sundberg (1991). Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1). Biochem. Biophys. Res. Commun. 179, 689–694.
Kunitoh, S., S. Imaoka, T. Hiroi, Y. Yabusaki, T. Monna, and Y. Funae (1997). Acetaldehyde as well as ethanol is metabolized by human CYP2E1. J. Pharmacol. Exp. Ther. 280, 527–532.
Bell-Parikh, L.C. and F.P. Guengerich (1999). Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J. Biol. Chem. 274, 23833–23840.
Tassaneeyakul, W., M.E. Veronese, D.J. Birkett, F.J. Gonzalez, and J.O. Miners (1993). Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 46, 1975–1981.
Peter, R., R.G. Böcker, P.H. Beaune, M. Iwasaki, F.P. Guengerich, and C.-S. Yang (1990). Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem. Res. Toxicol. 3, 566–573.
Yamazaki, H., Z. Guo, and F.P. Guengerich (1995). Selectivity of cytochrome P450 2E1 in chlorzoxazone 6-hydroxylation. Drug Metab. Dispos. 23, 438–440.
Preussmann, R. and B.W. Stewart (1984). N-Nitroso carcinogens. In C.E. Searle (ed.), Chemical Carcinogens, Vol. 2. American Chemical Society, Washington, D. C., pp. 643–828.
Argus, M.F., J.C. Arcos, K.M. Pastor, B.C. Wu, and N. Venkatesan (1976). Dimethylnitrosaminedemethylase: Absence of increased enzyme catabolism and multiplicity of effector sites in repression. Hemoprotein involvement. Chem. Biol. Interact. 13, 127–140.
Lake, B.G., C.E. Heading, J.C. Phillips, S.D. Gangolli, and A.G. Lloyd (1974). Some studies on the metabolism in vitro of dimethylnitrosamine by rat liver. Biochem. Soc. Transact. 2, 610–612.
Levin, W., P.E. Thomas, N. Oldfield, and D.E. Ryan (1986). N-Demethylation of N-nitrosodimethylamine catalyzed by purified rat hepatic microsomal cytochrome P-450: Isozyme specificity and role of cytochrome b 5. Arch. Biochem. Biophys. 248, 158–165.
Wrighton, S.A., P.E. Thomas, D.T. Molowa, M. Haniu, J.E. Shively, S.L. Maines et al. (1986). Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry 25, 6731–6735.
Bastien, M.C. and J.P. Villeneuve (1998). Characterization of cytochrome P450 2E1 activity by the [14C]nitrosodimethylamine breath test. Can. J. Physiol. Pharmacol. 76, 756–763.
Raucy, J.L., J.C. Kraner, and J.M. Lasker (1993). Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit. Rev. Toxicol. 23, 1–20.
Hong, J.Y., C.S. Yang, M. Lee, Y.Y. Wang, W. Huang, Y. Tan et al. (1997). Role of cytochromes P450 in the metabolism of methyl tert-butyl ether in human livers. Arch. Toxicol. 71, 266–269.
Wang, H., B. Chanas, and B.I. Ghanayem (2002). Cytochrome P450 2E1 (CYP2E1) is essential for acrylonitrile metabolism to cyanide: Comparative studies using CYP2E1-null and wild-type mice. Drug Metab. Dispos. 30, 911–917.
Hoffler, U., H.A. El-Masri, and B.I. Ghanayem (2003). Cytochrome P450 2E1 (CYP2E1) is the principal enzyme responsible for urethane metabolism: Comparative studies using CYP2E1-null and wildtype mice. J. Pharmacol. Exp. Ther. 305, 557–564.
Clarke, S.E., S.J. Baldwin, J.C. Bloomer, A.D. Ayrton, R.S. Sozio, and R.J. Chenery (1994). Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem. Res. Toxicol. 7, 836–842.
Castle, P.J., J.L. Merdink, J.R. Okita, S.A. Wrighton, and R.T. Okita (1995). Human liver lauric acid hydroxylase activities. Drug Metab. Dispos. 23, 1037–1043.
Gillam, E.M.J., A.M. Aguinaldo, L.M. Notley, D. Kim, R.G. Mundkowski, A. Volkov et al. (1999). Formation of indigo by recombinant mammalian cytochrome P450. Biochem. Biophys. Res. Commun. 265, 469–472.
Adachi, J., Y. Mori, S. Matsui, H. Takigami, J. Fujino, H. Kitagawa et al. (2001). Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276, 31475–31478.
Spracklin, D.K., D.C. Hankins, J.M. Fisher, K.E. Thummel, and E.D. Kharasch (1997). Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 281, 400–411.
Kharasch, E.D., D.C. Hankins, and K. Cox (1999). Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology 90, 766–771.
Bell, L.C. and F.P. Guengerich (1997). Oxidation kinetics of ethanol by human cytochrome P450 2E1. Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b 5 on steady-state kinetics. J. Biol. Chem. 272, 29643–29651.
Yamazaki, H., M. Nakano, E.M.J. Gillam, L.C. Bell, F.P. Guengerich, and T. Shimada (1996). Requirements for cytochrome b 5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochem. Pharmacol. 52, 301–309.
Cooper, M.T. and T.D. Porter (2001). Cytochrome b5 coexpression increases the CYP2E1-dependent mutagenicity of dialkylnitrosamines in methyltransferase-deficient strains of Salmonella typhimurium. Mutat. Res. 484, 61–68.
Schenkman, J.B. and I. Jansson (2003). The many roles of cytochrome b 5. Pharmacol. Ther. 97, 139–152.
Tan, Y., S.P. White, S.R. Paranawithana, and C.S. Yang (1997). A hypothetical model for the active site of human cytochrome P4502E1. Xenobiotica 27, 287–299.
Lewis, D.F., B.G. Lake, M.G. Bird, G.D. Loizou, M. Dickins, and P.S. Goldfarb (2003). Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: Investigation of enzyme-substrate and enzyme-inhibitor interactions. Toxicol. In Vitro 17, 93–105.
Smith, S.V., A.P. Koley, R. Dai, R.C. Robinson, H. Leong, A. Markowitz et al. (2000). Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates: A CO flash photolysis study. Biochemistry 39, 5731–5737.
Yin, H., M.W. Anders, K.R. Korzekwa, L. Higgins, K.E. Thummel, E.D. Kharasch et al. (1995). Designing safer chemicals: Predicting the rates of metabolism of halogenated alkanes. Proc. Natl. Acad. Sci. USA 92, 11076–11080.
Lewis, D.F., C. Sams, and G.D. Loizou (2003). A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome P450 2E1. J. Biochem. Mol. Toxicol. 17, 47–52.
Keefer, L.K., W. Lijinsky, and H. Garcia (1973). Deuterium isotope effect on the carcinogenicity of dimethylnitrosamine in rat liver. J. Natl. Cancer Inst. 51, 299–302.
Wade, D., C.S. Yang, C.J. Metral, J.M. Roman, J.A. Hrabie, C.W. Riggs et al. (1987). Deuterium isotope effect on denitrosation and demethylation of N-nitrosodimethylamine by rat liver microsomes. Cancer Res. 47, 3373–3377.
Yang, C.S., H. Ishizaki, M. Lee, D. Wade, and A. Fadel (1991). Deuterium isotope effect in the interaction of N-nitrosodimethylamine, ethanol, and related compounds with cytochrome P-450IIE1. Chem. Res. Toxicol. 4, 408–413.
Calcutt, W. and F.P. Guengerich (2003). Kinetic isotope effects in dialkylnitrosamine dealkylations catalyzed by human cytochrome P450s 2A6 and 2E1. FASEB J. 17, A1325.
Reitz, R.H., A. Mendrala, and F.P. Guengerich (1989). In vitro metabolism of methylene chloride in human and animal tissues: Use in physiologically-based pharmacokinetic models. Toxicol. Appl. Pharmacol. 97, 230–246.
Pernecky, S.J., T.D. Porter, and M.J. Coon (1990). Expression of rabbit cytochrome P-450IIE2 in yeast and stabilization of the enzyme by 4-methylpyrazole. Biochem. Biophys. Res. Commun. 172, 1331–1337.
Koop, D.R. (1990). Inhibition of ethanol-inducible cytochrome P450IIE1 by 3-amino-1, 2,4-triazole. Chem. Res. Toxicol. 3, 377–383.
Hultmark, D., K. Sundh, L. Johansson, and E. Arrhenius (1979). Ethanol inhibition of vinyl chloride metabolism in isolated rat hepatocytes. Chem. Biol. Interact. 25, 1–6.
Wong, L.C.K., J.M. Winston, C.B. Hong, and H. Plotnick (1982). Carcinogenicity and toxicity of 1,2-dibromoethane in the rat. Toxicol. Appl. Pharmacol. 63, 155–165.
Kwak, M.K., S.G. Kim, J.Y. Kwak, R.F. Novak, and N.D. Kim (1994). Inhibition of cytochrome P4502E1 expression by organosulfur compounds allylsulfide, allylmercaptan and allylmethylsulfide in rats. Biochem. Pharmacol. 47, 531–539.
Nakajima, M., R. Yoshida, N. Shimada, H. Yamazaki, and T. Yokoi (2001). Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab. Dispos. 29, 1110–1113.
Lucas, D., C. Farez, L.G. Bardou, J. Vaisse, J.R. Attali, and P. Valensi (1998). Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam. Clin. Pharmacol. 12, 553–558.
Le Marchand, L., G.R. Wilkinson, and L.R. Wilkens (1999). Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol. Biomarkers Prev. 8, 495–500.
Morimoto, M., A.L. Hagbjork, A.A. Nanji, M. Ingelman-Sundberg, K.O. Lindros, P.C. Fu et al. (1993). Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 10, 459–464.
Morgan, K., S.W. French, and T.R. Morgan (2002). Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 36, 122–134.
Koop, D.R., B. Klopfenstein, Y. Iimuro, and R.G. Thurman (1997). Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol. Pharmacol. 51, 944–950.
Lytton, S.D., A. Helander, Z.Q. Zhang-Gouillon, K. Stokkeland, R. Bordone, S. Aricó et al. (1999). Autoantibodies against cytochromes P-4502E1 and P-4503a in alcoholics. Mol. Pharmacol. 55, 223–233.
Clot, P., E. Albano, E. Eliasson, M. Tabone, S. Arico, Y. Israel et al. (1996). Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 111, 206–216.
Bourdi, M., W. Chen, R.M. Peter, J.L. Martin, J.T.M. Buters, S.D. Nelson et al. (1996). Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 9, 1159–1166.
Ekström, G. and M. Ingelman-Sundberg (1989). Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem. Pharmacol. 38, 1313–1319.
Nieto, N., S.L. Friedman, P. Greenwel, and A.I. Cederbaum (1999). CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 30, 987–996.
Cederbaum, A.I., D. Wu, M. Mari, and J. Bai (2001). CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic. Biol. Med. 31, 1539–1543.
Wan, J., J. Shi, L. Hui, D. Wu, X. Jin, N. Zhao et al. (2002). Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ. Health Perspect. 110, 1213–1218.
Uematsu, F., H. Kikuchi, M. Motomiya, T. Abe, I. Sagami, T. Ohmachi et al. (1991). Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 82, 254–256.
Hirvonen, A., K. Husgafvel-Pursiainen, S. Anttila, A. Karjalainen, M. Sorsa, and H. Vainio (1992). Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2, 259–263.
Ingelman-Sundberg, M., I. Johansson, I. Persson, Q.Y. Yue, M.L. Dahl, L. Bertilsson et al. (1992). Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2, 264–271.
Persson, I., I. Johansson, H. Bergling, M.L. Dahl, J., Seidegård, R. Rylander et al. (1993). Genetic polymorphism of cytochrome P4502E1 in a Swedish population: Relationship to incidence of lung cancer. FEBS Lett. 319, 207–211.
London, S.J., A.K. Daly, J. Cooper, C.L. Carpenter, W.C. Navidi, L. Ding et al. (1996). Lung cancer risk in relation to the CYP2E1 RsaI genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics 6, 151–158.
Kato, S., P.G. Shields, N.E. Caporaso, H. Sugimura, G.E. Trivers, M.A. Tucker et al. (1994). Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomarkers Prev. 3, 515–518.
Itoga, S., F. Nomura, Y. Makino, T. Tomonaga, H. Shimada, T. Ochiai et al. (2002). Tandem repeat polymorphism of the CYP2E1 gene: An association study with esophageal cancer and lung cancer. Alcohol. Clin. Exp. Res. 26, 15S–19S.
Bouchardy, C., A. Hirvonen, C. Coutelle, P.J. Ward, P. Dayer, and S. Benhamou (2000). Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int. J. Cancer 87, 734–740.
Liu, S., J.Y. Park, S.P. Schantz, J.C. Stern, and P. Lazarus (2001). Elucidation of CYP2E1 5′ regulatory RsaI/PstI allelic variants and their role in risk for oral cancer. Oral Oncol. 37, 437–445.
Kato, S., M. Onda, N. Matsukura, A. Tokunaga, T. Tajiri, D.Y. Kim et al. (1995). Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics 5, S141–S144.
Wong, R.H., C.L. Du, J.D. Wang, C.C. Chan, J.C. Luo, and T.J. Cheng (2002). XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomerexposed polyvinyl chloride workers. Cancer Epidemiol. Biomarkers Prev. 11, 475–482.
Nhamburo, P.T., S. Kimura, O.W. McBride, C.A. Kozak, H.V. Gelboin, and F.J. Gonzalez (1990). The human CYP2F gene subfamily: Identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29, 5491–5499.
Czerwinski, M., T.L. McLemore, R.M. Philpot, P.T. Nhamburo, K. Korzekwa, H.V. Gelboin et al. (1991). Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: Evidence for species-specific metabolism. Cancer Res. 51, 4636–4638.
Lanza, D.L., E. Code, C.L. Crespi, F.J. Gonzalez, and G.S. Yost (1999). Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells. Drug Metab. Dispos. 27, 798–803.
Nakajima, T., E. Elovaara, F.J. Gonzalez, H.V. Gelboin, H. Raunio, O. Pelkonen et al. (1994). Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7, 891–896.
Carr, B.A., J. Wan, R.N. Hines, and G.S. Yost (2003). Characterization of the human lung CYP2F1 gene and identification of a novel lungspecific binding motif. J. Biol. Chem. 278, 15473–15483.
Wu, S., C.R. Moomaw, K.B. Tomer, J.R. Falck, and D.C. Zeldin (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271, 3460–3468.
Zeldin, D.C., J. Foley, J. Ma, J.E. Boyle, J.M.S. Pascual, C.R. Moomaw et al. (1996). CYP2J subfamily P450s in the lung: Expression, localization, and potential functional significance. Mol. Pharmacol. 50, 1111–1117.
Zeldin, D.C., J. Foley, S.M. Goldsworthy, M.E. Cook, J.E. Boyle, J. Ma et al. (1997). CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol. Pharmacol. 51, 931–943.
Zeldin, D.C. (2001). Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276, 36059–36062.
King, L.M., J. Ma, S. Srettabunjong, J. Graves, J.A. Bradbury, L. Li et al. (2002). Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol. Pharmacol. 61, 840–852.
Nelson, D.R. (2003). Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch. Biochem. Biophys. 409, 18–24.
Rylander, T., E.P.A. Neve, M. Ingelman-Sundberg, and M. Oscarson (2001). Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. 281, 529–535.
Molowa, D.T., E.G. Schuetz, S.A. Wrighton, P.B. Watkins, P. Kremers, G. Mendez-Picon et al. (1986). Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc. Natl. Acad. Sci. USA 83, 5311–5315.
Beaune, P.H., D.R. Umbenhauer, R.W. Bork, R.S. Lloyd, and F.P. Guengerich (1986). Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc. Natl. Acad. Sci. USA 83, 8064–8068.
Bork, R.W., T. Muto, P.H. Beaune, P.K. Srivastava, R.S. Lloyd, and F.P. Guengerich (1989). Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem. 264, 910–919.
Kolars, J., P. Schmiedelin-Ren, W. Dobbins, R. Merion, S. Wrighton, and P. Watkins (1990). Heterogeneity of P-450 IIIA expression in human gut epithelia. FASEB J. 4, A2242.
Kolars, J.C., P. Schmiedlin-Ren, J.D. Schuetz, C. Fang, and P.B. Watkins (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871–1878.
Böcker, R.H. and F.P. Guengerich (1986). Oxidation of 4-ary1-and 4-alky1-substituted 2,6-dimethy1-3,5-bis(alkoxycarbonyl)-1,4-dihy-dropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 29, 1596–1603.
Waxman, D.J., C. Attisano, F.P. Guengerich, and D.P. Lapenson (1988). Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes. Arch. Biochem. Biophys. 263, 424–436.
Shimada, T. and F.P. Guengerich (1989). Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. USA 86, 462–465.
Brian, W.R., M.-A. Sari, M. Iwasaki, T. Shimada, L.S. Kaminsky, and F.P. Guengerich (1990). Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29, 11280–11292.
Guengerich, F.P. (1990). Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363–371.
Kelley, J.D., D.L. Eaton, F.P. Guengerich, and R.A. Coulombe, Jr. (1997). Aflatoxin B1 activation in human lung. Toxicol. Appl. Pharmacol. 144, 88–95.
Koch, I., R. Weil, R. Wolbold, J. Brockmoller, E. Hustert, O. Burk et al. (2002). Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30, 1108–1114.
Nakamoto, T., I. Hase, S. Imaoka, T. Hiroi, Y. Oda, A. Asada et al. (2000). Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: Induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics 10, 571–575.
de Wildt, S.N., G.L. Kearns, J.S. Leeder, and J.N. van den Anker (1999). Cytochrome P450 3A. Ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485–505.
El Mouelhi, M., M.S. Didolkar, E.G. Elias, F.P. Guengerich, and F.C. Kauffman (1987). Hepatic drug metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res. 47, 460–466.
Fujitaka, K., T. Oguri, T. Isobe, Y. Fujiwara, and N. Kohno (2001). Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother. Pharmacol. 48, 42–46.
Hughes, S.J., M.A. Morse, C.M. Weghorst, H. Kim, P.B. Watkins, F.P. Guengerich et al. (1999). Cytochromes P450 are expressed in proliferating cells in Barrett’s metaplasia. Neoplasia 1, 145–153.
Inoue, K., J. Inazawa, H. Nakagawa, T. Shimada, H. Yamazaki, F.P. Guengerich et al. (1992). Assignment of the human cytochrome P450 nifedipine oxidase gene (CYP3A4) to band 7q22.1 by in situ fluorescence hybridization. Jpn. J. Hum. Genet. 37, 133–138.
Lu, A.Y.H., A. Somogyi, S. West, R. Kuntzman, and A.H. Conney (1972). Pregnenolone-16α-carbonitrile: A new type of inducer of drug-metabolizing enzymes. Arch. Biochem. Biophys. 152, 457–462.
Guengerich, F.P. (1999). Human cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1–17.
Barwick, J.L., L.C. Quattrochi, A.S. Mills, C. Potenza, R.H. Tukey, and P.S. Guzelian (1996). Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol. Pharmacol. 50, 10–16.
Schuetz, E.G. and P.S. Guzelian (1984). Induction of cytochrome P-450 by glucocorticoids in rat liver: II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. J. Biol. Chem. 259, 2007–2012.
Calleja, C., J.M. Pascussi, J.C. Mani, P. Maurel, and M.J. Vilarem (1998). The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. 4, 92–96.
Ray, D.W., A.M. Lovering, J.R. Davis, and A. White (1998). Rifampicin: A glucocorticoid receptor ligand?. Nat. Med. 4, 1090–1091.
Kliewer, S.A., J.T. Moore, L. Wade, J.L. Staudinger, M.A. Watson, S.A. Jones et al. (1998). An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73–82.
Lehmann, J.M., D.D. McKee, M.A. Watson, T.M. Wilson, J.T. Moore, and S.A. Kliewer (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016–1023.
Coumoul, X., M. Diry, and R. Barouki (2002). PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol. 64, 1513–1519.
Jones, S.A., L.B. Moore, G.B. Wisely, and S.A. Kliewer (2002). Use of in vitro pregnane X receptor assays to assess CYP3A4 induction potential of drug candidates. Meth. Enzymol. 357, 161–170.
Raucy, J., L. Warfe, M.F. Yueh, and S.W. Allen (2002). A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J. Pharmacol. Exp. Ther. 303, 412–423.
Luo, G., M. Cunningham, S. Kim, T. Burn, J. Lin, M. Sinz et al. (2002). CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30, 795–804.
Zhang, J., P. Kuehl, E.D. Green, J.W. Touchman, P.B. Watkins, A. Daly et al. (2001). The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11, 555–572.
Goodwin, B., E. Hodgson, and C. Liddle (1999). The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329–1339.
El-Sankary, W., V. Bombail, G.G. Gibson, and N. Plant (2002). Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab. Dispos. 30, 1029–1034.
Takeshita, A., M. Taguchi, N. Koibuchi, and Y. Ozawa (2002). Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J. Biol. Chem. 277, 32453–32458.
Goodwin, B., E. Hodgson, D.J. D’Costa, G.R. Robertson, and C. Liddle (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62, 359–365.
Thummel, K.E., C. Brimer, K. Yasuda, J. Thottassery, T. Senn, Y. Lin et al. (2001). Transcriptional control of intestinal cytochrome P-4503A by 1α,25-dihydroxy vitamin D3. Mol. Pharmacol. 60, 1399–1406.
Hara, H., Y. Yasunami, and T. Adachi (2002). Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells. Biochem. Biophys. Res. Commun. 296, 182–188.
Ourlin, J.C., Y. Jounaidi, P. Maurel, and M.J. Vilarem (1997). Role of the liver-enriched transcription factors C/EBPα and DBP in the expression of human CYP3A4 and CYP3A7. J. Hepatol. 26(Suppl 2), 54–62.
Tirona, R.G., W. Lee, B.F. Leake, L.B. Lan, C.B. Cline, V. Lamba et al. (2003). The orphan nuclear receptor HNF4α determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. 9, 220–224.
Jover, R., R. Bort, M.J. Gomez-Lechon, and J.V. Castell (2002). Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: Molecular mechanism and transcription factors involved. FASEB J. 16, 1799–1801.
Danan, G., V. Descatoire, and D. Pessayre (1981). Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J. Pharmacol. Exp. Ther. 218, 509–514.
Bensoussan, C., M. Delaforge, and D. Mansuy (1995). Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of amino drugs. Biochem. Pharmacol. 49, 591–602.
Wang, X.Y., K.F. Medzihradszky, D. Maltby, and M.A. Correia (2001). Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: A mass spectrometric characterization of the phosphorylated peptides. Biochemistry 40, 11318–11326.
Sy, S.K., A. Ciaccia, W. Li, E.A. Roberts, A. Okey, W. Kalow et al. (2002). Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur. J. Clin. Pharmacol. 58, 357–365.
Ball, S.E., J. Scatina, J. Kao, G.M. Ferron, R. Fruncillo, P. Mayer et al. (1999). Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288–294.
Spurdle, A.B., B. Goodwin, E. Hodgson, J.L. Hopper, X. Chen, D.M. Purdie et al. (2002). The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12, 355–366.
Eiselt, R., T.L. Domanski, A. Zibat, R. Mueller, E. Presecan-Siedel, E. Hustert et al. (2001). Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447–458.
Garcia-Martin, E., C. Martinez, R.M. Pizarro, F.J. Garcia-Gamito, H. Gullsten, H. Raunio et al. (2002). CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71, 196–204.
Lamba, J.K., Y.S. Lin, K. Thummel, A. Daly, P.B. Watkins, S. Strom et al. (2002). Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121–132.
Dai, D., J. Tang, R. Rose, E. Hodgson, R.J. Bienstock, H.W. Mohrenweiser et al. (2001). Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825–831.
Lamba, J.K., Y.S. Lin, E.G. Schuetz, and K.E. Thummel (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271–1294.
Williams, J.A., B.J. Ring, V.E. Cantrell, D.R. Jones, J. Eckstein, K. Ruterbories et al. (2002). Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883–891.
Wang, R.W., P.H. Kari, A.Y.H. Lu, P.E. Thomas, F.P. Guengerich, and K.P. Vyas (1991). Biotransformation of lovastatin. IV. Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290, 355–361.
Huskey, S.E.W., D.C. Dean, R.R. Miller, G.H. Rasmusson, and S.H.L. Chiu (1995). Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab. Dispos. 23, 1126–1135.
Kronbach, T., V. Fischer, and U.A. Meyer (1988). Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43, 630–635.
Combalbert, J., I. Fabre, G. Fabre, I. Dalet, J. Derancourt, J.P. Cano et al. (1989). Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab. Dispos. 17, 197–207.
Koudriakova, T., E. Iatsimirskaia, I. Utkin, E. Gangl, P. Vouros, E. Storozhuk et al. (1998). Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26, 552–561.
Warrington, J.S., R.I. Shader, L.L. von Moltke, and D.J. Greenblatt (2000). In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab. Dispos. 28, 392–397.
Kudo, S., M.G. Okumura, and T. Ishizaki (1999). Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine. Drug Metab. Dispos. 27, 303–308.
Zhang, Z., Y. Li, R.A. Stearns, P.R. Ortiz De Montellano, T.A. Baillie, and W. Tang (2002). Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry 41, 2712–2718.
Hosea, N.A. and F.P. Guengerich (1998). Oxidation of non-ionic detergents by cytochrome P450 enzymes. Arch. Biochem. Biophys. 353, 365–373.
Bodin, K., L. Bretillon, Y. Aden, L. Bertilsson, U. Broome, C. Einarsson, and U. Diczfalusy (2001). Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: Evidence for involvement of cytochrome P450 3A4. J. Biol. Chem. 276, 38685–38689.
Bodin, K., U. Andersson, E. Rystedt, E. Ellis, M. Norlin, I. Pikuleva et al. (2002). Metabolism of 4β-hydroxycholesterol in humans. J. Biol. Chem. 277, 31534–31540.
Furster, C. and K. Wikvall (1999). Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5β-cholestane-3α,7α,12α-triol in human liver microsomes. Biochim. Biophys. Acta 1437, 46–52.
Honda, A., G. Salen, Y. Matsuzaki, A.K. Batta, G. Xu, E. Leitersdorf et al. (2001). Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. J. Biol. Chem. 276, 34579–34585.
Dussault, I., H.D. Yoo, M. Lin, E. Wang, M. Fan, A.K. Batta et al. (2003). Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. USA 100, 833–838.
Boocock, D.J., K. Brown, A.H. Gibbs, E. Sanchez, K.W. Turteltaub, and I.N. White (2002). Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23, 1897–1901.
Ueng, Y.-F., T. Shimada, H. Yamazaki, and F.P. Guengerich (1995). Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 218–225.
Iyer, R., B. Coles, K.D. Raney, R. Thier, F.P. Guengerich, and T.M. Harris (1994). DNA adduction by the potent carcinogen aflatoxin B1: Mechanistic studies. J. Am. Chem. Soc. 116, 1603–1609.
Crespi, C.L., V.P. Miller, and B.W. Penman (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188–190.
Stresser, D.M., S.D. Turner, A.P. Blanchard, V.P. Miller, and C.L. Crespi (2002). Cytochrome P450 fluorometric substrates: Identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab. Dispos. 30, 845–852.
Chauret, N., N. Tremblay, R.L. Lackman, J.-Y. Gauthier, J.M. Silva, J. Marois et al. (1999). Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. Anal. Biochem. 276, 215–226.
Kenworthy, K.E., J.C. Bloomer, S.E. Clarke, and J.B. Houston (1999). CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48, 716–727.
Schellens, J.H.M., P.A. Soons, and D.D. Breimer (1988). Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem. Pharmacol. 37, 2507–2510.
Lown, K., J. Kolars, K. Turgeon, R. Merion, S.A. Wrighton, and P.B. Watkins (1992). The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin. Pharmacol. Ther. 51, 229–238.
Gremse, D.A., H.H. A-Kader, T.J. Schroeder, and W.F. Balistreri (1990). Assessment of lidocaine metabolite formation as a quantitative liver function test in children. Hepatology 12, 565–569.
May, D.G., J. Porter, G.R. Wilkinson, and R.A. Branch (1994). Frequency distribution of dapsone N-hydroxylase, a putative probe for P450 3A4 activity, in a white population. Clin. Pharmacol. Ther. 55, 492–500.
Thummel, K.E., D.D. Shen, R.L. Carithers, Jr., P. Hartwell, T.D. Podoll, W.F. Tarager et al. (1993). Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1′-hydroxylation activity in liver transplant patients. In Abstracts, 5th North American ISSX Meeting, Vol. 4. p. 235, 17–21 October, Tucson, AZ.
Wanwimolruk, S., M.F. Paine, S.N. Pusek, and P.B. Watkins (2002). Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br. J. Clin. Pharmacol. 54, 643–651.
Ged, C., J.M. Rouillon, L. Pichard, J. Combalbert, N. Bressot, P. Bories et al. (1989). The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28, 373–387.
Watkins, P.B., T.A. Hamilton, T.M. Annesley, C.N. Ellis, J.C. Kolars, and J.J. Voorhees (1990). The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48, 120–129.
Kinirons, M.T., D. Oshea, T.E. Downing, A.T. Fitzwilliam, L. Joellenbeck, J.D. Groopman et al. (1993). Absence of correlations among 3 putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin. Pharmacol. Ther. 54, 621–629.
Krivoruk, Y., M.T. Kinirons, A.J.J. Wood, and M. Wood (1994). Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clin. Pharmacol. Ther. 56, 608–614.
Kivistö, K.T. and H.K. Kroemer (1997). Use of probe drugs as predictors of drug metabolism in humans. J. Clin. Pharmacol. 37, 40S–48S.
Thummel, K.E., D. O’Shea, M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins et al. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491–502.
Paine, M.F., D.A. Wagner, K.A. Hoffmaster, and P.B. Watkins (2002). Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin. Pharmacol. Ther. 72, 524–535.
Schuetz, E.G., W.T. Beck, and J.D. Schuetz (1996). Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311–318.
Gillam, E.M.J., T. Baba, B.-R. Kim, S. Ohmori, and F.P. Guengerich (1993). Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123–131.
Imaoka, S., Y. Imai, T. Shimada, and Y. Funae (1992). Role of phospholipids in reconstituted cytochrome P450 3A forms and mechanism of their activation of catalytic activity. Biochemistry 31, 6063–6069.
Ingelman-Sundberg, M., A.-L. Hagbjörk, Y.-F. Ueng, H. Yamazaki, and F.P. Guengerich (1996). High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: Influence of membrane charge. Biochem. Biophys. Res. Commun. 221, 318–322.
Peyronneau, M.A., J.P. Renaud, G. Truan, P. Urban, D. Pompon, and D. Mansuy (1992). Optimization of yeast-expressed human liver cytochrome-P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b 5. Eur. J. Biochem. 207, 109–116.
Guengerich, F.P. and W.W. Johnson (1997). Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: Rapid reduction in absence of substrate and variations among cytochrome P450 systems. Biochemistry 36, 14741–14750.
Shet, M.S., C.W. Fisher, P.L. Holmans, and R.W. Estabrook (1993). Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. USA 90, 11748–11752.
Gillam, E.M.J., Z. Guo, Y.-F. Ueng, H. Yamazaki, I. Cock, P.E.B. Reilly et al. (1995). Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modifications, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317, 374–384.
Yamazaki, H., M. Nakano, Y. Imai, Y.-F. Ueng, F.P. Guengerich, and T. Shimada (1996). Roles of cytochrome b 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 325, 174–182.
Yamazaki, H., M. Nakajima, M. Nakamura, S. Asahi, N. Shimada, E.M.J. Gillam et al. (1999). Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b 5 in bacterial membranes. Drug Metab. Dispos. 27, 999–1004.
Parikh, A., E.M.J. Gillam, and F.P. Guengerich (1997). Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15, 784–788.
Blake, J.A.R., M. Pritchard, S. Ding, G.C.M. Smith, B. Burchell, C.R. Wolf et al. (1996). Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli, FEBS Lett. 397, 210–214.
Nakajima, M., K. Tane, S. Nakamura, N. Shimada, H. Yamazaki, and T. Yokoi (2002). Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b 5 in the expression system and the differences in the marker activities. J. Pharm. Sci. 91, 952–963.
Noshiro, M. and T. Omura (1978). Immunochemical study on the electron pathway from NADH to cytochrome P-450 of liver microsomes. J. Biochem. (Tokyo) 83, 61–77.
Perret, A. and D. Pompon (1998). Electron shuttle between membrane-bound cytochrome P450 3A4 and b 5 rules uncoupling mechanisms. Biochemistry 37, 11412–11424.
Yamazaki, H., W.W. Johnson, Y.-F. Ueng, T. Shimada, and F.P. Guengerich (1996). Lack of electron transfer from cytochrome b 5 in stimulation of catalytic activities of cytochrome P450 3A4: Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b 5. J. Biol. Chem. 271, 27438–27444.
Auchus, R.J., T.C. Lee, and W.L. Miller (1998). Cytochrome b 5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158–3165.
Aitken, A.E., L.J. Roman, P.A. Loughran, M. de la Garza, and B.S.S. Masters (2001). Expressed CYP4A4 metabolism of prostaglandin E-1 and arachidonic acid. Arch. Biochem. Biophys. 393, 329–338.
Guryev, O.L., A.A. Gilep, S.A. Usanov, and R.W. Estabrook (2001). Interaction of apo-cytochrome b 5 with cytochromes P4503A4 and P45017A: Relevance of heme transfer reactions. Biochemistry 40, 5018–5031.
Yamazaki, H., T. Shimada, M.V. Martin, and F.P. Guengerich (2001). Stimulation of cytochrome P450 reactions by apo-cytochrome b 5. Evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b 5 or heme oxygenase. J. Biol. Chem. 276, 30885–30891.
Ekins, S., G. Bravi, J.H. Wikel, and S.A. Wrighton (1999). Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J. Pharmacol. Exp. Ther. 291, 424–433.
Ekins, S., G. Bravi, S. Binkley, J.S. Gillespie, B.J. Ring, J.H. Wikel et al. (1999). Three-and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J. Pharmacol. Exp. Ther. 290, 429–438.
Stevens, J.C., T.L. Domanski, G.R. Harlow, R.B. White, E. Orton, and J.R. Halpert (1999). Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J. Pharmacol. Exp. Ther. 290, 594–602.
Domanski, T.L., Y.A. He, G.R. Harlow, and J.R. Halpert (2000). Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. 293, 585–591.
Fowler, S.M., R.J. Riley, M.P. Pritchard, M.J. Sutcliffe, T. Friedberg, and C.R. Wolf (2000). Amino acid 305 determines catalytic center accessibility in CYP3A4. Biochemistry 39, 4406–4414.
Xue, L., H.F. Wang, Q. Wang, G.D. Szklarz, T.L. Domanski, J.R. Halpert et al. (2001). Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B1 oxidation. Chem. Res. Toxicol. 14, 483–491.
Fowler, S.M., J.M. Taylor, T. Friedberg, C.R. Wolf, and R.J. Riley (2002). CYP3A4 active site volume modification by mutagenesis of leucine 211. Drug Metab. Dispos. 30, 452–456.
Smith, D.A. and B.C. Jones (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44, 2089–2098.
Macdonald, T.L., W.G. Gutheim, R.B. Martin, and F.P. Guengerich (1989). Oxidation of substituted N,N-dimethylanilines by cytochrome P-450: Estimation of the effective oxidation-reduction potential of cytochrome P-450. Biochemistry 28, 2071–2077.
Yamazaki, H., Y.-F. Ueng, T. Shimada, and F.P. Guengerich (1995). Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, iron-sulfur proteins, and oxygen surrogates. Biochemistry 34, 8380–8389.
Northrop, D.B. (1975). Steady-state analysis of kinetic isotope effects in enzymic reactions. Biochemistry 14, 2644–2651.
Kuby, S.A. (1991). A Study of Enzymes, Vol. I, Enzyme Catalysis, Kinetics, and Substrate Binding. CRC Press, Boca Raton, FL.
Walsh, C. (1979). Enzymatic Reaction Mechanisms. W. H. Freeman Co, San Francisco, CA.
Obach, R.S. (2001). Mechanism of cytochrome P4503A4-and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab. Dispos. 29, 1599–1607.
Wiebel, F.J., J.C. Leutz, L. Diamond, and H.V. Gelboin (1971). Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in microsomes from rat tissues: Differential inhibition and stimulation by benzoflavones and organic solvents. Arch. Biochem. Biophys. 144, 78–86.
Kapitulnik, J., P.J. Poppers, M.K. Buening, J.G. Fortner, and A.H. Conney (1977). Activation of monooxygenases in human liver by 7,8-benzoflavone. Clin. Pharmacol. Ther. 22, 475–485.
Buening, M.K., J.G. Fortner, A. Kappas, and A.H. Conney (1978). 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver. Biochem. Biophys. Res. Commun. 82, 348–355.
Schwab, G.E., J.L. Raucy, and E.F. Johnson (1988). Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 33, 493–499.
Hosea, N.A., G.P. Miller, and F.P. Guengerich (2000). Elucidation of distinct binding sites for cytochrome P450 3A4. Biochemistry 39, 5929–5939.
Guengerich, F.P., B.-R. Kim, E.M.J. Gillam, and T. Shimada (1994). Mechanisms of enhancement and inhibition of cytochrome P450 catalytic activity In M. C. Lechner (ed.), Proceedings, 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology, John Libbey Eurotext, Paris, pp. 97–101.
Yun, C.-H., T. Shimada, and F.P. Guengerich (1992). Contributions of human liver cytochrome P-450 enzymes to the N-oxidation of 4, 4′-methylene-bis(2-chloroaniline). Carcinogenesis 13, 217–222.
Wang, R.W., D.J. Newton, T.D. Scheri, and A.Y.H. Lu (1997). Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation. Drug Metab. Dispos. 25, 502–507.
Ludwig, E., J. Schmid, K. Beschke, and T. Ebner (1999). Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J. Pharmacol. Exp. Ther. 290, 1–8.
Wang, R.W., D.J. Newton, N. Liu, W.M. Atkins, and A.Y.H. Lu (2000). Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28, 360–366.
Schrag, M.L. and L.C. Wienkers (2001). Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391, 49–55.
Masubuchi, Y., A. Ose, and T. Horie (2002). Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab. Dispos. 30, 1143–1148.
Shou, M., J. Grogan, J.A. Mancewicz, K.W. Krausz, F.J. Gonzalez, H.V. Gelboin et al. (1994). Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33, 6450–6455.
Korzekwa, K.R., N. Krishnamachary, M. Shou, A. Ogai, R.A. Parise, A.E. Rettie et al. (1998). Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37, 4137–4147.
Shou, M., R. Dai, D. Cui, K.R. Korzekwa, T.A. Baillie, and T.H. Rushmore (2001). A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J. Biol. Chem. 276, 2256–2262.
Kenworthy, K.E., S.E. Clarke, J. Andrews, and J.B. Houston (2001). Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos. 29, 1644–1651.
Galetin, A., S.E. Clarke, and J.B. Houston (2002). Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach. Drug Metab. Dispos. 30, 1512–1522.
Domanski, T.L., J. Liu, G.R. Harlow, and J.R. Halpert (1998). Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: Role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch. Biochem. Biophys. 350, 223–232.
Harlow, G.R. and J.R. Halpert (1998). Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc. Natl. Acad. Sci. USA 95, 6636–6641.
He, Y.A., F. Roussel, and J.R. Halpert (2003). Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch. Biochem. Biophys. 409, 92–101.
Domanski, T.L., Y.A. He, K.K. Khan, F. Roussel, Q. Wang, and J.R. Halpert (2001). Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40, 10150–10160.
Dabrowski, M.J., M.L. Schrag, L.C. Wienkers, and W.M. Atkins (2002). Pyrene-pyrene complexes at the active site of cytochrome P450 3A4: Evidence for a multiple substrate binding site. J. Am. Chem. Soc. 124, 11866–11867.
Cupp-Vickery, J., R. Anderson, and Z. Hatziris (2000). Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc. Natl. Acad. Sci. USA 97, 3050–3055.
Khan, K.K., H. Liu, and J.R. Halpert (2003). Homotropic versus heterotorpic cooperativity of cytochrome P450eryF: A substrate oxidation and spectral titration study. Drug Metab. Dispos. 31, 356–359.
Koley, A.P., J.T.M. Buters, R.C. Robinson, A. Markowitz, and F.K. Friedman (1995). CO binding kinetics of human cytochrome P450 3A4: Specific interaction of substrates with kinetically distinguishable conformers. J. Biol. Chem. 270, 5014–5018.
Koley, A.P., J.T.M. Buters, R.C. Robinson, A. Markowitz, and F.K. Friedman (1997). Differential mechanisms of cytochrome P450 inhibition and activation by α-naphthoflavone. J. Biol. Chem. 272, 3149–3152.
Koley, A.P., R.C. Robinson, and F.K. Friedman (1996). Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. Biochimie 78, 706–713.
Koley, A.P., R.C. Robinson, A. Markowitz, and F.K. Friedman (1997). Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem. Pharmacol. 53, 455–460.
Anzenbacherova’, E., N. Bec, P. Anzenbacher, J. Hudecek, P. Soucek, C. Jung et al. (2000). Flexibility and stability of the structure of cytochromes P450 3A4 and BM-3. Eur. J. Biochem. 267, 2916–2920.
Ma, B., M. Shatsky, H.J. Wolfson, and R. Nussinov (2002). Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations. Protein Sci. 11, 184–197.
Carlson, H.A. (2002). Protein flexibility and drug design: How to hit a moving target. Curr. Opin. Chem. Biol. 6, 447–452.
Carlson, H.A. (2002). Protein flexibility is an important component of structure-based drug discovery. Curr. Pharm. Des. 8, 1571–1578.
Schlichting, I., J. Berendzen, K. Chu, A.M. Stock, S.A. Maves, D.E. Benson et al. (2000). The catalytic pathway of cytochrome P450cam at atomic resolution. Science 287, 1615–1622.
Atkins, W.M., R.W. Wang, and A.Y.H. Lu (2001). Allosteric behavior in cytochrome P450-dependent in vitro drug-drug interactions: A prospective based on conformational dynamics. Chem. Res. Toxicol. 14, 338–347.
Segel, I.H. (1975). Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, New York.
Atkins, W.M., W.D. Lu, and D.L. Cook (2002). Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from “distributive catalysis.” J. Biol. Chem. 277, 33258–33266.
Di Petrillo, K., S. Wood, V. Kostrubsky, K. Chatfield, J. Bement, S. Wrighton et al. (2002). Effect of caffeine on acetaminophen hepatotoxicity in cultured hepatocytes treated with ethanol and isopentanol. Toxicol. Appl. Pharmacol. 185, 91–97.
Tang, W. and R.A. Stearns (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr. Drug Metab. 2, 185–198.
Egnell, A.C., J.B. Houston, and C.S. Boyer (2003). In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J. Pharmacol. Exp. Ther. 305, 1251–1262.
Yun, C.-H., R.A. Okerholm, and F.P. Guengerich (1993). Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21, 403–409.
Delaforge, M., M. Jaouen, and D. Mansuy (1983). Dual effects of macrolide antibiotics on rat liver cytochrome P-450: Induction and formation of metabolite-complexes: A structure-activity relationship. Biochem. Pharmacol. 32, 2309–2318.
Bailey, D.G., B. Edgar, J.D. Spence, C. Munzo, and J.M.O. Arnold (1990). Felodipine and nifedipine interactions with grapefruit juice. Clin. Pharmacol. Ther. 47, 180.
Greenblatt, D.J., K.C. Patki, L.L. von Moltke, and R.I. Shader (2001). Drug interactions with grapefruit juice: An update. J. Clin. Psychopharmacol. 21, 357–359.
Guengerich, F.P. and D.-H. Kim (1990). In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275–2279.
von Moltke, L.L., D.J. Greenblatt, J.M. Grassi, B.W. Granda, S.X. Duan, S.M. Fogelman et al. (1998). Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J. Clin. Pharmacol. 38, 106–111.
Unger, M., U. Holzgrabe, W. Jacobsen, C. Cummins, and L.Z. Benet (2002). Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (kava-kava). Planta Med. 68, 1055–1058.
Lin, H.L., U.M. Kent, and P.F. Hollenberg (2002). Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: Evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 301, 160–167.
Palovaara, S., K.T. Kivisto, P. Tapanainen, P. Manninen, P.J. Neuvonen, and K. Laine (2000). Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br. J. Clin. Pharmacol. 50, 333–337.
Kuhl, H., C. Jung-Hoffmann, and F. Heidt (1988). Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75μg gestodene. Contraception 38, 477–486.
Balogh, A., S. Gessinger, U. Svarovsky, M. Hippius, U. Mellinger, G. Klinger et al. (1998). Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?. Eur. J. Clin. Pharmacol. 54, 729–734.
Guengerich, F.P. (1986). Covalent binding to apoprotein is a major fate of heme in a variety of reactions in which cytochrome P-450 is destroyed. Biochem. Biophys. Res. Commun. 138, 193–198.
He, K., L.M. Bornheim, A.M. Falick, D. Maltby, H. Yin, and M.A. Correia (1998). Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. Biochemistry 37, 17448–17457.
Wienkers, L.C. (2001). Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J. Pharmacol. Toxicol. Methods 45, 79–84.
Plant, N.J. and G.G. Gibson (2003). Evaluation of the toxicological relevance of CYP3A4 induction. Curr. Opin. Drug Discov. Devel. 6, 50–56.
Yee, G.C., M.S. Kennedy, R. Storb, and E.D. Thomas (1984). Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. Blood 64, 1277–1279.
von Moltke, L.L. D.J. Greenblatt, S.X. Duan, J.S. Harmatz, and R.I. Shader (1994). In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34, 1222–1227.
Dorne, J.L., K. Walton, and A.G. Renwick (2003). Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem. Toxicol. 41, 201–224.
Yang, L.Q., S.J. Li, Y.F. Cao, X.B. Man, W.F. Yu, H.Y. Wang et al. (2003). Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J. Gastroenterol. 9, 359–363.
Lang, C.C., R.M. Brown, M.T. Kinirons, M.-A. Deathridge, F.P. Guengerich, D. Kelleher et al. (1996). Decreased intestinal P450 3A4 in celiac sprue: Reversal following successful gluten free diet. Clin. Pharmacol. Ther. 59, 41–46.
Zhou, S., Y. Gao, W. Jiang, M. Huang, A. Xu, and J.W. Paxton (2003). Interactions of herbs with cytochrome P450. Drug Metab. Rev. 35, 35–98.
Moore, L.B., B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson et al. (2000). St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 97, 7500–7502.
Watkins, R.E., J.M. Maglich, L.B. Moore, G.B. Wisely, S.M. Noble, P.R. Davis-Searles et al. (2003). 2.1 Å crystal structure of human PXR in complex with the St. John’s wort compound hyperforin. Biochemistry 42, 1430–1438.
Henderson, L., Q.Y. Yue, C. Bergquist, B. Gerden, and P. Arlett (2002). St. John’s wort (Hypericum perforatum): Drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 54, 349–356.
Kolars, J.C., P. Benedict, P. Schmiedlin-Ren, and P.B. Watkins (1994). Aflatoxin B1-adduct formation in rat and human small bowel enterocytes. Gastroenterology 106, 433–439.
Felix, C.A., A.H. Walker, B.J. Lange, T.M. Williams, N.J. Winick, N.-K.V. Cheung et al. (1998). Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95, 13176–13181.
Miyoshi, Y., A. Ando, Y. Takamura, T. Taguchi, Y. Tamaki, and S. Noguchi (2002). Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 97, 129–132.
Blanco, J.G., M.J. Edick, M.L. Hancock, N.J. Winick, T. Dervieux, M.D. Amylon et al. (2002). Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12, 605–611.
Rebbeck, T.R., J.M. Jaffe, A.H. Walker, A.J. Wein, and S.B. Malkowicz (1998). Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225–1228.
Tayeb, M.T., C. Clark, L. Sharp, N.E. Haites, P.H. Rooney, G.I. Murray et al. (2002). CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol. Rep. 9, 653–655.
Tayeb, M.T., C. Clark, N.E. Haites, L. Sharp, G.I. Murray, and H.L. McLeod (2003). CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 88, 928–932.
Ando, Y., T. Tateishi, Y. Sekido, T. Yamamoto, T. Satoh, Y. Hasegawa et al. (1999). Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 91, 1587–1588.
Kittles, R.A., W. Chen, R.K. Panguluri, C. Ahaghotu, A. Jackson, C.A. Adebamowo et al. (2002). CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification?. Hum. Genet. 110, 553–560.
Wojnowski, L., E. Hustert, K. Klein, M. Goldammer, M. Haberl, J. Kirchheiner et al. (2002). Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 94, 630–631.
Wrighton, S.A., B.J. Ring, P.B. Watkins, and M. VandenBranden (1989). Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 86, 97–105.
Aoyama, T., S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, V. Fischer et al. (1989). Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264, 10388–10395.
Murray, G.I., S. Pritchard, W.T. Melvin, and M.D. Burke (1995). Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Lett. 364, 79–82.
Yamakoshi, Y., T. Kishimoto, K. Sugimura, and H. Kawashima (1999). Human prostate CYP3A5: Identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun. 260, 676–681.
Hukkanen, J., T. Vaisanen, A. Lassila, R. Piipari, S. Anttila, O. Pelkonen et al. (2003). Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J. Pharmacol. Exp. Ther. 304, 745–752.
Janardan, S.K., K.S. Lown, P. Schmiedlin-Ren, K.E. Thummel, and P.B. Watkins (1996). Selective expression of CYP3A5 and not CYP3A4 in human blood. Pharmacogenetics 6, 379–385.
Hakkola, J., H. Raunio, R. Purkunen, S. Saarikoski, K. Vahakangas, O. Pelkonen et al. (2001). Cytochrome P450 3A expression in the human fetal liver: Evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate 80, 193–201.
Jounaïdi, Y., P.S. Guzelian, and M.J. Vilarem (1994). Sequence of the 5′-flanking region of CYP3A5: Comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophys. Res. Commun. 205, 1741–1747.
Schuetz, J.D., E.G. Schuetz, J.V. Thottassery, P.S. Guzelian, S. Strom, and D. Sun (1996). Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol. 49, 63–72.
Lin, Y.S., A.L. Dowling, S.D. Quigley, F.M. Farin, J. Zhang, J. Lamba et al. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162–172.
Hustert, E., M. Haberl, O. Burk, R. Wolbold, Y.Q. He, K. Klein et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773–779.
Paulussen, A., K. Lavrijsen, H. Bohets, J. Hendrickx, P. Verhasselt, W. Luyten et al. (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10, 415–424.
Shih, P.S. and J.D. Huang (2002). Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30, 1491–1496.
Wrighton, S.A., W.R. Brian, M.A. Sari, M. Iwasaki, F.P. Guengerich, J.L. Raucy et al. (1990). Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207–213.
Gibbs, M.A., K.E. Thummel, D.D. Shen, and K.L. Kunze (1999). Inhibition of cytochrome P-450 3A(CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 27, 180–187.
Kamataki, T., M. Sugiura, Y. Yamazoe, and R. Kato (1979). Purification and properties of cytochrome P-450 and NADPH-cytochrome c (P-450) reductase from human liver microsomes. Biochem. Pharmacol. 28, 1993–2000.
Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa, R. Kato, and Y. Kanakubo (1985). Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch. Biochem. Biophys. 241, 275–280.
Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa, R. Kato, and Y. Kanakubo (1985). Immunochemical examinations of cytochrome P-450 in various tissues of human fetuses using antibodies to human fetal cytochrome P-450, P-450 HFLa. Biochem. Biophys. Res. Commun. 131, 1154–1159.
Okajima, Y., N. Inaba, I. Fukazawa, Y. Ota, Y. Hirai, N. Sato et al. (1993). Immunohistochemical and immunoelectron microscopic study of cytochrome P-450 of human fetal livers (P-450HFLa): Implications for an onco-feto-placental enzyme. Asia Oceania J. Obstet. Gynaecol. 19, 329–341.
Schuetz, J.D., S. Kauma, and P.S. Guzelian (1993). Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J. Clin. Invest. 92, 1018–1024.
Sarkar, M.A., V. Vadlamuri, S. Ghosh, and D.D. Glover (2003). Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab. Dispos. 31, 1–6.
Hakkola, J., H. Raunio, R. Purkunen, O. Pelkonen, S. Saarikoski, T. Cresteil et al. (1996). Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 52, 379–383.
Yang, H.Y.L., Q.P. Lee, A.E. Rettie, and M.R. Juchau (1994). Functional cytochrome P4503A isoforms in human embryonic tissues: Expression during organogenesis. Mol. Pharmacol. 46, 922–928.
Schuetz, J.D., D.L. Beach, and P.S. Guzelian (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4, 11–20.
Tateishi, T., H. Nakura, M. Asoh, M. Watanabe, M. Tanaka, T. Kumai et al. (1997). A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 61, 2567–2574.
Komori, M., K. Nishio, H. Ohi, M. Kitada, and T. Kamataki (1989). Molecular cloning and sequence analysis of cDNA containing entire coding region for human fetal liver cytochrome P-450. J. Biochem. (Tokyo) 106, 161–163.
Itoh, S., T. Yanagimoto, S. Tagawa, H. Hashimoto, R. Kitamura et al. (1992). Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)-related gene (s) and interaction of transcriptional regulatory factor with its DNA element in the 5′ flanking region. Biochim. Biophys. Acta 1130, 133–138.
Greuet, J., L. Pichard, C. Bonfils, J. Domergue, and P. Maurel (1996). The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochem. Biophys. Res. Commun. 225, 689–694.
Pascussi, J.M., Y. Jounaidi, L. Drocourt, J. Domergue, C. Balabaud, P. Maurel et al. (1999). Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun. 260, 377–381.
Bertilsson, G., A. Berkenstam, and P. Blomquist (2001). Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 280, 139–144.
Saito, T., Y. Takahashi, H. Hashimoto, and T. Kamataki (2001). Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor κB-like element. J. Biol. Chem. 276, 38010–38022.
Finta, C. and P.G. Zaphiropoulos (2000). The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260, 13–23.
Burk, O., H. Tegude, I. Koch, E. Hustert, R. Wolbold, H. Glaeser, K. et al. (2002). Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277, 24280–24288.
Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo (1987). Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Biochem. Pharmacol. 36, 453–456.
Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo (1987). P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biol. Chem. 262, 13534–13537.
Ohmori, S., N. Fujiki, H. Nakasa, H. Nakamura, I. Ishii, K. Itahashi et al. (1998). Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res. Commun. Mol. Pathol. Pharmacol. 100, 15–28.
Gorski, J.C., S.D. Hall, D.R. Jones, M. VandenBranden, and S.A. Wrighton (1994). Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643–1653.
Gillam, E.M.J., R.M. Wunsch, Y.-F. Ueng, T. Shimada, P.E.B. Reilly, T. Kamataki et al. (1997). Expression of cytochrome P450 3A7 in Escherichia coli: Effects of 5′ modification and catalytic characterization of recombinant enzymes expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 346, 81–90.
Hashimoto, H., Y. Yanagawa, M. Sawada, S. Itoh, T. Deguchi, and T. Kamataki (1995). Simultaneous expression of human CYP3A7 and N-acetyltransferase in Chinese hamster CHL cells results in high cytotoxicity for carcinogenic heterocyclic amines. Arch. Biochem. Biophys. 320, 323–329.
Li, Y., T. Yokoi, M. Katsuki, J.S. Wang, J.D. Groopman, and T. Kamataki (1997). In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene. Cancer Res. 57, 641–645.
Yamada, A., K. Fujita, T. Yokoi, S. Muto, A. Suzuki, Y. Gondo et al. (1998). In vivo detection of mutations induced by aflatoxin B1 using human CYP3A7/HITEC hybrid mice. Biochem. Biophys. Res. Commun. 250, 150–153.
Li, Y., T. Yokoi, R. Kitamura, M. Sasaki, M. Gunji, M. Katsuki et al. (1996). Establishment of transgenic mice carrying human fetus-specific CYP3A7. Arch. Biochem. Biophys. 329, 235–240.
Chen, H., A.G. Fantel, and M.R. Juchau (2000). Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab. Dispos. 28, 1051–1057.
Inoue, E., Y. Takahashi, Y. Imai, and T. Kamataki (2000). Development of bacterial expression system with high yield of CYP3A7, a human fetuspecific form of cytochrome P450. Biochem. Biophys. Res. Commun. 269, 623–627.
Kondoh, N., T. Wakatsuki, A. Ryo, A. Hada, T. Aihara, S. Horiuchi et al. (1999). Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59, 4990–4996.
Gellner, K., R. Eiselt, E. Hustert, H. Arnold, I. Koch, M. Haberl et al. (2001). Genomic organization of the human CYP3A locus: Identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111–121.
Domanski, T.L., C. Finta, J.R. Halpert, and P.G. Zaphiropoulos (2001). cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59, 386–392.
Westlind, A., S. Malmebo, I. Johansson, C. Otter, T.B. Andersson, M. Ingelman-Sundberg et al. (2001). Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281, 1349–1355.
Palmer, C.N., T.H. Richardson, K.J. Griffin, M.H. Hsu, A.S. Muerhoff, J.E. Clark et al. (1993). Characterization of a cDNA encoding a human kidney, cytochrome P-450 4A fatty acid ω-hydroxylase and the cognate enzyme expressed in Escherichia coli. Biochim. Biophys. Acta 1172, 161–166.
Bell, D.R., N.J. Plant, C.G. Rider, L. Na, S. Brown, I. Ateitalla et al. (1993). Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem. J. 294, 173–180.
Imaoka, S., H. Ogawa, S. Kimura, and F.J. Gonzalez (1993). Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid ω-hydroxylase expressed in human kidney. DNA Cell Biol. 12, 893–899.
Powell, P.K., I. Wolf, and J.M. Lasker (1996). Identification of CYP4A11 as the major lauric acid ω-hydroxylase in human liver microsomes. Arch. Biochem. Biophys. 335, 219–226.
Bellamine, A., Y. Wang, M.R. Waterman, J.V. Gainer, III, E.P. Dawson, N.J. Brown et al. (2003). Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch. Biochem. Biophys. 409, 221–227.
Lu, A.Y.H. and M.J. Coon (1968). Role of hemoprotein P-450 in fatty acid ω-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 243, 1331–1332.
Gonzalez, M.C., C. Marteau, J. Franchi, and D. Migliore-Samour (2001). Cytochrome P450 4A11 expression in human keratinocytes: Effects of ultraviolet irradiation. Br. J. Dermatol. 145, 749–757.
Cummings, B.S., J.M. Lasker, and L.H. Lash (2000). Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney. J. Pharmacol. Exp. Ther. 293, 677–685.
Savas, Ü., M.H. Hsu, and E.F. Johnson (2003). Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. 409, 212–220.
Kawashima, H., T. Naganuma, E. Kusunose, T. Kono, R. Yasumoto, K. Sugimura et al. (2000). Human fatty acid ω-hydroxylase. CYP4A11: Determination of complete genomic sequence and characterization of purified recombinant protein. Arch. Biochem. Biophys. 378, 333–339.
Cattley, R.C., J. DeLuca, C. Elcombe, P. Fenner-Crisp, B.G. Lake, D.S. Marsman et al. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?. Regul. Toxicol. Pharmacol. 27, 47–60.
Dierks, E.A., Z. Zhang, E.F. Johnson, and P.R. Ortiz de Montellano (1998). The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. J. Biol. Chem. 273, 23055–23061.
Hoch, U., Z. Zhang, D.L. Kroetz, and P.R. Ortiz de Montellano (2000). Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid ω-hydroxylases. Arch. Biochem. Biophys. 373, 63–71.
Powell, P.K., I. Wolf, R. Jin, and J.M. Lasker (1998). Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 285, 1327–1336.
Lasker, J.M., W.B. Chen, I. Wolf, B.P. Bloswick, P.D. Wilson, and P.K. Powell (2000). Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. J. Biol. Chem. 275, 4118–4126.
Oliw, E.H., K. Stark, and J. Bylund (2001). Oxidation of prostaglandin H2 and prostaglandin H2 analogues by human cytochromes P450: Analysis of ω-side chain hydroxy metabolites and four steroisomers of 5-hydroxyprostaglandin I1 by mass spectrometry. Biochem. Pharmacol. 62, 407–415.
Chang, Y.T. and G.H. Loew (1999). Homology modeling and substrate binding study of human CYP4A11 enzyme. Proteins 34, 403–415.
LeBrun, L.A., U. Hoch, and P. R. Ortiz de Montellano (2002). Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family. J. Biol. Chem. 277, 12755–12761.
Nhamburo, P.T., F.J. Gonzalez, O.W. McBride, H.V. Gelboin, and S. Kimura (1989). Identification of a new P450 expressed in human lung: Complete cDNA sequence, cDNA-directed expression, and chromosome mapping. Biochemistry 28, 8060–8066.
Imaoka, S., Y. Yoneda, T. Sugimoto, T. Hiroi, K. Yamamoto, T. Nakatani et al. (2000). CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. 277, 776–780.
Iscan, M., T. Klaavuniemi, T. Coban, N. Kapucuoglu, O. Pelkonen, and H. Raunio (2001). The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res. Treat. 70, 47–54.
Finnstrom, N., C. Bjelfman, T.G. Soderstrom, G. Smith, L. Egevad, B.J. Norlen et al. (2001). Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 31, 880–886.
Lo-Guidice, J.M., D. Allorge, C. Cauffiez, D. Chevalier, J.J. Lafitte, M. Lhermitte et al. (2002). Genetic polymorphism of the human cytochrome P450 CYP4B1: Evidence for a non-functional allelic variant. Pharmacogenetics 12, 367–374.
Zheng, Y.-M., M.B. Fisher, N. Yokotani, Y. Fujii-Kuriyama, and A.E. Rettie (1998). Identification of a meander region proline residue critical for heme binding to cytochrome P450: Implications for the catalytic function of human CYP4B1. Biochemistry 37, 12847–12851.
Imaoka, S., K. Hayashi, T. Hiroi, Y. Yabusaki, T. Kamataki, and Y. Funae (2001). A transgenic mouse expressing human CYP4B1 in the liver. Biochem. Biophys. Res. Commun. 284, 757–762.
Henne, K.R., M.B. Fisher, K.R. Iyer, D.H. Lang, W.F. Trager, and A.E. Rettie (2001). Active site characteristics of CYP4B1 probed with aromatic ligands. Biochemistry 40, 8597–8605.
Henne, K.R., K.L. Kunze, Y.M. Zheng, P. Christmas, R.J. Soberman, and A.E. Rettie (2001). Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry 40, 12925–12931.
Hoch, U. and P.R. Ortiz de Montellano (2001). Covalently linked heme in cytochrome P4504A fatty acid hydroxylases. J. Biol. Chem. 276, 11339–11346.
Frank, S., S. Steffens, U. Fischer, A. Tlolko, N.G. Rainov, and C.M. Kramm (2002). Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy. Cancer Gene Ther. 9, 178–188.
Kikuta, Y., E. Kusunose, T. Kondo, S. Yamamoto, H. Kinoshita, and M. Kusunose (1994). Cloning and expression of a novel form of leukotriene B4 omega-hydroxylase from human liver. FEBS Lett. 348, 70–74.
Kikuta, Y., E. Kusunose, and M. Kusunose (2002). Prostaglandin and leukotriene ω-hydroxylases. Prostaglandins Other Lipid Mediat. 68–69, 345–362.
Jin, R., D.R. Koop, J.L. Raucy, and J.M. Lasker (1998). Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Arch. Biochem. Biophys. 359, 89–98.
Kikuta, Y., Y. Miyauchi, E. Kusunose, and M. Kusunose (1999). Expression and molecular cloning of human liver leukotriene B4 ω-hydroxylase (CYP4F2) gene. DNA Cell Biol. 18, 723–730.
Kikuta, Y., E. Kusunose, and M. Kusunose (2000). Characterization of human liver leukotriene B4 ω-hydroxylase P450 (CYP4F2). J. Biochem. (Tokyo) 127, 1047–1052.
Kikuta, Y., E. Kusunose, K. Endo, S. Yamamoto, K. Sogawa, Y. Fujii-Kuriyama et al. (1993). A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes: cDNA cloning and expression of leukotriene B4 ω-hydroxylase. J. Biol. Chem. 268, 9376–9380.
Kikuta, Y., M. Kato, Y. Yamashita, Y. Miyauchi, K. Tanaka, N. Kamada et al. (1998). Human leukotriene B4 ω-hydroxylase (CYP4F3) gene: Molecular cloning and chromosomal localization. DNA Cell Biol. 17, 221–230.
Christmas, P., S.R. Ursino, J.W. Fox, and R.J. Soberman (1999). Expressio of the CYP4F3 gene. J. Biol. Chem. 274, 21191–21199.
Christmas, P., J.P. Jones, C.J. Patten, D.A. Rock, Y. Zheng, S.M. Cheng et al. (2001). Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J. Biol. Chem. 276, 38166–38172.
Bylund, J., N. Finnstrom, and E.H. Oliw (1999). Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. Biochem. Biophys. Res. Commun. 261, 169–174.
Bylund, J., M. Hidestrand, M. Ingelman-Sundberg, and E.H. Oliw (2000). Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. J. Biol. Chem. 275, 21844–21849.
Stark, K., H. Torma, M. Cristea, and E.H. Oliw (2003). Expression of CYP4F8 (prostaglandin H 19-hydroxylase) in human epithelia and prominent induction in epidermis of psoriatic lesions. Arch. Biochem. Biophys. 409, 188–196.
Cui, X., D.R. Nelson, and H.W. Strobel (2000). A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics 68, 161–166.
Bylund, J., M. Bylund, and E.H. Oliw (2001). cDNA cloning and expression of CYP4F12, a novel human cytochrome P450. Biochem. Biophys. Res. Commun. 280, 892–897.
Hashizume, T., S. Imaoka, T. Hiroi, Y. Terauchi, T. Fujii, H. Miyazaki et al. (2001). cDNA cloning and expression of a novel cytochrome P450 (CYP4F12) from human small intestine. Biochem. Biophys. Res. Commun. 280, 1135–1141.
Hashizume, T., S. Imaoka, M. Mise, Y. Terauchi, T. Fujii, H. Miyazaki et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 300, 298–304.
Bylund, J., C. Zhang, and D.R. Harder (2002). Identification of a novel cytochrome P450, CYP4X1, with unique localization specific to the brain. Biochem. Biophys. Res. Commun. 296, 677–684.
Ullrich, V. (2003). Thoughts on thiolate tethering. Tribute and thanks to a teacher. Arch. Biochem. Biophys. 409, 45–51.
Yokoyama, C., A. Miyata, H. Ihara, V. Ullrich, and T. Tanabe (1991). Molecular cloning of human platelet thromboxane A synthase. Biochem. Biophys. Res. Commun. 178, 1479–1484.
Nusing, R. and V. Ullrich (1992). Regulation of cyclooxygenase and thromboxane synthase in human monocytes. Eur. J. Biochem. 206, 131–136.
Young, V., M. Ho, H. Vosper, J.J. Belch, and C.N. Palmer (2002). Elevated expression of the genes encoding TNF-α and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 41, 869–875.
Nusing, R., P.M. Fehr, F. Gudat, E. Kemeny, M.J. Mihatsch, and V. Ullrich (1994). The localization of thromboxane synthase in normal and pathological human kidney tissue using a monoclonal antibody Tu 300. Virchows Arch. 424, 69–74.
Ihara, H., C. Yokoyama, A. Miyata, T. Kosaka, R. Nusing, V. Ullrich et al. (1992). Induction of thromboxane synthase and prostaglandin endoperoxide synthase mRNAs in human erythroleukemia cells by phorbol ester. FEBS Lett. 306, 161–164.
Yaekashiwa, M. and L.H. Wang (2002). Transcriptional control of the human thromboxane synthase gene in vivo and in vitro. J. Biol. Chem. 277, 22497–22508.
Chevalier, D., J.M. Lo-Guidice, E. Sergent, D. Allorge, H. Debuysere, N. Ferrari et al. (2001). Identification of genetic variants in the human thromboxane synthase gene (CYP5A1). Mutat. Res. 432, 61–67.
Ullrich, V. and M. Haurand (1983). Thromboxane synthase as a cytochrome P450 enzyme. Adv. Prostaglandin Thromboxane Leukot. Res. 11, 105–110.
Haurand, M. and V. Ullrich (1985). Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. J. Biol. Chem. 260, 15059–15067.
Yokoyama, C., A. Miyata, K. Suzuki, Y. Nishikawa, T. Yoshimoto, S. Yamamoto et al. (1993). Expression of human thromboxane synthase using a baculovirus system. FEBS Lett. 318, 91–94.
Hecker, M., M. Haurand, V. Ullrich, U. Diczfalusy, and S. Hammarstrom (1987). Products, kinetics, and substrate specificity of homogeneous thromboxane synthase from human platelets: Development of a novel enzyme assay. Arch. Biochem. Biophys. 254, 124–135.
Hecker, M., W.J. Baader, P. Weber, and V. Ullrich (1987). Thromboxane synthase catalyses hydroxylation of prostaglandin H2 analogs in the presence of iodosylbenzene. Eur. J. Biochem. 169, 563–569.
Hecker, M. and V. Ullrich (1989). On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J. Biol. Chem. 264, 141–150.
Alusy, U.D. and S. Hammarstrom (1977). Inhibitors of thromboxane synthase in human platelets. FEBS Lett. 82, 107–110.
Gorman, R.R., G.L. Bundy, D.C. Peterson, F.F. Sun, O.V. Miller, and F.A. Fitzpatrick (1977). Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Proc. Natl. Acad. Sci. USA 74, 4007–4011.
Vane, J.R. (1978). Inhibitors of prostaglandin, prostacyclin, and thromboxane synthesis. Adv. Prostaglandin Thromboxane Res. 4, 27–44.
Hecker, M., M. Haurand, V. Ullrich, and S. Terao (1986). Spectral studies on structure-activity relationships of thromboxane synthase inhibitors. Eur. J. Biochem. 157, 217–223.
Pace-Asciak, C.R., D. Reynaud, P. Demin, R. Aslam, and A. Sun (2002). A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J. Pharmacol. Exp. Ther. 301, 618–624.
Miki, N., R. Miura, and Y. Miyake (1987). Purification and characterization of cholesterol 7α-hydroxylase cytochrome P-450 of untreated rabbit liver microsomes. J. Biochem. (Tokyo) 101, 1087–1094.
Ogishima, T., S. Deguchi, and K. Okuda (1987). Purification and characterization of cholesterol 7α-hydroxylase from rat liver microsomes. J. Biol. Chem. 262, 7646–7650.
Nguyen, L.B., S. Shefer, G. Salen, G. Ness, R.D. Tanaka, V. Packin et al. (1990). Purification of cholesterol 7α-hydroxylase from human and rat liver and production of inhibiting polyclonal antibodies. J. Biol. Chem. 265, 4541–4546.
Noshiro, M. and K. Okuda (1990). Molecular cloning and sequence analysis of cDNA encoding human cholesterol 7 α-hydroxylase. FEBS Lett. 268, 137–140.
Li, Y.C., D.P. Wang, and J.Y.L. Chiang (1990). Regulation of cholesterol 7α-hydroxylase in the liver: Cloning, sequencing, and regulation of cholesterol 7α-hydroxylase mRNA. J. Biol. Chem. 265, 12012–12019.
Jelinek, D.F., S. Andersson, C.A. Slaughter, and D.W. Russell (1990). Cloning and regulation of cholesterol 7α-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis. J. Biol. Chem. 265, 8190–8197.
Cohen, J.C., J.J. Cali, D.F. Jelinek, M. Mehrabian, R.S. Sparkes, A.J. Lusis et al. (1992). Cloning of the human cholesterol 7α-hydroxylase gene (CYP7) and localization to chromosome 8q11–q12. Genomics 14, 153–161.
Nishimoto, M., M. Noshiro, and K. Okuda (1993). Structure of the gene encoding human liver cholesterol 7α-hydroxylase. Biochim. Biophys. Acta 1172, 147–150.
Wang, D.P. and J.Y. Chiang (1994). Structure and nucleotide sequences of the human cholesterol 7α-hydroxylase gene (CYP7). Genomics 20, 320–323.
Xu, G., G. Salen, S. Shefer, G.C. Ness, L.B. Nguyen, T.S. Parker et al. (1995). Unexpected inhibition of cholesterol 7α-hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits. J. Clin. Invest. 95, 1497–1504.
Breuer, O., E. Sudjana-Sugiaman, G. Eggertsen, J.Y. Chiang, and I. Björkhem (1993). Cholesterol 7α-hydroxylase is up-regulated by the competitive inhibitor 7-oxocholesterol in rat liver. Eur. J. Biochem. 215, 705–710.
Shibata, A., P.F. Ohneseit, Y.C. Tsai, C.H. Spruck, III, P.W. Nichols, H.S. Chiang et al. (1994). Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15, 1085–1087.
Schwarz, M., E.G. Lund, K.D. Setchell, H.J. Kayden, J.E. Zerwekh, I. Bjorkhem et al. (1996). Disruption of cholesterol 7α-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7α-hydroxylase. J. Biol. Chem. 271, 18024–18031.
Lehmann, J.M., S.A. Kliewer, L.B. Moore, T.A. Smith-Oliver, B.B. Oliver, J.L. Su et al. (1997). Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137–3140.
Peet, D.J., S.D. Turley, W. Ma, B.A. Janowski, J.M. Lobaccaro, R.E. Hammer et al. (1998). Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93, 693–704.
Russell, D.W. (1999). Nuclear orphan receptors control cholesterol catabolism. Cell 97, 539–542.
Makishima, M., A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, A. Luk et al. (1999). Identification of a nuclear receptor for bile acids. Science 284, 1362–1365.
Nitta, M., S. Ku, C. Brown, A.Y. Okamoto, and B. Shan (1999). CPF: An orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7α-hydroxylase gene. Proc. Natl. Acad. Sci. USA 96, 6669–6665.
Chiang, J.Y., R. Kimmel, C. Weinberger, and D. Stroup (2000). Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem. 275, 10918–10924.
Staudinger, J.L., B. Goodwin, S.A. Jones, D. Hawkins-Brown, K.I. MacKenzie, A. LaTour et al. (2001). The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 98, 3369–3374.
Gupta, S., W.M. Pandak, and P.B. Hylemon (2002). LXRα is the dominant regulator of CYP7A1 transcription. Biochem. Biophys. Res. Commun. 293, 338–343.
Patel, D.D., B.L. Knight, A.K. Soutar, G.F. Gibbons, and D.P. Wade (2000). The effect of peroxisome-proliferator-activated receptor-α on the activity of the cholesterol 7α-hydroxylase gene. Biochem. J. 351, 747–753.
Cheema, S.K. and L.B. Agellon (2000). The murine and human cholesterol 7α-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor α. J. Biol. Chem. 275, 12530–12536.
Palmer, C.N.a., M.H. Hsu, K.J. Griffin, J.L. Raucy, and E.F. Johnson (1998). Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. 53, 14–22.
Marrapodi, M. and J.Y. Chiang (2000). Peroxisome proliferator-activated receptor α (PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41, 514–520.
De Fabiani, E., N. Mitro, A.C. Anzulovich, A. Pinelli, G. Galli, and M. Crestani (2001). The negative effects of bile acids and tumor necrosis factor-α on the transcription of cholesterol 7α-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: A novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J. Biol. Chem. 276, 30708–30716.
Feingold, K.R., D.K. Spady, A.S. Pollock, A.H. Moser, and C. Grunfeld (1996). Endotoxin, TNF, and IL-1 decrease cholesterol 7α-hydroxylase mRNA levels and activity. J. Lipid Res. 37, 223–228.
Drover, V.A., N.C. Wong, and L.B. Agellon (2002). A distinct thyroid hormone response element mediates repression of the human cholesterol 7α-hydroxylase (CYP7A1) gene promoter. Mol. Endocrinol., 16 14–23.
Björkhem, I., Z. Araya, M. Rudling, B. Angelin, C. Einarsson, and K. Wikvall (2002). Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J. Biol. Chem. 277, 26804–26807.
Wang, D., D. Stroup, M. Marrapodi, M. Crestani, G. Galli, and J.Y.L. Chiang (1996). Transcriptional regulation of the human cholesterol 7α-hydroxylase gene (CYP7A) in HepG2 cells. J. Lipid Res. 37, 1831–1841.
Kushwaha, R.S. and K.M. Born (1991). Effect of estrogen and progesterone on the hepatic cholesterol 7α-hydroxylase activity in ovariectomized baboons. Biochim. Biophys. Acta 1084, 300–302.
Crestani, M., A. Sadeghpour, D. Stroup, G. Galli, and J.Y. Chiang (1996). The opposing effects of retinoic acid and phorbol esters converge to a common response element in the promoter of the rat cholesterol 7α-hydroxylase gene (CYP7A). Biochem. Biophys. Res. Commun. 225, 585–592.
Goodart, S.A., C. Huynh, W. Chen, A.D. Cooper, and B. Levy-Wilson (1999). Expression of the human cholesterol 7α-hydroxylase gene in transgenic mice. Biochem. Biophys. Res. Commun. 266, 454–459.
Chen, J.Y., B. Levy-Wilson, S. Goodart, and A.D. Cooper (2002). Mice expressing the human CYP7A1 gene in the mouse CYP7A1 knock-out background lack induction of CYP7A1 expression by cholesterol feeding and have increased hypercholesterolemia when fed a high fat diet. J. Biol. Chem. 277, 42588–42595.
Reihner, E., I. Björkhem, B. Angelin, S. Ewerth, and K. Einarsson (1989). Bile acid synthesis in humans: Regulation of hepatic microsomal cholesterol 7α-hydroxylase activity. Gastroenterology 97, 1498–1505.
Mayer, D. (1976). The circadian rhythm of synthesis and catabolism of cholesterol. Arch. Toxicol. 36, 267–276.
Gielen, J., J. Van Cantfort, B. Robaye, and J. Renson (1975). Rat-liver cholesterol 7α-hydroxylase. 3. New results about its circadian rhythm. Eur. J. Biochem. 55, 41–48.
Danielsson, H. and K. Wikvall (1981). Evidence for a specific cytochrome P-450 with short half-life catalyzing 7α-hydroxylation of cholesterol. Biochem. Biophys. Res. Commun. 103, 46–51.
Hulcher, F.H., R.D. Margolis, and D.J. Bowman (1978). Circadian rhythm of cholesterol-7α-hydroxylase and cortisol in the African green monkey (Cercopithecus aethiops). Biochim. Biophys. Acta 529, 409–418.
Chiang, J.Y., W.F. Miller, and G.M. Lin (1990). Regulation of cholesterol 7 alpha-hydroxylase in the liver. Purification of cholesterol 7α-hydroxylase and the immunochemical evidence for the induction of cholesterol 7α-hydroxylase by cholestyramine and circadian rhythm. J. Biol. Chem. 265, 3889–3897.
Kinowaki, M., S. Tanaka, Y. Maeda, S. Higashi, K. Okuda, and T. Setoguchi (2002). Half-life of cholesterol 7α-hydroxylase activity and enzyme mass differ in animals and humans when determined by a monoclonal antibody against human cholesterol 7α-hydroxylase. J. Steroid Biochem. Mol. Biol. 81, 377–380.
Noshiro, M., M. Nishimoto, and K. Okuda (1990). Rat liver cholesterol 7α-hydroxylase: Pretranslational regulation for circadian rhythm. J. Biol. Chem. 265, 10036–10041.
Sanghvi, A., E. Grassi, V. Warty, W. Diven, C. Wight, and R. Lester (1981). Reversible activation-inactivation of cholesterol 7α-hydroxylase possibly due to phosphorylation-dephosphorylation. Biochem. Biophys. Res. Commun. 103, 886–892.
Goodwin, C.D., B.W. Cooper, and S. Margolis (1982). Rat liver cholesterol 7α-hydroxylase: Modulation of enzyme activity by changes in phosphorylation state. J. Biol. Chem. 257, 4469–4472.
Holsztynska, E.J. and D.J. Waxman (1987). Cytochrome P-450 cholesterol 7α-hydroxylase: Inhibition of enzyme deactivation by structurally diverse calmodulin antagonists and phosphatase inhibitors. Arch. Biochem. Biophys. 256, 543–559.
Nguyen, L.B., S. Shefer, G. Salen, J.Y. Chiang, and M. Patel (1996). Cholesterol 7α-hydroxylase activities from human and rat liver are modulated in vitro posttranslationally by phosphorylation/dephosphorylation. Hepatology 24, 1468–1474.
Karam, W.G. and J.Y.L. Chiang (1992). Plymorphisms of human cholesterol 7α-hydroxylase. Biochem. Biophys. Res. Commun. 185, 588–595.
Setchell, K.D., M. Schwarz, N.C. O’Connell, E.G. Lund, D.L. Davis, R. Lathe et al. (1998). Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest. 102, 1690–1703.
Hegele, R.A., J. Wang, S.B. Harris, J.H. Brunt, T.K. Young, A.J. Hanley et al. (2001). Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis 154, 579–587.
Balasubramaniam, S., K.A. Mitropoulos, and N.B. Myant (1975). The substrate for cholesterol 7α-hydroxylase. Biochim. Biophys. Acta 398, 172–177.
Norlin, M., A. Toll, I. Björkhem, and K. Wikvall (2000). 24-hydroxycholesterol is a substrate for hepatic cholesterol 7α-hydroxylase (CYP7A). J. Lipid Res. 41, 1629–1639.
Norlin, M., U. Andersson, I. Björkhem, and K. Wikvall (2000). Oxysterol 7α-hydroxylase activity by cholesterol 7α-hydroxylase (CYP7A). J. Biol. Chem. 275, 34046–34053.
Lathe, R. (2002). Steroid and sterol 7-hydroxylation: Ancient pathways. Steroids 67, 967–977.
Nakayama, K., A. Puchkaev, and I.A. Pikuleva (2001). Membrane binding and substrate access merge in cytochrome P450 7A1, a key enzyme in degradation of cholesterol. J. Biol. Chem. 276, 31459–31465.
Stahlberg, D., M. Rudling, B. Angelin, I. Björkhem, P. Forsell, K. Nilsell et al. (1997). Hepatic cholesterol metabolism in human obesity. Hepatology 25, 1447–1450.
Post, S.M., E.C. de Wit, and H.M. Princen (1997). Cafestol, the cholesterol-raising factor in boiled coffee, suppresses bile acid synthesis by downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase in rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 17, 3064–3070.
Pandak, W.M., C. Schwarz, P.B. Hylemon, D. Mallonee, K. Valerie, D.M. Heuman et al. (2001). Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G878–G889.
Sauter, G., M. Weiss, and R. Hoermann (1997). Cholesterol 7α-hydroxylase activity in hypothyroidism and hyperthyroidism in humans. Horm. Metab. Res. 29, 176–179.
Pullinger, C.R., C. Eng, G. Salen, S. Shefer, A.K. Batta, S.K. Erickson et al. (2002). Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J. Clin. Invest. 110, 109–117.
Beigneux, A., A.F. Hofmann, and S.G. Young (2002). Human CYP7A1 deficiency: Progress and enigmas. J. Clin. Invest. 110, 29–31.
Stapleton, G., M. Steel, M. Richardson, J.O. Mason, K.A. Rose, R.G.M. Morris et al. (1995). A novel cytochrome P450 expressed primarily in brain. J. Biol. Chem. 270, 29739–29745.
Rose, K.A., G. Stapleton, K. Dott, M.P. Kieny, R. Best, M. Schwarz et al. (1997). Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7α-hydroxy dehydroepiandrosterone and 7α-hydroxy pregnenolone. Proc. Natl. Acad. Sci. USA 94, 4925–4930.
Rose, K., A. Allan, S. Gauldie, G. Stapleton, L. Dobbie, K. Dott et al. (2001). Neurosteroid hydroxylase CYP7B: Vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation. J. Biol. Chem. 276, 23937–23944.
Bunting, S., S. Moncada, and J.R. Vane (1983). The prostacyclin-thromboxane A2 balance: Pathophysiological and therapeutic implications. Br. Med. Bull. 39, 271–276.
Miyata, A., S. Hara, C. Yokoyama, H. Inoue, V. Ullrich, and T. Tanabe (1994). Molecular cloning and expression of human prostacyclin synthase. Biochem. Biophys. Res. Commun. 200, 1728–1734.
Ullrich, V., L. Castle, and P. Weber (1981). Spectral evidence for the cytochrome P450 nature of prostacyclin synthetase. Biochem. Pharmacol. 30, 2033–2036.
DeWitt, D.L. and W.L. Smith (1983). Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography. Evidence that the enzyme is a hemoprotein. J. Biol. Chem. 258, 3285–3293.
Hara, S., A. Miyata, C. Yokoyama, H. Inoue, R. Brugger, F. Lottspeich et al. (1994). Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. J. Biol. Chem. 269, 19897–19903.
Spisni, E., G. Bartolini, M. Orlandi, B. Belletti, S. Santi, and V. Tomasi (1995). Prostacyclin (PG12) synthase is a constitutively expressed enzyme in human endothelial cells. Exp. Cell Res. 219, 507–513.
Mehl, M., H.J. Bidmon, H. Hilbig, K. Zilles, R. Dringen, and V. Ullrich (1999). Prostacyclin synthase is localized in rat, bovine and human neuronal brain cells. Neurosci. Lett. 271, 187–190.
Siegle, I., T. Klein, M.H. Zou, P. Fritz, and M. Komhoff (2000). Distribution and cellular localization of prostacyclin synthase in human brain. J. Histochem. Cytochem. 48, 631–641.
Huang, J.C., F. Arbab, K.J. Tumbusch, J.S. Goldsby, N. Matijevic-Aleksic, and K.K. Wu (2002). Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI. J. Clin. Endocrinol. Metab. 87, 4361–4368.
Yokoyama, C., T. Yabuki, H. Inoue, Y. Tone, S. Hara, T. Hatae et al. (1996). Human gene encoding prostacyclin synthase (PTGIS): Genomic organization, chromosomal localization, and promoter activity. Genomics 36, 296–304.
Nakayama, T., M. Soma, Y. Izumi, and K. Kanmatsuse (1996). Organization of the human prostacyclin synthase gene. Biochem. Biophys. Res. Commun. 221, 803–806.
Wang, L.H. and L. Chen (1996). Organization of the gene encoding human prostacyclin synthase. Biochem. Biophys. Res. Commun. 226, 631–637.
Chevalier, D., C. Cauffiez, C. Bernard, J.M. Lo-Guidice, D. Allorge, F. Fazio et al. (2001). Characterization of new mutations in the coding sequence and 5′-untranslated region of the human prostacylcin synthase gene (CYP8A1). Hum. Genet. 108, 148–155.
Chevalier, D., D. Allorge, J.M. Lo-Guidice, C. Cauffiez, C. Lepetit, F. Migot-Nabias et al. (2002). Sequence analysis, frequency and ethnic distribution of VNTR polymorphism in the 5′-untranslated region of the human prostacyclin synthase gene (CYP8A1). Prostaglandins Other Lipid Mediat. 70, 31–37.
Nakayama, T., M. Soma, D. Rehemudula, Y. Takahashi, H. Tobe, M. Satoh et al. (2000). Association of 5′ upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am. J. Hypertens. 13, 1263–1267.
Nakayama, T., M. Soma, S. Saito, J. Honye, J. Yajima, D. Rahmutula et al. (2002). Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am. Heart J. 143, 797–801.
Nakayama, T., M. Soma, Y. Takahashi, D. Rehemudula, H. Tobe, M. Sato et al. (2001). Polymorphism of the promoter region of prostacyclin synthase gene is not related to essential hypertension. Am. J. Hypertens. 14, 409–411.
Nakayama, T., M. Soma, D. Rahmutula, H. Tobe, M. Sato, J. Uwabo et al. (2002). Association study between a novel single nucleotide polymorphism of the promoter region of the prostacyclin synthase gene and essential hypertension. Hypertens. Res. 25, 65–68.
Nakayama, T., M. Soma, Y. Watanabe, B. Hasimu, M. Sato, N. Aoi et al. (2002). Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. Biochem. Biophys. Res. Commun. 297, 1135–1139.
Hatae, T., S. Hara, C. Yokoyama, T. Yabuki, H. Inoue, V. Ullrich et al. (1996). Site-directed mutagenesis of human prostacyclin synthase: Alteration of Cys441 of the Cys-pocket, and Glu347 and Arg350 of the EXXR motif. FEBS Lett. 389, 268–272.
Shyue, S.K., K.H. Ruan, L.H. Wang, and K.K. Wu (1997). Prostacyclin synthase active sites. Identification by molecular modeling-guided site-directed mutagenesis. J. Biol. Chem. 272, 3657–3662.
Lin, Y., K.K. Wu, and K.H. Ruan (1998). Characterization of the secondary structure and membrane interaction of the putative membrane anchor domains of prostaglandin I2 synthase and cytochrome P450 2C1. Arch. Biochem. Biophys. 352, 78–84.
Lin, Y.Z., H. Deng, and K.H. Ruan (2000). Topology of catalytic portion of prostaglandin I2 synthase: Identification by molecular modeling-guided site-specific antibodies. Arch. Biochem. Biophys. 379, 188–197.
Deng, H., A. Huang, S.P. So, Y.Z. Lin, and K.H. Ruan (2002). Substrate access channel topology in membrane-bound prostacyclin synthase. Biochem. J. 362, 545–551.
Reed, G.A., I.O. Griffin, and T.E. Eling (1985). Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. Mol. Pharmacol. 27, 109–114.
Wade, M.L., N.F. Voelkel, and F.A. Fitzpatrick (1995). “Suicide” inactivation of prostaglandin I2 synthase: Characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Arch. Biochem. Biophys. 321, 453–458.
Zou, M.H. and V. Ullrich (1996). Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 382, 101–104.
Crow, J.P. and J.S. Beckman (1995). Reactions between nitric oxide, superoxide, and peroxynitrite: Footprints of peroxynitrite in vivo. Adv. Pharmacol. 34, 17–43.
Zou, M., C. Martin, and V. Ullrich (1997). Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol. Chem. 378, 707–713.
Schmidt, P., N. Youhnovski, A. Daiber, A. Balan, M. Arsic, M. Bachschmid et al. (2003). Specific nitration at tyrosine-430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J. Biol. Chem. 278, 12813–12819.
Tuder, R.M., C.D. Cool, M.W. Geraci, J. Wang, S.H. Abman, L. Wright et al. (1999). Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159, 1925–1932.
Iwai, N., T. Katsuya, K. Ishikawa, T. Mannami, J. Ogata, J. Higaki et al. (1999). Human prostacyclin synthase gene and hypertension: The Suita study. Circulation 100, 2231–2236.
Geraci, M.W., B. Gao, D.C. Shepherd, M.D. Moore, J.Y. Westcott, K.A. Fagan et al. (1999). Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest. 103, 1509–1515.
Todaka, T., C. Yokoyama, H. Yanamoto, N. Hashimoto, I. Nagata, T. Tsukahara et al. (1999). Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 30, 419–426.
Pradono, P., R. Tazawa, M. Maemondo, M. Tanaka, K. Usui, Y. Saijo et al. (2002). Gene transfer of thromboxane A2 synthase and prostaglandin I2 synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62, 63–66.
Leeder, J.S., X. Lu, Y. Timsit, and A. Gaedigk (1998). Non-monooxygenase cytochromes P450 as potential human auto antigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics 8, 211–225.
Gafvels, M., M. Olin, B.P. Chowdhary, T. Raudsepp, U. Andersson, B. Persson et al. (1999). Structure and chromosomal assignment of the sterol 12α-hydroxylase gene (CYP8B1) in human and mouse: Eukaryotic cytochrome P-450 gene devoid of introns. Genomics 56, 184–196.
Zhang, M. and J.Y. Chiang (2001). Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): Roles of hepatocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem. 276, 41690–41699.
Gerbod-Giannone, M.C., A. Del Castillo-Olivares, S. Janciauskiene, G. Gil, and P.B. Hylemon (2002). Suppression of cholesterol 7α-hydroxylase transcription and bile acid synthesis by an α1-antitrypsin peptide via interaction with α1-fetoprotein transcription factor. J. Biol. Chem. 277, 42973–42980.
Yang, Y., M. Zhang, G. Eggertsen, and J.Y. Chiang (2002). On the mechanism of bile acid inhibition of rat sterol 12α-hydroxylase gene (CYP8B1) transcription: Roles of α-fetoprotein transcription factor and hepatocyte nuclear factor 4α. Biochim. Biophys. Acta 1583, 63–73.
Wang, H.P. and T. Kimura (1976). Purification and characterization of adrenal cortex mitochondrial cytochrome P-450 specific for cholesterol side chain cleavage activity. J. Biol. Chem. 251, 6068–6074.
Morohashi, K., K. Sogawa, T. Omura, and Y. Fujii-Kuriyama (1987). Gene structure of human cytochrome P-450(SCC), cholesterol desmolase. J. Biochem. (Tokyo) 101, 8879–8887.
Poulos, T.L., B.C. Finzel, I.C. Gunsalus, G.C. Wagner, and J. Kraut (1985). The 2.6-Å crystal structure of Pseudomonas putida cytochrome P-450. J. Biol. Chem. 260, 16122–16130.
Belfiore, C.J., D.E. Hawkins, M.C. Wiltbank, and G.D. Niswender (1994). Regulation of cytochrome P450scc synthesis and activity in the ovine corpus luteum. J. Steroid Biochem. Mol. Biol. 51, 283–290.
Matocha, M.F. and M.R. Waterman (1986). Import and processing of P-450scc and P-45011β precursors by corpus luteal mitochondria: A processing pathway recognizing homologous and heterologous precursors. Arch. Biochem. Biophys. 250, 456–460.
Sasano, H., M. Okamoto, J.I. Mason, E.R. Simpson, C.R. Mendelson, N. Sasano et al. (1989). Immunolocalization of aromatase, 17α-hydroxylase and side-chain-cleavage cytochromes P-450 in the human ovary. J. Reprod. Fertil. 85, 163–169.
Chung, B.C., I.C. Guo, and S.J. Chou (1997). Transcriptional regulation of the CYP11A1 and ferredoxin genes. Steroids 62, 37–42.
Walther, B., J.F. Ghersi-Egea, A. Minn, and G. Siest (1987). Brain mitochondrial cytochrome P-450scc: Spectral and catalytic properties. Arch. Biochem. Biophys. 254, 592–596.
Warner, M. and J.A. Gustafsson (1995). Cytochrome P450 in the brain: Neuroendocrine functions. Front. Neuroendocrinol. 16, 224–236.
Beyenburg, S., B. Stoffel-Wagner, M. Watzka, I. Blumcke, J. Bauer, J. Schramm et al. (1999). Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy. Neuroreport 10, 3067–3070.
Watzka, M., F. Bidlingmaier, J. Schramm, D. Klingmuller, and B. Stoffel-Wagner (1999). Sex-and age-specific differences in human brain CYP11A1 mRNA expression. J. Neuroendocrinol. 11, 901–905.
Morales, A., A. Cuellar, J. Ramirez, F. Vilchis, and V. Diaz-Sanchez (1999). Synthesis of steroids in pancreas: Evidence of cytochrome P-450scc activity. Pancreas 19, 39–44.
Ou, W., A. Ito, K. Morohashi, Y. Fujii-Kuriyama, and T. Omura (1986). Processing-independent in vitro translocation of cytochrome P-450SCC precursor across mitochondrial membranes. J. Biochem. (Tokyo) 100, 1287–1296.
Kumamoto, T., K. Morohashi, A. Ito, and T. Omura (1987). Site-directed mutagenesis of basic amino acid residues in the extension peptide of P-450SCC precursor: Effects on the import of the precursor into mitochondria. J. Biochem. (Tokyo) 102, 833–838.
Black, S.M., J.A. Harikrishna, G.D. Szklarz, and W.L. Miller (1994). The mitochondrial environment is required for activity of the cholesterol side-chain cleavage enzyme, cytochrome P450scc. Proc. Natl. Acad. Sci. USA 91, 7247–7251.
Venepally, P. and M.R. Waterman (1995). Two Sp1-binding site mediate cAMP-induced transcription of the bovine CYP11A gene through the protein kinase A signaling pathway. J. Biol. Chem. 270, 25402–25410.
Ahlgren, R., G. Suske, M.R. Waterman, and J. Lund (1999). Role of Sp1 in cAMP-dependent transcriptional regulation of the bovine CYP11A gene. J. Biol. Chem. 274, 19422–19428.
Guo, I.C. and B.C. Chung (1999). Cell-type specificity of human CYP11A1 TATA box. J. Steroid Biochem. Mol. Biol. 69, 329–334.
Huang, Y., M. Hu, N. Hsu, C.L. Wang, and B. Chung (2001). Action of hormone responsive sequence in 2.3 kb promoter of CYP11A1. Mol. Cell Endocrinol. 175, 205–210.
Hu, M.C., N.C. Hsu, C.I. Pai, C.K. Wang, and B. Chung (2001). Functions of the upstream and proximal steroidogenic factor 1 (SF-1)-binding sites in the CYP11A1 promoter in basal transcription and hormonal response. Mol. Endocrinol. 15, 812–818.
Liu, Z. and E.R. Simpson (1999). Molecular mechanism for cooperation between Sp1 and steroidogenic factor-1 (SF-1) to regulate bovine CYP11A gene expression. Mol. Cell Endocrinol. 153, 183–196.
Gizard, F., B. Lavallee, F. DeWitte, and D.W. Hum (2001). A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression. J. Biol. Chem. 276, 33881–33892.
Gizard, F., B. Lavallee, F. DeWitte, E. Teissier, B. Staels, and D.W. Hum (2002). The transcriptional regulating protein of 132 kDa (TReP-132) enhances P450scc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells. J. Biol. Chem. 277, 39144–39155.
Doi, J., H. Takemori, X.Z. Lin, N. Horike, Y. Katoh, and M. Okamoto (2002). Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain. J. Biol. Chem. 277, 15629–15637.
Ben-Zimra, M., M. Koler, and J. Orly (2002). Transcription of cholesterol side-chain cleavage cytochrome P450 in the placenta: Activating protein-2 assumes the role of steroidogenic factor-1 by binding to an overlapping promoter element. Mol. Endocrinol. 16, 1864–1880.
Katsumata, N., M. Ohtake, T. Hojo, E. Ogawa, T. Hara, N. Sato et al. (2002). Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J. Clin. Endocrinol. Metab. 87, 3808–3813.
Tuckey, R.C. and K.J. Cameron (1993). Human placental cholesterol side-chain cleavage: Enzymatic synthesis of (22R)-20α,22-dihydroxycholesterol. Steroids 58, 230–233.
Murray, R.I. and S.G. Sligar (1985). Oxidative cleavage of 1-phenyl-1,2-ethanediol by 4-cyano-N,N-dimethylaniline N-oxide and chloro (5,10,15,20-tetraphenylporphinato) chromium (III): A model for cholesterol side-chain cleavage by cytochrome P-450scc. J. Am. Chem. Soc. 107, 2186–2187.
Okamoto, T., K. Sasaki, and S. Oka (1988). Biomimetic oxidation with molecular oxygen. Selective carbon-carbon bond cleavage of 1,2-diols by molecular oxygen and dihydropyridine in the presence of iron-porphyrin catalysts. J. Am. Chem. Soc. 110, 1187–1196.
Ortiz de Montellano, P.R. (1995). Oxygen activation and reactivity. In P.R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry. Plenum Press, New York, pp. 245–303.
Tuckey, R.C., S.T. Woods, and M. Tajbakhsh (1997). Electron transfer to cytochrome P-450scc limits cholesterol-side-chain-cleavage activity in the human placenta. Eur. J. Biochem. 244, 835–839.
Beckert, V. and R. Bernhardt (1997). Specific aspects of electron transfer from adrenodoxin to cytochromes P450scc and P45011β. J. Biol. Chem. 272, 4883–4888.
Cao, P. and R. Bernhardt (1999). Interaction of CYP11B1 (cytochrome P-45011β) with CYP11A1 (cytochrome P-450scc) in COS-1 cells. Eur. J. Biochem. 262, 720–726.
Usanov, S.A. and V.L. Chashchin (1991). Interaction of cytochrome P-450scc with cytochrome b 5. FEBS Lett. 278, 279–282.
Wada, A. and M.R. Waterman (1992). Identification by site-directed mutagenesis of two lysine residues in cholesterol side chain cleavage cytochrome P450 that are essential for adrenodoxin binding. J. Biol. Chem. 267, 22877–22882.
Woods, S.T., J. Sadleir, T. Downs, T. Triantopoulos, M.J. Headlam, and R.C. Tuckey (1998). Expression of catalytically active human cytochrome P450scc in Escherichia coli and mutagenesis of isoleucine-462. Arch. Biochem. Biophys. 353, 109–115.
Vickery, L.E. and J.T. Kellis (1983). Inhibition of adrenocortical cytochrome P-450scc by (20R)-20-phenyl-5-pregnene-3β,20-diol: Mechanism and implications for the structure of the active site. J. Biol. Chem. 258, 3832–3836.
Vickery, L.E. and J. Singh (1988). 22-Thio-23,24-bisnor-5-cholen-3 β-ol: An active site-directed inhibitor of cytochrome P450scc. J. Steroid Biochem. 29, 539–543.
Olakanmi, O. and D.W. Seybert (1990). Modified acetylenic steroids as potent mechanism-based inhibitors of cytochrome P-450scc. J. Steroid Biochem. 36, 273–280.
Jarman, M., S.E. Barrie, C.S. Leung, and M.G. Rowlands (1988). Selective inhibition of cholesterol side-chain cleavage by potential pro-drug forms of aminoglutethimide. Anticancer Drug Design 3, 185–190.
Ohnishi, T. and Y. Ichikawa (1997). Direct inhibitions of the activities of steroidogenic cytochrome P-450 mono-oxygenase systems by anticonvulsants. J. Steroid Biochem. Mol. Biol. 60, 77–85.
Yang, X., K. Iwamoto, M. Wang, J. Artwohl, J.I. Mason, and S. Pang (1993). Inherited congenital adrenal hyperplasia in the rabbit is caused by a deletion in the gene encoding cytochrome P450 cholesterol side-chain cleavage enzyme. Endocrinology 132, 1977–1982.
Hu, M.C., N.C. Hsu, N.B. El Hadj, C.I. Pai, H.P. Chu, C.K. Wang et al. (2002). Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1. Mol. Endocrinol. 16, 1943–1950.
Chen, S., J. Sawicka, C. Betterle, M. Powell, L. Prentice, M. Volpato et al. (1996). Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison’s disease, and premature ovarian failure. J. Clin. Endocrinol. Metab. 81, 1871–1876.
Seissler, J., M. Schott, H. Steinbrenner, P. Peterson, and W.A. Scherbaum (1999). Autoantibodies to adrenal cytochrome P450 antigens in isolated Addison’s disease and autoimmune polyendocrine syndrome type II. Exp. Clin. Endocrinol. Diabetes 107, 208–213.
Bureik, M., M. Lisurek, and R. Bernhardt (2002). The human steroid hydroxylases CYP11B1 and CYP11B2. Biol. Chem. 383, 1537–1551.
Watanuki, M., B.E. Tilley, and P.F. Hall (1978). Cytochrome P-450 for 11β-and 18-hydroxylase activities of bovine adrenocortical mitochondria: One enzyme or two?. Biochemistry 17, 127–130.
Mornet, E., J. Dupont, A. Vitek, and P.C. White (1989). Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11)β). J. Biol. Chem. 264, 20961–20967.
Kawamoto, T., Y. Mitsuuchi, K. Toda, K. Miyahara, Y. Yokoyama, K. Nakao et al. (1990). Cloning of cDNA and genomic DNA for human cytochrome P-45011α. FEBS Lett. 269, 345–349.
Zhang, G. and W.L. Miller (1996). The human genome contains only two CYP11B (P450c11) genes. J. Clin. Endocrinol. Metab. 81, 3254–3256.
Kawamoto, T., Y. Mitsuuchi, K. Toda, Y. Yokoyama, K. Miyahara, S. Miura et al. (1992). Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc. Natl. Acad. Sci. USA 89, 1458–1462.
Freije, W.A., V. Pezzi, A. Arici, B.R. Carr, and W.E. Rainey (1997). Expression of 11 beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) in the human fetal adrenal. J. Soc. Gynecol. Investig. 4, 305–309.
Morohashi, K., U.M. Zanger, S. Honda, M. Hara, M.R. Waterman, and T. Omura (1993). Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP. Mol. Endocrinol. 7, 1196–1204.
Honda, S., K. Morohashi, M. Nomura, H. Takeya, M. Kitajima, and T. Omura (1993). Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor superfamily. J. Biol. Chem. 268, 7494–7502.
Hashimoto, T., K. Morohashi, K. Takayama, S. Honda, T. Wada, H. Handa et al. (1992). Cooperative transcription activation between Ad1, a CRE-like element, and other elements in the CYP11B gene promoter. J. Biochem. (Tokyo) 112, 573–575.
Mukai, K., F. Mitani, R. Agake, and Y. Ishimura (1998). Adrenocorticotropic hormone stimulates CYP11B1 gene transcription through a mechanism involving AP-1 factors. Eur. J. Biochem. 256, 190–200.
Wang, X.L., M. Bassett, Y. Zhang, S. Yin, C. Clyne, P.C. White et al. (2000). Transcriptional regulation of human 11β-hydroxylase (hCYP11B1). Endocrinology 141, 3587–3594.
Bassett, M.H., Y. Zhang, C. Clyne, P.C. White, and W.E. Rainey (2002). Differential regulation of aldosterone synthase and 11β-hydroxylase transcription by steroidogenic factor-1. J. Mol. Endocrinol. 28, 125–135.
Skinner, C.A. and G. Rumsby (1994). Steroid 11 beta-hydroxylase deficiency caused by a five base pair duplication in the CYP11B1 gene. Hum. Mol. Genet. 3, 377–378.
Curnow, K.M., L. Slutsker, J. Vitek, T. Cole, P.W. Speiser, M.I. New et al. (1993). Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc. Natl. Acad. Sci. USA 90, 4552–4556.
Lifton, R.P., R.G. Dluhy, M. Powers, G.M. Rich, S. Cook, S. Ulick et al. (1992). A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355, 262–265.
Pascoe, L., K.M. Curnow, L. Slutsker, J.M. Connell, P.W. Speiser, M.I. New et al. (1992). Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2, Proc. Natl. Acad. Sci. USA 89, 8327–8331.
Hampf, M., N.T. Dao, N.T. Hoan, and R. Bernhardt (2001). Unequal crossing-over between aldosterone synthase and 11β-hydroxylase genes causes congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 86, 4445–4452.
Portrat, S., P. Mulatero, K.M. Curnow, J.L. Chaussain, Y. Morel, and L. Pascoe (2001). Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone synthase) cause steroid 11β-hydroxylase deficiency and congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 86, 3197–3201.
Chabre, O., S. Portrat-Doyen, J. Vivier, Y. Morel, and G. Defaye (2000). Two novel mutations in splice donor sites of CYP11B1 in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrinol. Res. 26, 797–801.
Mulatero, P., K.M. Curnow, B. Aupetit-Faisant, M. Foekling, C. Gomez-Sanchez, F. Veglio, X. Jeunemaitre et al. (1998). Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J. Clin. Endocrinol. Metab. 83, 3996–4001.
Fisher, A., E. Davies, R. Fraser, and J.M. Connell (1998). Structure-function relationships of aldosterone synthase and 11β-hydroxylase enzymes: Implications for human hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 25, S42–S46.
Fisher, A., R. Fraser, J. McConnell, and E. Davies (2000). Amino acid residue 147 of human aldosterone synthase and 11β-hydroxylase plays a key role in 11β-hydroxylation. J. Clin. Endocrinol. Metab. 85, 1261–1266.
Böttner, B., K. Denner, and R. Bernhardt (1998). Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur. J. Biochem. 252, 458–466.
Lewis, D.F. and P. Lee-Robichaud (1998). Molecular modelling of steroidogenic cyto-chromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J. Steroid Biochem. Mol. Biol. 66, 217–233.
Belkina, N.V., M. Lisurek, A.S. Ivanov, and R. Bernhardt (2001). Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. J. Inorg. Biochem. 87, 197–207.
Denner, K., R. Vogel, W. Schmalix, J. Doehmer, and R. Bernhardt (1995). Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics 5, 89–96.
Johnston, J.O., C.L. Wright, and G.W. Holbert (1995). Enzyme-activated inhibitors of steroidal hydroxylases. J. Steroid Biochem. Mol. Biol. 52, 17–34.
Delorme, C., A. Piffeteau, F. Sobrio, and A. Marquet (1997). Mechanism-based inactivation of bovine cytochrome P45011β by 18-unsaturated progesterone derivatives. Eur. J. Biochem. 248, 252–260.
White, P.C. (2001). Steroid 11β-hydroxylase deficiency and related disorders. Endocrinol. Metab. Clin. North Am. 30, 61–79.
Peter, M., J.M. Dubuis, and W.G. Sippell (1999). Disorders of the aldosterone synthase and steroid 11β-hydroxylase deficiencies. Horm. Res. 51, 211–222.
Pascoe, L., K.M. Curnow, L. Slutsker, A. Rösler, and P.C. White (1992). Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc. Natl. Acad. Sci. USA 89, 4996–5000.
Mitsuuchi, Y., T. Kawamoto, K. Miyahara, S. Ulick, D.H. Morton, Y. Naiki et al. (1993). Congenitally defective aldosterone biosynthesis in humans: Inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem. Biophys. Res. Commun. 190, 864–869.
Kawamoto, T., Y. Mitsuuchi, T. Ohnishi, Y. Ichikawa, Y. Yokoyama, H. Sumimoto et al. (1990). Cloning and expression of a cDNA for human cytochrome P-450aldo as related to primary aldosteronism. Biochem. Biophys. Res. Commun. 173, 309–316.
Curnow, K.M., M.T. Tusie-Luna, L. Pascoe, R. Natarajan, J.L. Gu, J.L. Nadler et al. (1991). The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol. Endocrinol. 5, 1513–1522.
Li, X., Y. Meng, X.S. Yang, P.S. Wu, S.M. Li, and W.Y. Lai (2000). CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis. World J. Gastroenterol. 6, 885–887.
Bassett, M.H., Y. Zhang, P.C. White, and W.E. Rainey (2000). Regulation of human CYP11B2 and CYP11B1: Comparing the role of the common CRE/Ad1 element. Endocrinol. Res. 26, 941–951.
Clyne, C.D., P.C. White, and W.E. Rainey (1996). Calcium regulates human CYP11B2 transcription. Endocrinol. Res. 22, 485–492.
Bureik, M., A. Zeeh, and R. Bernhardt (2002). Modulation of steroid hydroxylase activity in stably transfected V79MZh11B1 and V79MZh11B2 cells by PKC and PKD inhibitors. Endocrinol. Res. 28, 351–355.
J.G. LeHoux, G. Dupuis, and A. Lefebvre (2000). Regulation of CYP11B2 gene expression by protein kinase C. Endocrinol. Res. 26, 1027–1031.
Ise, T., A. Shimoda, H. Takakuwa, T. Kato, Y. Izumiya, K. Shimizu et al. (2001). A chimeric CYP11B1/CYP11B2 gene in glucocorticoid-insuppressible familial hyperaldosteronism. Clin. Endocrinol. (Oxford) 55, 131–134.
Jackson, R.V., A. Lafferty, D.J. Torpy, and C. Stratakis (2002). New genetic insights in familial hyperaldosteronism. Ann. N. Y. Acad. Sci. 970, 77–88.
Zhang, G., H. Rodriguez, C.E. Fardella, D.A. Harris, and W.L. Miller (1995). Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency. Am. J. Hum. Genet. 57, 1037–1043.
Mulatero, P., D. Schiavone, F. Fallo, F. Rabbia, C. Pilon, L. Chiandussi et al. (2000). CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 35, 694–698.
Tsukada, K., T. Ishimitsu, M. Teranishi, M. Saitoh, M. Yoshii, H. Inada et al. (2002). Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J. Hum. Hypertens. 16, 789–793.
Bechtel, S., N. Belkina, and R. Bernhardt (2002). The effect of amino-acid substitutions I112P, D147E and K152N in CYP11B2 on the catalytic activities of the enzyme. Eur. J. Biochem. 269, 1118–1127.
Ehmer, P.B., M. Bureik, R. Bernhardt, U. Muller, and R.W. Hartmann (2002). Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): Screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 81, 173–179.
Griffing, G.T., M. Holbrook, J.C. Melby, J. Alberta, and N.R. Orme-Johnson (1989). 19-Hydroxylase inhibition of adrenal mitochondrial P450 11β/18/19-hydroxylase by a suicide inhibitor. Am. J. Med. Sci. 298, 83–88.
Davies, E., C.D. Holloway, M.C. Ingram, G.C. Inglis, E.C. Friel, C. Morrison et al. (1999). Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33, 703–707.
White, P.C., A. Hautanen, and M. Kupari (1999). Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function. J. Steroid Biochem. Mol. Biol. 69, 409–412.
Kupari, M., A. Hautanen, L. Lankinen, P. Koskinen, J. Virolainen, H. Nikkila et al. (1998). Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97, 569–575.
Satoh, M., M. Nakamura, H. Saitoh, H. Satoh, T. Akatsu, J. Iwasaka et al. (2002). Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. (London) 102, 381–386.
Russo, P., A. Siani, A. Venezia, R. Iacone, O. Russo, G. Barba et al. (2002). Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: Cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. J. Hypertens. 20, 1785–1792.
Lim, P.O., T.M. Macdonald, C. Holloway, E. Friel, N.H. Anderson, E. Dow et al. (2002). Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J. Clin. Endocrinol. Metab. 87, 4398–4402.
Tsujita, Y., N. Iwai, T. Katsuya, J. Higaki, T. Ogihara, S. Tamaki et al. (2001). Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: The Suita Study. Hypertens. Res. 24, 105–109.
Chung, B., J. Picado-Leonard, M. Haniu, M. Bienkowski, P.F. Hall, J.E. Shively et al. (1987). Cytochrome P450c17 (steroid 17α-hydroxylase/17, 20 lyase): Cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. USA 84, 407–411.
Picado-Leonard, J. and W.L. Miller (1987). Cloning and sequence of the human gene for P450c17 (steroid 17 α-hydroxylase/17, 20 lyase): Similarity with the gene for P450c21. DNA 6, 439–448.
Nakajin, S., J.E. Shively, P.M. Yuan, and P.F. Hall (1981). Microsomal cytochrome P-450 from neonatal pig testis: Two enzymatic activities (17α-hydroxylase and C17,20-lyase) associated with one protein. Biochemistry 20, 4037–4042.
Katagiri, M., K. Suhara, M. Shiroo, and Y. Fujimura (1982). Role of cytochrome b 5 in the cytochrome P-450-mediated C21-steroid 17,20-lyase reaction. Biochem. Biophys. Res. Commun. 108, 379–384.
Shinzawa, K., S. Kominami, and S. Takemori (1985). Studies on cytochrome P-450 (P-45017α, lyase) from guinea pig adrenal microsomes. Dual function of a single enzyme and effect of cytochrome b 5. Biochim. Biophys. Acta 833, 151–160.
Casey, M.L. and P.C. MacDonald (1982). Demonstration of steroid 17α-hydroxylase activity in human fetal kidney, thymus, and spleen. Steroids 40, 91–97.
Kayes-Wandover, K.M. and P.C. White (2000). Steroidogenic enzyme gene expression in the human heart. J. Clin. Endocrinol. Metab. 85, 2519–2525.
Puche, C., M. Jose, A. Cabero, and A. Meseguer (2002). Expression and enzymatic activity of the P450c17 gene in human adipose tissue. Eur. J. Endorinol. 146, 223–229.
Kusano, K., M. Sakaguchi, N. Kagawa, M.R. Waterman, and T. Omura (2001). Microsomal P450s use specific proline-rich sequences for efficient folding, but not for maintenance of the folded structure. J. Biochem. (Tokyo) 129, 259–269.
Hales, D.B., L.L. Sha, and A.H. Payne (1987). Testosterone inhibits cAMP-induced de novo synthesis of Leydig cell cytochrome P-450(17α) by an androgen receptor-mediated mechanism. J. Biol. Chem. 262, 11200–11206.
Zhang, P., X.G. Han, S.H. Mellon, and P.F. Hall (1996). Expression of the gene for cytochrome P-450 17α-hydroxylase/C17-20 lyase (CYP17) in porcine Leydig cells: Identification of a DNA sequence that mediates cAMP response. Biochim. Biophys. Acta 1307, 73–82.
Ogo, A., M.R. Waterman, J.M. McAllister, and N. Kagawa (1997). The homeodomain protein Pbx1 is involved in cAMP-dependent transcription of human CYP17. Arch. Biochem. Biophys. 348, 226–231.
Bischof, L.J., N. Kagawa, and M.R. Waterman (1998). The bovine CYP17 promoter contains a transcriptional regulatory element cooperatively bound by tale homeodomain proteins. Endocrinol. Res. 24, 489–495.
Lin, C.J., J.W. Martens, and W.L. Miller (2001). NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17α-hydroxylase/17, 20 lyase) in human adrenal NCI-H295A cells. Mol. Endocrinol. 15, 1277–1293.
Sewer, M.B., V.Q. Nguyen, C.J. Huang, P.W. Tucker, N. Kagawa, and M.R. Waterman (2002). Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54nrb/NonO, protein-associated splicing factor, and SF-1, a complex that also participates in repression of transcription. Endocrinology 143, 1280–1290.
Sewer, M.B. and M.R. Waterman (2002). Adrenocorticotropin/cyclic adenosine 3′,5′-monophosphate-mediated transcription of the human CYP17 gene in the adrenal cortex is dependent on phosphatase activity. Endocrinology 143, 1769–1777.
Sewer, M.B. and M.R. Waterman (2002). cAMP-dependent transcription of steroidogenic genes in the human adrenal cortex requires a dual-specificity phosphatase in addition to protein kinase A. J. Mol. Endocrinol. 29, 163–174.
Sewer, M.B. and M.R. Waterman (2003). cAMP-dependent protein kinase enhances CYP17 transcription via MKP-1 activation in H295R human adrenocortical cells. J. Biol. Chem. 278, 8106–8111.
Yanase, T. (1995). 17α-Hydroxylase/17,20-lyase defects. J. Steroid Biochem. Mol. Biol. 53, 153–157.
Fardella, C.E., D.W. Hum, J. Homoki, and W.L. Miller (1994). Point mutation of Arg440 to His in cytochrome P450c17 causes severe 17α-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 79, 160–164.
Imai, T., H. Globerman, J.M. Gertner, N. Kagawa, and M.R. Waterman (1993). Expression and purification of functional human 17α-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17α-hydroxylase/17,20-lyase deficiency. J. Biol. Chem. 268, 19681–19689.
Monno, S., Y. Mizushima, N. Toyoda, T. Kashii, and M. Kobayashi (1997). A new variant of the cytochrome P450c17 (CYP17) gene mutation in three patients with 17α-hydroxylase deficiency. Ann. Hum. Genet. 61, 275–279.
Kagimoto, K., M.R. Waterman, M. Kagimoto, P. Ferreira, E.R. Simpson, and J.S. Winter (1989). Identification of a common molecular basis for combined 17α-hydroxylase/17,20-lyase deficiency in two Mennonite families. Hum. Genet. 82, 285–286.
Yamaguchi, H., M. Nakazato, M. Miyazato, K. Kangawa, and S. Matsukura (1997). A 5′-splice site mutation in the cytochrome P450 steroid 17α-hydroxylase gene in 17α-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 82, 1934–1938.
Geller, D.H., R.J. Auchus, B.B. Mendonça, and W.L. Miller (1997). The genetic and functional basis of isolated 17,20-lyase deficiency. Nat. Genet. 17, 201–205.
Miller, W.L., D.H. Geller, and R.J. Auchus (1998). The molecular basis of isolated 17, 20 lyase deficiency. Endocrinol. Res. 24, 817–825.
Auchus, R.J. and M.K. Gupta (2002). Towards a unifying mechanism for CYP17 mutations that cause isolated 17,20-lyase deficiency. Endocrinol. Res. 28, 443–447.
Kagawa, N. and M.R. Waterman (1995). Regulation of steroidogenic and related P450s. In P.R. Ortiz de Montellano (ed.), Cytochrome P450-Structure, Mechanism, and Biochemistry, 2nd edn. Plenum Press, New York, pp. 419–442.
P. Lee-Robichaud, A.Z. Shyadehi, J.N. Wright, M.E. Akhtar, and M. Akhtar (1995). Mechanistic kinship between hydroxylation and desaturation reactions: Acyl-carbon bond cleavage promoted by pig and human CYP17 (P-45017a; 17α-hydroxylase-17,20-lyase). Biochemistry 34, 14104–14113.
Lieberman, S. and P.A. Warne (2001). 17-Hydroxylase: An evaluation of the present view of its catalytic role in steroidogenesis. J. Steroid Biochem. Mol. Biol. 78, 299–312.
Soucy, P., L. Lacoste, and V. Luu-The (2003). Assessment of porcine and human 16-enesynthase, a third activity of P450c17, in the formation of an androstenol precursor. Eur. J. Biochem. 270, 1349–1355.
Katagiri, M., N. Kagawa, and M.R. Waterman (1995). The role of cytochrome b 5 in the biosynthesis of androgens by human P450c17. Arch. Biochem. Biophys. 317, 343–347.
Miller, W.L., R.J. Auchus, and D.H. Geller (1997). The regulation of 17, 20 lyase activity. Steroids 62, 133–142.
Biason-Lauber, A., B. Kempken, E. Werder, M.G. Forest, S. Einaudi, M.B. Ranke et al. (2000). 17α-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: Role of phosphorylation. J. Clin. Endocrinol. Metab. 85, 1226–1231.
Soucy, P. and V. Luu-The (2002). Assessment of the ability of type 2 cytochrome b 5 to modulate 17,20-lyase activity of human P450c17. J. Steroid Biochem. Mol. Biol. 80, 71–75.
Brock, B.J. and M.R. Waterman (1999). Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry 38, 1598–1606.
Yamazaki, T., T. Ohno, T. Sakaki, M. Akiyoshi-Shibata, Y. Yabusaki, T. Imai et al. (1998). Kinetic analysis of successive reactions catalyzed by bovine cytochrome P45017α,lyase. Biochemistry 37, 2800–2806.
Soucy, P. and V. Luu-The (2000). Conversion of pregnenolone to DHEA by human 17α-hydroxylase/17,20-lyase (P450c17). Evidence that DHEA is produced from the released intermediate, 17α-hydroxypregnenolone. Eur. J. Biochem. 267, 3243–3247.
Monno, S., H. Ogawa, T. Date, M. Fujioka, W.L. Miller, and M. Kobayashi (1993). Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17α-hydroxylase deficiency. J. Biol. Chem. 268, 25811–25817.
Lam, C.W., W. Arlt, C.K. Chan, J.W. Honour, C.J. Lin, S.F. Tong et al. (2001). Mutation of proline 409 to arginine in the meander region of cytochrome p450c17 causes severe 17α-hydroxylase deficiency. Mol. Genet. Metab. 72, 254–259.
Lee-Robichaud, P., M.E. Akhtar, and M. Akhtar (1998). An analysis of the role of active site protic residues of cytochrome P-450s: Mechanistic and mutational studies on 17α-hydroxylase-17,20-lyase (P-45017α also CYP17). Biochem. J. 330, 967–974.
Kitamura, M., E. Buczko, and M.L. Dufau (1991). Dissociation of hydroxylase and lyase activities by site-directed mutagenesis of the rat P45017α. Mol. Endocrinol. 5, 1373–1380.
Biason-Lauber, A., E. Leiberman, and M. Zachmann (1997). A single amino acid substitution in the putative redox partner-binding site of P450c17 as cause of iolated 17,20-lyase deficiency. J. Clin. Endocrinol. Metab. 82, 3807–3812.
Lee-Robichaud, P., M.E. Akhtar, and M. Akhtar (1998). Control of androgen biosynthesis in the human through the interaction of Arg347 and Arg358 of CYP17 with cytochrome b 5. Biochem. J. 332, 293–296.
LeeRobichaud, P., M.E. Akhtar, and M. Akhtar (1999). Lysine mutagenesis identifies cationic charges of human CYP17 that interact with cytochrome b 5 to promote male sex-hormone biosynthesis. Biochem. J. 342, 309–312.
Auchus, R.J., K. Worthy, D.H. Geller, and W.L. Miller (2000). Probing structural and functional domains of human P450c17. Endocrinol. Res. 26, 695–703.
Gupta, M.K., D.H. Geller, and R.J. Auchus (2001). Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. J. Clin. Endocrinol. Metab. 86, 4416–4423.
Di Cerbo, A., A. Biason-Lauber, M. Savino, M.R. Piemontese, A. Di Giorgio, M. Perona et al. (2002). Combined 17α-hydroxylase/17,20-lyase deficiency caused by Phe93Cys mutation in the CYP17 gene. J. Clin. Endocrinol. Metab. 87, 898–905.
Katsumata, N., M. Satoh, A. Mikami, S. Mikami, A. Nagashima-Miyokawa, N. Sato et al. (2001). New compound heterozygous mutation in the CYP17 gene in a 46,XY girl with 17α-hydroxylase/17,20-lyase deficiency. Horm. Res. 55, 141–146.
Brock, B.J. and M.R. Waterman (2000). The use of random chimeragenesis to study structure/function properties of rat and human P450c17. Arch. Biochem. Biophys. 373, 401–408.
Mathieu, A.P., R.J. Auchus, and J.G. LeHoux (2002). Comparison of the hamster and human adrenal P450c17 (17α-hydroxylase/17,20-lyase) using site-directed mutagenesis and molecular modeling. J. Steroid Biochem. Mol. Biol. 80, 99–107.
Lin, D., L.H. Zhang, E. Chiao, and W.L. Miller (1994). Modeling and mutagenesis of the active site of human P450c17. Mol. Endocrinol. 8, 392–402.
Burke, D.F., C.A. Laughton, and S. Neidle (1997). Homology modelling of the enzyme P450 17α-hydroxylase/17,20-lyase—a target for prostate cancer chemotherapy—from the crystal structure of P450BM-3. Anticancer Drug Des. 12, 113–123.
Auchus, R.J. and W.L. Miller (1999). Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): Insights into reaction mechanisms and effects of mutations. Mol. Endocrinol. 13, 1169–1182.
Ahmed, S. (1999). A novel molecular modelling study of inhibitors of the 17α-hydroxylase component of the enzyme system 17α-hydroxylase/17,20-lyase (P-45017α). Bioorg. Med. Chem. 7, 1487–1496.
Schappach, A. and H.D. Holtje (2001). Molecular modelling of 17α-hydroxylase-17,20-lyase. Pharmazie 56, 435–442.
Kan, P.B., M.A. Hirst, and D. Feldman (1985). Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J. Steroid Biochem. 23, 1023–1029.
Kossor, D.C., S. Kominami, S. Takemori, and H.D. Colby (1992). Destruction of testicular cytochrome P-450 by 7α-thiospironolactone is catalyzed by the 17α-hydroxylase. J. Steroid Biochem. Mol. Biol. 42, 421–424.
Potter, G.A., S.E. Barrie, M. Jarman, and M.G. Rowlands (1995). Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471.
Li, J.S., Y. Li, C. Son, and A.M. Brodie (1996). Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17α-hydroxylase/C17,20-lyase. J. Med. Chem. 39, 4335–4339.
Njar, V.C. and A.M. Brodie (1999). Inhibitors of 17α-hydroxylase/17,20-lyase (CYP17): Potential agents for the treatment of prostate cancer. Curr. Pharm. Des. 5, 163–180.
Hartmann, R.W., M. Hector, B.G. Wachall, A. Palusczak, M. Palzer, V. Huch et al. (2000). Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17α-hydroxylase/C17-20-lyase (P450 17). J. Med. Chem. 43, 4437–4445.
Burkhart, J.P., P.M. Weintraub, C.A. Gates, R.J. Resvick, R.J. Vaz, D. Friedrich et al. (2002). Novel steroidal vinyl fluorides as inhibitors of steroid C17 (20) lyase. Bioorg. Med. Chem. 10, 929–934.
Auchus, R.J., A. Sampath Kumar, C. Andrew Boswell, M.K. Gupta, K. Bruce, N.P. Rath et al. (2003). The enantiomer of progesterone (ent-progesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21. Arch. Biochem. Biophys. 409, 134–144.
Owen, C.P., P.J. Nicholls, H.J. Smith, and R. Whomsley (1999). Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl) imidazoles. J. Pharm. Pharmacol. 51, 427–433.
Recanatini, M., A. Bisi, A. Cavalli, F. Belluti, S. Gobbi, A. Rampa et al. (2001). A new class of nonsteroidal aromatase inhibitors: Design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17α-hydroxylase/C17,20-lyase. J. Med. Chem. 44, 672–680.
Cavalli, A. and M. Recanatini (2002). Looking for selectivity among cytochrome P450 inhibitors. J. Med. Chem. 45, 251–254.
Ehmer, P.B., J. Jose, and R.W. Hartmann (2000). Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C17,20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 75, 57–63.
Grigoryev, D.N., K. Kato, V.C. Njar, B.J. Long, Y.Z. Ling, X. Wang et al. (1999). Cytochrome P450c17-expressing Escherichia coli as a first-step screening system for 17α-hydroxylase-C17,20-lyase inhibitors. Anal. Biochem. 267, 319–330.
Auchus, R.J. (2001). The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol. Metab. Clin. North Am. 30, 101–119, vii.
Kaufman, F.R., G. Costin, U. Goebelsmann, F.Z. Stanczyk, and M. Zachmann (1983). Male pseudohermaphroditism due to 17,20-desmolase deficiency. J. Clin. Endocrinol. Metab. 57, 32–36.
Huang, J., T. Ushiyama, K. Inoue, K. Mori, and S. Hukuda (1999). Possible association of CYP17 gene polymorphisms with the onset of rheumatoid arthritis. Clin. Exp. Rheumatol. 17, 721–724.
Lai, J., D. Vesprini, W. Chu, H. Jernstrom, and S.A. Narod (2001). CYP gene polymorphisms and early menarche. Mol. Genet. Metab. 74, 449–457.
Feigelson, H.S., R. McKean-Cowdin, M.C. Pike, G.A. Coetzee, L.N. Kolonel, A.M. Nomura et al. (1999). Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 59, 3908–3910.
Marszalek, B., M. Lacinski, N. Babych, E. Capla, J. Biernacka-Lukanty, A. Warenik-Szymankiewicz et al. (2001). Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecol. Endocrinol. 15, 123–128.
Kristensen, V.N., E.H. Kure, B. Erikstein, N. Harada, and A. Borresen-Dale (2001). Genetic susceptibility and environmental estrogen-like compounds. Mutat. Res. 482, 77–82.
Feigelson, H.S., G.A. Coetzee, L.N. Kolonel, R.K. Ross, and B.E. Henderson (1997). A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57, 1063–1065.
Feigelson, H.S., R. McKean-Cowdin, G.A. Coetzee, D.O. Stram, L.N. Kolonel, and B.E. Henderson (2001). Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 61, 785–789.
Thompson, P.A. and C. Ambrosone (2000). Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J. Natl. Cancer Inst. Monogr., 125–134.
Mitrunen, K., N. Jourenkova, V. Kataja, M. Eskelinen, V.M. Kosma, S. Benhamou et al. (2000). Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 1343–1348.
Ye, Z. and J.M. Parry (2002). The CYP17 MspA1 polymorphism and breast cancer risk: A metanalysis. Mutagenesis 17, 119–126.
Feigelson, H.S., R. McKean-Cowdin, and B.E. Henderson (2002). Concerning the CYP17 MspA1 polymorphism and breast cancer risk: A meta-analysis. Mutagenesis 17, 445–446.
Ambrosone, C.B., K.B. Moysich, H. Furberg, J.L. Freudenheim, E.D. Bowman, S. Ahmed et al. (2003). CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 5, R45–51.
Stanford, J.L., E.A. Noonan, L. Iwasaki, S. Kolb, R.B. Chadwick, Z. Feng et al. (2002). A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 243–247.
Haiman, C.A., M.J. Stampfer, E. Giovannucci, J. Ma, N.E. Decalo, P.W. Kantoff et al. (2001). The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 10, 743–748.
McKean-Cowdin, R., H.S. Feigelson, M.C. Pike, G.A. Coetzee, L.N. Kolonel, and B.E. Henderson (2001). Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 61, 848–849.
de Carmo Silva, R., C.E. Kater, S.A. Dib, S. Laureti, F. Forini, A. Cosentino et al. (2000). Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, sidechain cleavage and 17α-hydroxylase in Addison’s disease and autoimmune polyendocrine syndrome type III. Eur. J. Endocrinol. 142, 187–194.
Simpson, E.R., C. Clyne, G. Rubin, W.C. Boon, K. Robertson, K. Britt et al. (2002). Aromatase—a brief overview. Annu. Rev. Physiol. 64, 93–127.
Roselli, C.E. and J.A. Resko (2001). Cytochrome P450 aromatase (CYP19) in the non-human primate brain: Distribution, regulation, and functional significance. J. Steroid Biochem. Mol. Biol. 79, 247–253.
Harada, N. (1992). A unique aromatase (P-450AROM) mRNA formed by alternative use of tissue-specific exons 1 in human skin fibroblasts. Biochem. Biophys. Res. Commun. 189, 1001–1007.
Hinshelwood, M.M. and C.R. Mendelson (2001). Tissue-specific expression of the human CYP19 (aromatase) gene in ovary and adipose tissue of transgenic mice. J. Steroid Biochem. Mol. Biol. 79, 193–201.
Shozu, M., H. Sumitani, T. Segawa, H.J. Yang, K. Murakami, T. Kasai et al. (2002). Over-expression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19). J. Clin. Endocrinol. Metab. 87, 2540–2548.
Rubin, G.L., J.H. Duong, C.D. Clyne, C.J. Speed, Y. Murata, C. Gong et al. (2002). Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. Endocrinology 143, 2863–2871.
Clyne, C.D., C.J. Speed, J. Zhou, and E.R. Simpson (2002). Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J. Biol. Chem. 277, 20591–20597.
Kamat, A. and C.R. Mendelson (2001). Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placenta-specific expression. J. Steroid Biochem. Mol. Biol. 79, 173–180.
Haiman, C.A., S.E. Hankinson, I. De Vivo, C. Guillemette, N. Ishibe, D.J. Hunter et al. (2003). Polymorphisms in steroid hormone pathway genes and mammographic density. Breast Cancer Res. Treat. 77, 27–36.
Cole, P.A. and C.H. Robinson (1988). A peroxide model reaction for placental aromatase. J. Am. Chem. Soc. 110, 1284–1285.
Akhtar, M., D. Corina, S. Miller, A.Z. Shyadehi, and J.N. Wright (1994). Mechanism of the acyl-carbon cleavage and related reactions catalyzed by multifunctional P-450s: Studies on cytochrome P45017α. Biochemistry 33, 4410–4418.
Roberts, E.S., A.D.N. Vaz, and M.J. Coon (1991). Catalysis by cytochrome P-450 of an oxidative reaction in xenobiotic aldehyde metabolism: Deformylation with olefin formation. Proc. Natl. Acad. Sci. USA 88, 8963–8966.
Takayanagi, R., K. Goto, S. Suzuki, S. Tanaka, S. Shimoda, and H. Nawata (2002). Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: Correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mech. Ageing Dev. 123, 1107–1114.
Zhang, F., D. Zhou, Y.C. Kao, J. Ye, and S. Chen (2002). Expression and purification of a recombinant form of human aromatase from Escherichia coli. Biochem. Pharmacol. 64, 1317–1324.
Kagawa, N., Q. Cao, and K. Kusano (2003). Expression of human aromatase (CYP19) in Escherichia coli by N-terminal replacement and induction of cold stress response. Steroids 68, 205–209.
Graham-Lorence, S., M.W. Khalil, M.C. Lorence, C.R. Mendelson, and E.R. Simpson (1991). Structure-function relationships of human aromatase cytochrome P-450 using molecular modeling and site-directed mutagenesis. J. Biol. Chem. 266, 11939–11946.
Conley, A., S. Mapes, C.J. Corbin, D. Greger, and S. Graham (2002). Structural determinants of aromatase cytochrome P450 inhibition in substrate recognition site-1. Mol. Endocrinol. 16, 1456–1468.
Marcotte, P.A. and C.H. Robinson (1982). Design of mechanism-based inactivators of human placental aromatase. Cancer Res. 42, 3322s–3326s.
Brueggemeier, R.W. (2002). Aromatase inhibitors in breast cancer therapy. Expert Rev. Anticancer Ther. 2, 181–191.
Lombardi, P. (2002). Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim. Biophys. Acta 1587, 326–337.
Lonning, P.E. (2002). The role of aromatase inactivators in the treatment of breast cancer. Int. J. Clin. Oncol. 7, 265–270.
Lonning, P.E. (2002). Aromatase inhibitors and inactivators for breast cancer treatment. Eur. J. Cancer 38(Suppl 6), S47–S48.
Jones, S.A. and S.E. Jones (2000). Exemestane: A novel aromatase inactivator for breast cancer. Clin. Breast Cancer 1, 211–216.
Winnett, G., D. van Hagen, and M. Schrey (2003). Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: Potential implications for breast cancer therapy. Int. J. Cancer 103, 600–605.
Pouget, C., C. Fagnere, J.P. Basly, G. Habrioux, and A.J. Chulia (2002). Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorg. Med. Chem. Lett. 12, 2859–2861.
Smith, M.R., D. Kaufman, D. George, W.K. Oh, M. Kazanis, J. Manola et al. (2002). Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 95, 1864–1868.
Murata, Y., K.M. Robertson, M.E. Jones, and E.R. Simpson (2002). Effect of estrogen deficiency in the male: The ArKO mouse model. Mol. Cell Endocrinol. 193, 7–12.
Herrmann, B.L., B. Saller, O.E. Janssen, P. Gocke, A. Bockisch, H. Sperling et al. (2002). Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 87, 5476–5484.
Meinhardt, U. and P.E. Mullis (2002). The aromatase cytochrome P-450 and its clinical impact. Horm. Res. 57, 145–152.
Britt, K.L., A.E. Drummond, M. Dyson, N.G. Wreford, M.E. Jones, E.R. Simpson et al. (2001). The ovarian phenotype of the aromatase knockout (ArKO) mouse. J. Steroid Biochem. Mol. Biol. 79, 181–185.
Bakker, J., S. Honda, N. Harada, and J. Balthazart (2002). The aromatase knock-out mouse provides new evidence that estradiol is required during development in the female for the expression of sociosexual behaviors in adulthood. J. Neurosci. 22, 9104–9112.
Lonning, P.E., L.E. Kragh, B. Erikstein, A. Hagen, T. Risberg, E. Schlichting et al. (2001). The potential for aromatase inhibition in breast cancer prevention. Clin. Cancer Res. 7, 4423s–4428s; discussion 4411s–4412s.
Suspitsin, E.N., M.Y. Grigoriev, A.V. Togo, E.S. Kuligina, E.V. Belogubova, K.M. Pozharisski et al. (2002). Distinct prevalence of the CYP19 Δ3 (TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur. J. Cancer 38, 1911–1916.
Kado, N., J. Kitawaki, H. Obayashi, H. Ishihara, H. Koshiba, I. Kusuki et al. (2002). Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum. Reprod. 17, 897–902.
Bryan, G.T., A.M. Lewis, J.B. Harkins, S.F. Micheletti, and G.S. Boyd (1974). Cytochrome P450 and steroid 21-hydroxylation in microsomes from beef adrenal cortex. Steroids 23, 185–201.
Zhou, Z., V.R. Agarwal, N. Dixit, P. White, and P.W. Speiser (1997). Steroid 21-hydroxylase expression and activity in human lymphocytes. Mol. Cell Endocrinol. 127, 11–18.
Yu, L., D.G. Romero, C.E. Gomez-Sanchez, and E.P. Gomez-Sanchez (2002). Steroidogenic enzyme gene expression in the human brain. Mol. Cell Endocrinol. 190, 9–17.
Zanger, U.M., N. Kagawa, J. Lund, and M.R. Waterman (1992). Distinct biochemical mechanisms for cAMP-dependent transcription of CYP17 and CYP21. FASEB J. 6, 719–723.
Watanabe, N., M. Kitazume, J. Fujisawa, M. Yoshida, and Y. Fujii-Kuriyama (1993). A novel cAMP-dependent regulatory region including a sequence like the cAMP-responsive element, far upstream of the human CYP21A2 gene. Eur. J. Biochem. 214, 521–531.
Chang, S.F. and B.C. Chung (1995). Difference in transcriptional activity of two homologous CYP21A genes. Mol. Endocrinol. 9, 1330–1336.
Bird, I.M., J.I. Mason, and W.E. Rainey (1998). Protein kinase A, protein kinase C, and Ca2+-regulated expression of 21-hydroxylase cytochrome P450 in H295R human adrenocortical cells. J. Clin. Endocrinol. Metab. 83, 1592–1597.
Wijesuriya, S.D., G. Zhang, A. Dardis, and W.L. Miller (1999). Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene. J. Biol. Chem. 274, 38097–38106.
White, P.C., M.T. Tusie-Luna, M.I. New, and P.W. Speiser (1994). Mutations in steroid 21-hydroxylase (CYP21). Hum. Mutat. 3, 373–378.
M.T. Tusie-Luna, P.W. Speiser, M. Dumic, M.I. New, and P.C. White (1991). A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol. Endocrinol. 5, 685–692.
Amor, M., K.L. Parker, H. Globerman, M.I. New, and P.C. White (1988). Mutation in the CYP21B gene (Ile-172→Asn) causes steroid 21-hydroxylase deficiency. Proc. Natl. Acad. Sci. USA 85, 1600–1604.
Owerbach, D., L. Sherman, A.L. Ballard, and R. Azziz (1992). Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency. Mol. Endocrinol. 6, 1211–1215.
Bobba, A., E. Marra, P. Lattanzio, A. Iolascon, and S. Giannattasio (2000). Characterization of the CYP21 gene 5′ flanking region in patients affected by 21-OH deficiency. Hum. Mutat. 15, 481.
White, P.C. and P.W. Speiser (2000). Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrinol. Rev. 21, 245–291.
Lee, H. (2001). CYP21 mutations and congenital adrenal hyperplasia. Clin. Genet. 59, 293–301.
Krone, N., A. Braun, A.A. Roscher, D. Knorr, and H.P. Schwarz (2000). Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J. Clin. Endocrinol. Metab. 85, 1059–1065.
Levo, A. and J. Partanen (2001). Novel mutations in the human CYP21 gene. Prenat. Diagn. 21, 885–889.
Koyama, S., T. Toyoura, S. Saisho, K. Shimozawa, and J. Yata (2002). Genetic analysis of Japanese patients with 21-hydroxylase deficiency: Identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21. J. Clin. Endocrinol. Metab. 87, 2668–2673.
Lee, H.H., D.M. Niu, R.W. Lin, P. Chan, and C.Y. Lin (2002). Structural analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency. J. Hum. Genet. 47, 517–522.
Koppens, P.F., T. Hoogenboezem, and H.J. Degenhart (2002). Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: Characteristics of three unusual haplotypes. Hum. Genet. 111, 405–410.
Dain, L.B., N.D. Buzzalino, A. Oneto, S. Belli, M. Stivel, T. Pasqualini et al. (2002). Classical and nonclassical 21-hydroxylase deficiency: A molecular study of Argentine patients. Clin. Endocrinol. (Oxford) 56, 239–245.
Mornet, E. and J.F. Gibrat (2000). A 3D model of human P450c21: Study of the putative effects of steroid 21-hydroxylase gene mutations. Hum. Genet. 106, 330–339.
Menard, R.H., F.C. Bartter, and J.R. Gillette (1976). Spironolactone and cytochrome P-450: Impairment of steroid 21-hydroxylation in the adrenal cortex. Arch. Biochem. Biophys. 173, 395–402.
Tajima, T., T. Okada, X.M. Ma, W. Ramsey, S. Bornstein, and G. Aguilera (1999). Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther. 6, 1898–1903.
Pedersen, J.I., H.H. Shobaki, I. Holmberg, S. Bergseth, and I. Björkhem (1983). 25-Hydroxyvitamin D3-24-hydroxylase in rat kidney mitochondria. J. Biol. Chem. 258, 742–746.
Ohyama, Y., S. Hayashi, and K. Okuda (1989). Purification of 25-hydroxyvitamin D3 24-hydroxylase from rat kidney mitochondria. FEBS Lett. 255, 405–408.
Ettinger, R.A., R. Ismail, and H.F. DeLuca (1994). cDNA cloning and characterization of a vitamin D3 hydroxylase-associated protein. J. Biol. Chem. 269, 176–182.
Chen, K.S., J.M. Prahl, and H.F. DeLuca (1993). Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA. Proc. Natl. Acad. Sci. USA 90, 4543–4547.
Yang, W., P.A. Friedman, R. Kumar, J.L. Omdahl, B.K. May, M.L. SiuCaldera et al. (1999). Expression of 25 (OH)D3 24-hydroxylase in distal nephron: Coordinate regulation by 1, 25 (OH)2D3 and cAMP or PTH. Am. J. Physiol. 276, E793–E805.
Jones, G., H. Ramshaw, A. Zhang, R. Cook, V. Byford, J. White et al. (1999). Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1α and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 140, 3303–3310.
Chen, M.L., G. Heinrich, Y.I. Ohyama, K. Okuda, J.L. Omdahl, T.C. Chen et al. (1994). Expression of 25-hydroxyvitamin D3-24-hydroxylase mRNA in cultured human keratinocytes. Proc. Soc. Exp. Biol. Med. 207, 57–61.
Schuster, I., H. Egger, N. Astecker, G. Herzig, M. Schussler, and G. Vorisek (2001). Selective inhibitors of CYP24: Mechanistic tools to explore vitamin D metabolism in human keratinocytes. Steroids 66, 451–462.
Bareis, P., E. Kallay, M.G. Bischof, G. Bises, H. Hofer, C. Potzi et al. (2002). Clonal differences in expression of 25-hydroxyvitamin D3-1α-hydroxylase, of 25-hydroxyvitamin D3-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: Effects of epidermal growth factor and 1α,25-dihydroxyvitamin D3. Exp. Cell Res. 276, 320–327.
Farhan, H. and H.S. Cross (2002). Transcriptional inhibition of CYP24 by genistein. Ann. N. Y. Acad. Sci. 973, 459–462.
Zierold, C., H.M. Darwish, and H.F. DeLuca (1994). Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc. Natl. Acad. Sci. USA 91, 900–902.
Ohyama, Y., K. Ozono, M. Uchida, T. Shinki, S. Kato, T. Suda et al. (1994). Identification of a vitamin D-responsive element in the 5′-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J. Biol. Chem. 269, 10545–10550.
Kerry, D.M., P.P. Dwivedi, C.N. Hahn, H.A. Morris, J.L. Omdahl, and B.K. May (1996). Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter. J. Biol. Chem. 271, 29715–29721.
Dwivedi, P.P., J.L. Omdahl, I. Kola, D.K. Hume, and B.K. May (2000). Regulation of rat cytochrome P450C24 (CYP24) gene expression. Evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D3-mediated induction. J. Biol. Chem. 275, 47–55.
Raval-Pandya, M., P. Dhawan, F. Barletta, and S. Christakos (2001). YY1 represses vitamin D receptor-mediated 25-hydroxyvitamin D3 24-hydroxylase transcription: Relief of repression by CREB-binding protein. Mol. Endocrinol. 15, 1035–1046.
Dwivedi, P.P., C.S. Hii, A. Ferrante, J. Tan, C.J. Der, J.L. Omdahl et al. (2002). Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. J. Biol. Chem. 277, 29643–29653.
Jones, G. and H.S. Tenenhouse (2002). 1,25(OH)2D, the preferred substrate for CYP24. J. Bone Miner. Res. 17, 179–181.
Sakaki, T., N. Sawada, K. Komai, S. Shiozawa, S. Yamada, K. Yamamoto et al. (2000). Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem. 267, 6158–6165.
Beckman, M.J., P. Tadikonda, E. Werner, J. Prahl, S. Yamada, and H.F. DeLuca (1996). Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35, 8465–8472.
Miyamoto, Y., T. Shinki, K. Yamamoto, Y. Ohyama, H. Iwasaki, R. Hosotani et al. (1997). 1α,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) hydroxylates the carbon at the end of the side chain (C-26) of the C-24-fluorinated analog of 1α,25-dihydroxyvitamin D3. J. Biol. Chem. 272, 14115–14119.
Hayashi, K., M. Akiyoshi-Shibata, T. Sakaki, and Y. Tabusaki (1998). Rat CYP24 catalyses 23S-hydroxylation of 26,26,26,27,27,27-hexafluorocalcitriol in vitro. Xenobiotica 28, 457–463.
Sakaki, T., N. Sawada, Y. Nonaka, Y. Ohyama, and K. Inouye (1999). Metabolic studies using recombinant Escherichia coli cells producing rat mitochondrial CYP24. CYP24 can convert 1α,25-dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem. 262, 43–48.
Inouye, K. and T. Sakaki (2001). Enzymatic studies on the key enzymes of vitamin D metabolism; 1α-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol. Annu. Rev. 7, 179–194.
Omdahl, J.L., E.V. Bobrovnikova, A. Annalora, P. Chen, and R. Serda (2003). Expression, structure-function, and molecular modeling of vitamin D P450s. J. Cell. Biochem. 88, 356–362.
Dilworth, F.J., I. Scott, A. Green, S. Strugnell, Y.D. Guo, E.A. Roberts et al. (1995). Different mechanisms of hydroxylation site selection by liver and kidney cytochrome P450 species (CYP27 and CYP24) involved in vitamin D metabolism. J. Biol. Chem. 270, 16766–16774.
Schuster, I., H. Egger, P. Nussbaumer, and R.T. Kroemer (2003). Inhibitors of vitamin D hydroxylases: Structure-activity relationships. J. Cell. Biochem. 88, 372–380.
Schuster, I., H. Egger, D. Bikle, G. Herzig, G.S. Reddy, A. Stuetz et al. (2001). Selective inhibition of vitamin D hydroxylases in human keratinocytes. Steroids 66, 409–422.
Henry, H.L. (2001). The 25(OH)D3/1α,25(OH)2D3-24R-hydroxylase: A catabolic or biosynthetic enzyme? Steroids 66, 391–398.
Kasuga, H., N. Hosogane, K. Matsuoka, I. Mori, Y. Sakura, K. Shimakawa et al. (2002). Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem. Biophys. Res. Commun. 297, 1332–1338.
Martini, R. and M. Murray (1993). Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Arch. Biochem. Biophys. 303, 57–66.
White, J.A., B. Beckett-Jones, Y.D. Guo, F.J. Dilworth, J. Bonasoro, G. Jones et al. (1997). cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26). J. Biol. Chem. 272, 18539–18541.
White, J.A., H. Ramshaw, M. Taimi, W. Stangle, A. Zhang, S. Everingham et al. (2000). Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. Proc. Natl. Acad. Sci. USA 97, 6403–6408.
Trofimova-Griffin, M.E. and M.R. Juchau (1998). Expression of cytochrome P450RAI (CYP26) in human fetal hepatic and cephalic tissues. Biochem. Biophys. Res. Commun. 252, 487–491.
Nelson, D.R. (1999). A second CYP26 P450 in humans and zebrafish: CYP26B1. Arch. Biochem. Biophys. 371, 345–347.
Abu-Abed, S., G. MacLean, V. Fraulob, P. Chambon, M. Petkovich, and P. Dolle (2002). Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. Mech. Dev. 110, 173–177.
Trofimova-Griffin, M.E. and M.R. Juchau (2002). Developmental expression of cytochrome CYP26B1 (P450RAI-2) in human cephalic tissues. Brain. Res. Develop. Brain Res. 136, 175–178.
Matsuzaki, Y., B. Bouscarel, T. Ikegami, A. Honda, M. Doy, S. Ceryak et al. (2002). Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver. Biochim. Biophys. Acta 1588, 139–148.
Postlind, H., E. Axén, T. Bergman, and K. Wikvall (1997). Cloning, structure, and expression of a cDNA encoding vitamin D3 25-hydroxylase. Biochem. Biophys. Res. Commun. 241, 491–497.
Hayashi, S., M. Noshiro, and K. Okuda (1984). Purification of cytochrome P-450 catalyzing 25-hydroxylation of vitamin D3 from rat liver microsomes. Biochem. Biophys. Res. Commun. 121, 994–1000.
Saarem, K. and J.I. Pedersen (1985). 25-Hydroxylation of 1α-hydroxyvitamin D3 in rat and human liver. Biochim. Biophys. Acta 840, 177–126.
Akiyoshi-Shibata, M., E. Usui, T. Sakaki, Y. Yabusaki, M. Noshiro, K. Okuda et al. (1991). Expression of rat liver vitamin D3 25-hydroxylase cDNA in Saccharomyces cerevisiae. FEBS Lett. 280, 367–370.
Guo, Y.D., S. Strugnell, D.W. Back, and G. Jones (1993). Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc. Natl. Acad. Sci. USA 90, 8668–8672.
Shiga, K., R. Fukuyama, S. Kimura, K. Nakajima, and S. Fushiki (1999). Mutation of the sterol 27-hydroxylase gene (CYP27) results in truncation of mRNA expressed in leucocytes in a Japanese family with cerebrotendinous xanthomatosis. J. Neurol. Neurosurg. Psychiatr. 67, 675–677.
Garuti, R., M.A. Croce, R. Tiozzo, M.T. Dotti, A. Federico, S. Bertolini et al. (1997). Four novel mutations of sterol 27-hydroxylase gene in Italian patients with cerebrotendinous xanthomatosis. J. Lipid Res. 38, 2322–2334.
Gascon-Barre, M., C. Demers, O. Ghrab, C. Theodoropoulos, R. Lapointe, G. Jones et al. (2001). Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney. Clin. Endocrinol. (Oxford) 54, 107–115.
Shanahan, C.M., K.L. Carpenter, and N.R. Cary (2001). A potential role for sterol 27-hydroxylase in atherogenesis. Atherosclerosis 154, 269–276.
Lee, M.J., Y.C. Huang, M.G. Sweeney, N.W. Wood, M.M. Reilly, and P.K. Yip (2002). Mutation of the sterol 27-hydroxylase gene (CYP27A1) in a Taiwanese family with cerebrotendinous xanthomatosis. J. Neurol. 249, 1311–1312.
Chen, W., S. Kubota, H. Ujike, T. Ishihara, and Y. Seyama (1998). A novel Arg362Ser mutation in the sterol 27-hydroxylase gene (CYP27): Its effects on pre-mRNA splicing and enzyme activity. Biochemistry 37, 15050–15056.
Su, P., H. Rennert, R.M. Shayiq, R. Yamamoto, Y. Zheng, S. Addya et al. (1990). A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3: Gonadotropic regulation of the cognate mRNA in ovaries. DNA Cell Biol. 9, 657–665.
Wikvall, K. (2001). Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int. J. Mol. Med. 7, 201–209.
Pikuleva, I.A., I. Björkhelm, and M.R. Waterman (1997). Expression, purification, and enzymatic properties of recombinant human cytochrome P450c27 (CYP27). Arch. Biochem. Biophys. 343, 123–130.
Pikuleva, I.A., A. Babiker, M.R. Waterman, and I. Björkhem (1998). Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways. J. Biol. Chem. 273, 18153–18160.
Sawada, N., T. Sakaki, M. Ohta, and K. Inouye (2000). Metabolism of vitamin D3 by human CYP27A1. Biochem. Biophys. Res. Commun. 273, 977–984.
Sawada, N., T. Sakaki, S. Kitanaka, S. Kato, and K. Inouye (2001). Structure-function analysis of CYP27B1 and CYP27A1—Studies on mutants from patients with vitamin D-dependent rickets type I (VDDR-I) and cerebrotendinous xanthomatosis (CTX). Eur. J. Biochem. 268, 6607–6615.
Pikuleva, I.A., A. Puchkaev, and I. Bjorkhem (2001). Putative helix F contributes to regioselectivity of hydroxylation in mitochondrial cytochrome P450 27A1. Biochemistry 40, 7621–7629.
Murtazina, D., A.V. Puchkaev, C.H. Schein, N. Oezguen, W. Braun, A. Nanavati et al. (2002). Membrane-protein interactions contribute to efficient 27-hydroxylation of cholesterol by mitochondrial cytochrome P450 27A1. J. Biol. Chem. 277, 37582–37589.
Hosseinpour, F., M. Hidestrand, M. Ingelman-Sundberg, and K. Wikvall (2001). The importance of residues in substrate recognition site 3 for the catalytic function of CYP2D25 (vitamin D 25-hydroxylase). Biochem. Biophys. Res. Commun. 288, 1059–1063.
Wills, M.R. and J. Savory (1984). Vitamin D metabolism and chronic liver disease. Ann. Clin. Lab. Sci. 14, 189–197.
Sugama, S., A. Kimura, W. Chen, S. Kubota, Y. Seyama, N. Taira et al. (2001). Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27). J. Inherit. Metab. Dis. 24, 379–392.
Björkhem, I. (2002). Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 110, 725–730.
Rosen, H., A. Reshef, N. Maeda, A. Lippoldt, S. Shpizen, L. Triger et al. (1998). Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J. Biol. Chem. 273, 14805–14812.
Reiss, A.B., N.W. Awadallah, S. Malhotra, M.C. Montesinos, E.S. Chan, N.B. Javitt et al. (2001). Immune complexes and IFN-γ decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J. Lipid Res. 42, 1913–1922.
Goodwin, B., K.C. Gauthier, M. Umetani, M.A. Watson, M.I. Lochansky, J.L. Collins et al. (2003). Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. USA 100, 223–228.
Escher, G., Z. Krozowski, K.D. Croft, and D. Sviridov (2003). Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux. J. Biol. Chem. 278, 11015–11019.
Fu, X., J.G. Menke, Y. Chen, G. Zhou, K.L. MacNaul, S.D. Wright et al. (2001). 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276, 38378–38387.
H.F. DeLuca (1977). Vitamin D as a prohormone. Biochem. Pharmacol. 26, 563–566.
Paulson, S.K. and H.F. DeLuca (1985). Subcellular location and properties of rat renal 25-hydroxyvitamin D3-1α-hydroxylase. J. Biol. Chem. 260, 11488–11492.
M. Burgos-Trinidad, R. Ismail, R.A. Ettinger, J.M. Prahl, and H.F. DeLuca (1992). Immunopurified 25-hydroxyvitamin D 1α-hydroxylase and 1,25-dihydroxyvitamin D 24-hydroxylase are closely related but distinct enzymes. J. Biol. Chem. 267, 3498–3505.
Arabian, A., J. Grover, M.G. Barre, and E.E. Delvin (1993). Rat kidney 25-hydroxyvitamin D3 1α-and 24-hydroxylases: Evidence for two distinct gene products. J. Steroid Biochem. Mol. Biol. 45, 513–516.
Axén, E., H. Postlind, H. Sjöberg, and K. Wikvall (1994). Liver mitochondrial cytochrome P450 CYP27 and recombinant expressed human CYP27 catalyze 1α-hydroxylation of 25-hydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 91, 10014–10018.
Monkawa, T., T. Yoshida, S. Wakino, T. Shinki, H. Anazawa, H.F. DeLuca et al. (1997). Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3 1α-hydroxylase. Biochem. Biophys. Res. Commun. 239, 527–533.
Fu, G.K., A.A. Portale, and W.L. Miller (1997). Complete structure of the human gene for the vitamin D 1α-hydroxylase, P450c1α. DNA Cell Biol. 16, 1499–1507.
Zehnder, D., R. Bland, E.A. Walker, A.R. Bradwell, A.J. Howie, M. Hewison et al. (1999). Expression of 25-hydroxyvitamin D3-1α-hydroxylase in the human kidney. J. Am. Soc. Nephrol. 10, 2465–2473.
Zehnder, D., R. Bland, M.C. Williams, R.W. McNinch, A.J. Howie, P.M. Stewart et al. (2001). Extrarenal expression of 25-hydroxyvitamin D3-1α-hydroxylase. J. Clin. Endocrinol. Metab. 86, 888–894.
Zehnder, D., K.N. Evans, M.D. Kilby, J.N. Bulmer, B.A. Innes, P.M. Stewart et al. (2002). The ontogeny of 25-hydroxyvitamin D3 1α-hydroxylase expression in human placenta and decidua. Am. J. Pathol. 161, 105–114.
Diaz, L., C. Arranz, E. Avila, A. Halhali, F. Vilchis, and F. Larrea (2002). Expression and activity of 25-hydroxyvitamin D-1α-hydroxylase are restricted in cultures of human syncytiotrophoblast cells from preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 87, 3876–3882.
Friedrich, M., C. Villena-Heinsen, R. Axt-Fliedner, R. Meyberg, W. Tilgen, W. Schmidt et al. (2002). Analysis of 25-hydroxyvitamin D3-1α-hydroxylase in cervical tissue. Anticancer Res. 22, 183–186.
Segersten, U., P. Correa, M. Hewison, P. Hellman, H. Dralle, T. Carling et al. (2002). 25-hydroxyvitamin D3-1α-hydroxylase expression in normal and pathological parathyroid glands. J. Clin. Endocrinol. Metab. 87, 2967–2972.
Brenza, H.L. and H.F. DeLuca (2001). Analysis of basal regulatory elements in the 25-hydroxyvitamin D3 1α-hydroxylase gene promoter. Arch. Biochem. Biophys. 388, 121–126.
Baxter, L.A. and H.F. DeLuca (1976). Stimulation of 25-hydroxyvitamin D3-1α-hydroxylase by phosphate depletion. J. Biol. Chem. 251, 3158–3161.
Yoshida, T., N. Yoshida, T. Monkawa, M. Hayashi, and T. Saruta (2001). Dietary phosphorus deprivation induces 25-hydroxyvitamin D3 1α-hydroxylase gene expression. Endocrinology 142, 1720–1726.
Zhang, M.Y., X. Wang, J.T. Wang, N.A. Compagnone, S.H. Mellon, J.L. Olson et al. (2002). Dietary phosphorus transcriptionally regulates 25-hydroxyvitamin D-1α-hydroxylase gene expression in the proximal renal tubule. Endocrinology 143, 587–595.
Bland, R., E.A. Walker, S.V. Hughes, P.M. Stewart, and M. Hewison (1999). Constitutive expression of 25-hydroxyvitamin D3-1α-hydroxylase in a transformed human proximal tubule cell line: Evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 140, 2027–2034.
Takeyama, K., S. Kitanaka, T. Sato, M. Kobori, J. Yanagisawa, and S. Kato (1997). 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277, 1827–1830.
Murayama, A., K. Takeyama, S. Kitanaka, Y. Kodera, T. Hosoya, and S. Kato (1998). The promoter of the human 25-hydroxyvitamin D3 1α-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1α,25(OH)2D3. Biochem. Biophys. Res. Commun. 249, 11–16.
Kong, X.F., X.H. Zhu, Y.L. Pei, D.M. Jackson, and M.F. Holick (1999). Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1α-hydroxylase gene. Proc. Natl. Acad. Sci. USA 96, 6988–6993.
Gao, X.H., P.P. Dwivedi, S. Choe, F. Alba, H.A. Morris, J.L. Omdahl et al. (2002). Basal and parathyroid hormone induced expression of the human 25-hydroxyvitamin D 1α-hydroxylase gene promoter in kidney AOK-B50 cells: Role of Sp1, Ets and CCAAT box protein binding sites. Int. J. Biochem. Cell Biol. 34, 921–930.
Michigami, T., H. Yamato, H. Suzuki, Y. Nagai-Itagaki, K. Sato, and K. Ozono (2001). Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D3-1α-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy. J. Endocrinol. 171, 249–257.
Kato, S., T. Yoshizazawa, S. Kitanaka, A. Murayama, and K. Takeyama (2002). Molecular genetics of vitamin D-dependent hereditary rickets. Horm. Res. 57, 73–78.
Wang, J.T., C.J. Lin, S.M. Burridge, G.K. Fu, M. Labuda, A.A. Portale et al. (1998). Genetics of vitamin D 1α-hydroxylase deficiency in 17 families. Am. J. Hum. Genet. 63, 1694–1702.
Portale, A.A. and W.L. Miller (2000). Human 25-hydroxyvitamin D-1α-hydroxylase: Cloning, mutations, and gene expression. Pediatr. Nephrol. 14, 620–625.
Porcu, L., A. Meloni, L. Casula, I. Asunis, M.G. Marini, A. Cao et al. (2002). A novel splicing defect (IVS6 + 1G>T) in a patient with pseudovitamin D deficiency rickets. J. Endocrinol. Invest. 25, 557–560.
Kitanaka, S., K. Takeyama, A. Murayama, T. Sato, K. Okumura, M. Nogami et al. (1998). Inactivating mutations in the 25-hydroxyvitamin D3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N. Engl. J. Med. 338, 653–661.
Smith, S.J., A.K. Rucka, J.L. Berry, M. Davies, S. Mylchreest, C.R. Paterson et al. (1999). Novel mutations in the 1α-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in blood-derived macrophages. J. Bone Miner. Res. 14, 730–739.
Sawada, N., T. Sakaki, S. Kitanaka, K. Takeyama, S. Kato, and K. Inouye (1999). Enzymatic properties of human 25-hydroxyvitamin D3 1α-hydroxylase coexpression with adrenodoxin and NADPH-adrenodoxin reductase in Escherichia coli. Eur. J. Biochem. 265, 950–956.
Wang, X., M.Y. Zhang, W.L. Miller, and A.A. Portale (2002). Novel gene mutations in patients with 1α-hydroxylase deficiency that confer partial enzyme activity in vitro. J. Clin. Endocrinol. Metab. 87, 2424–2430.
Muralidharan, K.R., M. Rowland-Goldsmith, A.S. Lee, G. Park, A.W. Norman, H.L. Henry et al. (1997). Inhibitors of 25-hydroxyvitamin D3-1α-hydroxylase: Thiavitamin D analogs and biological evaluation. J. Steroid Biochem. 62, 73–78.
Hewison, M., D. Zehnder, R. Bland, and P.M. Stewart (2000). 1α-Hydroxylase and the action of vitamin D. J. Mol. Endocrinol. 25, 141–148.
Kitanaka, S., K. Takeyama, A. Murayama, and S. Kato (2001). The molecular basis of vitamin D-dependent rickets type I. Endocrinol. J. 48, 427–432.
Portale, A.A. and W.L. Miller (2000). Human 25-hydroxyvitamin D-1α-hydroxylase: Cloning, mutations, and gene expression. Pediatr. Nephrol. 14, 620–625.
Kitanaka, S., A. Murayama, T. Sakaki, K. Inouye, Y. Seino, S. Fukumoto et al. (1999). No enzyme activity of 25-hydroxyvitamin D3 1α-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J. Clin. Endocrinol. Metab. 84, 4111–4117.
Dardenne, O., J. Prud’homme, A. Arabian, F.H. Glorieux, and R. St-Arnaud (2001). Targeted inactivation of the 25-hydroxyvitamin D3-1α-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142, 3135–3141.
Panda, D.K., D. Miao, M.L. Tremblay, J. Sirois, R. Farookhi, G.N. Hendy et al. (2001). Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 98, 7498–7503.
St-Arnaud, R., O. Dardenne, J. Prud’homme, S.A. Hacking, and F.H. Glorieux (2003). Conventional and tissue-specific inactivation of the 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1). J. Cell. Biochem. 88, 245–251.
Satomura, K., Y. Seino, K. Yamaoka, Y. Tanaka, M. Ishida, H. Yabuuchi et al. (1988). Renal 25-hydroxyvitamin D3-1-hydroxylase in patients with renal disease. Kidney Int. 34, 712–716.
Correa, P., U. Segersten, P. Hellman, G. Akerstrom, and G. Westin (2002). Increased 25-hydroxyvitamin D3 1α-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors—new prospects for treatment of hyperparathyroidism with vitamin D. J. Clin. Endocrinol. Metab. 87, 5826–5829.
Maas, R.M., K. Reus, B. Diesel, W.I. Steudel, W. Feiden, U. Fischer et al. (2001). Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D3 1,α-hydroxylase (CYP 27B1) in human malignant glioma. Clin. Cancer Res. 7, 868–875.
Tangpricha, V., J.N. Flanagan, L.W. Whitlatch, C.C. Tseng, T.C. Chen, P.R. Holt et al. (2001). 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 357, 1673–1674.
Cross, H.S., P. Bareis, H. Hofer, M.G. Bischof, E. Bajna, S. Kriwanek et al. (2001). 25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287–292.
Ogunkolade, B.W., B.J. Boucher, P.D. Fairclough, G.A. Hitman, S. Dorudi, P.J. Jenkins et al. (2002). Expression of 25-hydroxyvitamin D-1-α-hydroxylase mRNA in individuals with colorectal cancer. Lancet 359, 1831–1832.
Hsu, J.Y., D. Feldman, J.E. McNeal, and D.M. Peehl (2001). Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61, 2852–2856.
Whitlatch, L.W., M.V. Young, G.G. Schwartz, J.N. Flanagan, K.L. Burnstein et al. (2002). 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 81, 135–140.
Flanagan, J.N., L.W. Whitlatch, T.C. Chen, X.H. Zhu, M.T. Holick, X.F. Kong et al. (2001). Enhancing 1α-hydroxylase activity with the 25-hydroxyvitamin D-1α-hydroxylase gene in cultured human keratinocytes and mouse skin. J. Invest. Dermatol. 116, 910–914.
Li-Hawkins, J., E.G. Lund, A.D. Bronson, and D.W. Russell (2000). Expression cloning of an oxysterol 7α-hydroxylase selective for 24-hydroxycholesterol. J. Biol. Chem. 275, 16543–16549.
Lund, E.G., J.M. Guileyardo, and D.W. Russell (1999). cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA 96, 7238–7243.
Russell, D.W. (2000). Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 1529, 126–135.
Bogdanovic, N., L. Bretillon, E.G. Lund, U. Diczfalusy, L. Lannfelt, B. Winblad et al. (2001). On the turnover of brain cholesterol in patients with Alzheimer’s disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci. Lett. 314, 45–48.
Papassotiropoulos, A., D. Lutjohann, M. Bagli, S. Locatelli, F. Jessen, R. Buschfort et al. (2002). 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36, 27–32.
Kolsch, H., D. Lutjohann, M. Ludwig, A. Schulte, U. Ptok, F. Jessen et al. (2002). Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease. Mol. Psychiatry 7, 899–902.
Desai, P., S.T. DeKosky, and M.I. Kamboh (2002). Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer’s disease. Neurosci. Lett. 328, 9–12.
Mast, N., R. Norcross, U. Andersson, M. Shou, K. Nakayama, I. Bjorkhem, and I.A. Pikuleva (2003). Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry 42, 14284–14292.
Aoyama, Y., Y. Funae, M. Noshiro, T. Horiuchi, and Y. Yoshida (1994). Occurrence of a P450 showing high homology to yeast lanosterol 14-demethylase (P45014DM) in rat liver. Biochem. Biophys. Res. Commun. 201, 1320–1326.
Aoyama, Y., T. Horiuchi, and Y. Yoshida (1996). Lanosterol 14-demethylase activity expressed in rat brain microsomes. J. Biochem. (Tokyo) 120, 982–986.
Rozman, D., M. Strömstedt, and M.R. Waterman (1996). The three human cytochrome P450 lanosterol 14α-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: Structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch. Biochem. Biophys. 333, 466–474.
Cotman, M., D. Rozma, L. Banek, and D. Jezek (2001). Localisation of lanosterol 14α-demethylase in round and elongated spermatids of the mouse testis: An immunoelectron microscopic and stereological study. Pflugers Arch. 442, R167–R168.
Rozman, D. (2000). Lanosterol 14α-demethylase (CYP51)—a cholesterol biosynthetic enzyme involved in production of meiosis activating sterols in oocytes and testis—a minireview. Pflugers Arch. 439, R56–R57.
Kelley, R.I., L.E. Kratz, R.L. Glaser, M.L. Netzloff, L.M. Wolf, and E.W. Jabs (2002). Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am. J. Med. Genet. 110, 95–102.
Debeljak, N., M. Fink, and D. Rozman (2003). Many facets of mammalian lanosterol 14α-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch. Biochem. Biophys. 409, 159–171.
Strömstedt, M., D. Rozman, and M.R. Waterman (1996). The ubiquitously expressed human CYP51 cDNA encodes lanosterol 14α-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch. Biochem. Biophys. 329, 73–81.
Rozman, D., M. Fink, G.M. Fimia, P. Sassone-Corsi, and M.R. Waterman (1999). Cyclic adenosine 3′,5′-monophosphate(cAMP)/ cAMP-responsive element modulator (CREM)-dependent regulation of cholesterogenic lanosterol 14α-demethylase (CYP51) in spermatids. Mol. Endocrinol. 13, 1951–1962.
Halder, S.K., M. Fink, M.R. Waterman, and D. Rozman (2002). A cAMP-responsive element binding site is essential for sterol regulation of the human lanosterol 14α-demethylase gene (CYP51). Mol. Endocrinol. 16, 1853–1863.
Yamashita, C., M. Kudo, H. Ishida, M. Noshiro, Y. Aoyama, and Y. Yoshida (2000). Insulin is the essential factor maintaining the constitutive expression of hepatic sterol 14-demethylase P450 (CYP51). J. Biochem. (Tokyo) 128, 93–99.
Rodriguez, C., J. Martinez-Gonzalez, S. Sanchez-Gomez, and L. Badimon (2001). LDL downregulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism. Circ. Res. 88, 268–274.
Lamb, D.C., N.N. Kaderbhai, K. Venkateswarlu, D.E. Kelly, S.L. Kelly, and M.A. Kaderbhai (2001). Human sterol 14α-demethylase activity is enhanced by the membrane-bound state of cytochrome b 5. Arch. Biochem. Biophys. 395, 78–84.
Lamb, D.C., D.E. Kelly, and S.L. Kelly (1998). Molecular diversity of sterol 14α-demethylase substrates in plants, fungi and humans. FEBS Lett. 425, 263–265.
Podust, L.M., T.L. Poulos, and M.R. Waterman (2001). Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. USA 98, 3068–3073.
Podust, L.M., J. Stojan, T.L. Poulos, and M.R. Waterman (2001). Substrate recognition sites in 14 α-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J. Inorg. Biochem. 87, 227–235.
Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten et al. (1999). Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, CYP51p) to azole resistance in Candida albicans. Microbiology 145, 2701–2713.
Lepesheva, G.I., L.M. Podust, A. Bellamine, and M.R. Waterman (2001). Folding requirements are different between sterol 14α-demethylase (CYP51) from Mycobacterium tuberculosis and human or fungal orthologs. J. Biol. Chem. 276, 28413–28420.
Lamb, D.C., D.E. Kelly, M.R. Waterman, M. Stromstedt, D. Rozman, and S.L. Kelly (1999). Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents. Yeast 15, 755–763.
Rozman, D. and M.R. Waterman (1998). Lanosterol 14α-demethylase (CYP51) and spermatogenesis. Drug Metab. Dispos. 26, 1199–1201.
Majdic, G., M. Parvinen, A. Bellamine, H.J. Harwood, Jr., W.W. Ku, M.R. Waterman, and D. Rozman (2000). Lanosterol 14α-demethylase (CYP51), NADPH-cytochrome P450 reductase and squalene synthase in spermatogenesis: Late spermatids of the rat express proteins needed to synthesize follicular fluid meiosis activating sterol. J. Endocrinol. 166, 463–474.
Yamashita, C., Y. Aoyama, M. Noshiro, and Y. Yoshida (2001). Gonadotropin-dependent expression of sterol 14-demethylase P450 (CYP51) in rat ovaries and its contribution to the production of a meiosis-activating steroid. J. Biochem. (Tokyo) 130, 849–856.
Rozman, D., M. Cotman, and R. Frangez (2002). Lanosterol 14α-demethylase and MAS sterols in mammalian gametogenesis. Mol. Cell Endocrinol. 187, 179–187.
Kodaira, H., C.A. Lisek, A. Arimura, I. Jardine, and S. Spector (1989). Identification of the convulsant opiate thebaine in mammalian brain. Proc. Natl. Acad. Sci. USA 86, 716–719.
Kodaira, H. and S. Spector (1988). Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proc. Natl. Acad. Sci. USA 85, 1267–1271.
Dayer, P., J. Desmeules, T. Leemann, and R. Striberni (1988). Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 152, 411–416.
Mikus, G., F. Bochner, M. Eichelbaum, P. Horak, A.A. Somogyi, and S. Spector (1994). Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J. Pharmacol. Exp. Ther. 268, 546–551.
Trewick, S.C., T.F. Henshaw, R.P. Hausinger, T. Lindahl, and B. Sedgwick (2002). Oxidative demethylation by Escherichia coli AlkB directly reverts DNA base damage. Nature 12, 174–178.
Welford, R.W., I. Schlemminger, L.A. McNeill, K.S. Hewitson, and C.J. Schofield (2003). The selectivity and inhibition of AlkB. J. Biol. Chem. 278, 10157–10161.
Pai, H.V., R.P. Kommaddi, S.J. Chinta, T. Mori, M.R. Boyd, and V. Ravindranath (2004, in press). A frame shift mutation and alternate splicing in human brain generates a functional form of the pseudogene, cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem. 39774.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Kluwer Academic/Plenum Publishers, New York
About this chapter
Cite this chapter
Guengerich, F.P. (2005). Human Cytochrome P450 Enzymes. In: Ortiz de Montellano, P.R. (eds) Cytochrome P450. Springer, Boston, MA. https://doi.org/10.1007/0-387-27447-2_10
Download citation
DOI: https://doi.org/10.1007/0-387-27447-2_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-48324-0
Online ISBN: 978-0-387-27447-8
eBook Packages: MedicineMedicine (R0)